

Depemokimab (Exdensur)

GlaxoSmithKline GmbH & Co. KG

Anhang 4-G zu Modul 4A

Zusätzliche Erhaltungstherapie bei Erwachsenen und Jugendlichen ab 12 Jahren mit schwerem Asthma mit Typ-2-Inflammation, gekennzeichnet durch die Anzahl der Eosinophilen im Blut, da trotz hochdosierter inhalativer Kortikosteroide (ICS) plus einem weiteren Arzneimittel zur Asthma-Erhaltungstherapie unzureichend kontrolliert ist

Stand: 30.03.2026

Inhaltsverzeichnis

1	Mortalität	2
2	Morbidität	3
2.1	Asthma-Exazerbation (Jahresrate) - Klinisch signifikante Exazerbationen	3
2.2	Asthma-Exazerbation (Jahresrate) - Klinisch signifikante Exazerbationen, die einen Krankenhausaufenthalt und/oder Behandlung in einer Notfallambulanz erfordern .	5
2.3	Asthma-Exazerbation (Zeit bis zur ersten Exazerbation) - Klinisch signifikante Exazerbationen	8
2.4	Asthma-Exazerbation (Zeit bis zur ersten Exazerbation) - Klinisch signifikante Exazerbationen, die einen Krankenhausaufenthalt und/oder Behandlung in einer Notfallambulanz erfordern	15
2.5	Asthma-Exazerbation (Anzahl der Tage mit OCS)	22
2.6	ACQ-5 - Veränderung im Vergleich zu Baseline	25
2.7	ACQ-5 - Responderanalyse	59
2.8	PGI-C - Responderanalyse	77
2.9	PGI-S - Responderanalyse	89
2.10	ADSD - Veränderung im Vergleich zu Baseline	101
2.11	ANSD - Veränderung im Vergleich zu Baseline	157
2.12	ADSD - Responderanalyse	213
2.13	ANSD - Responderanalyse	265
3	Gesundheitsbezogene Lebensqualität	317
3.1	SGRQ - Veränderung im Vergleich zu Baseline	317
3.2	SGRQ - Responderanalyse	331
4	Sicherheit	343
4.1	Anzahl an Patienten mit UE (jeglicher Schweregrad)	343
4.2	Anzahl an Patienten mit UE (jeglicher Schweregrad) nach SOC und PT	347
4.3	Anzahl an Patienten mit SUE	411
4.4	Anzahl an Patienten mit Therapieabbruch aufgrund von UE	415
4.5	Anzahl an Patienten mit Therapieabbruch aufgrund von UE nach SOC und PT . . .	419
5	Compliance	424

1 Mortalität

Protocol: 212138 Depemokimab ISS SWIFT Pool
Population: Safety

Page 1 of 1

Table 3.127
Summary of Deaths (Pre-, On- and Post-Treatment)
(206713, 213744)

No data to report

/mnt/code/iss/prod/tfl/t_sf_death_d1.sas 28JUN2024 20:07

2 Morbidität
2.1 Asthma-Exazerbation (Jahresrate) - Klinisch signifikante Exazerbationen

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 1 of 1
Data as of 29APR2024


Table 27.11
Analysis of Annualised Rate of Clinically Significant Exacerbations over 52 Weeks

	SWIFT-1		SWIFT-2		SWIFT-1 & SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n	71	132	68	158	139	290
Annualised Exacerbation Rate	1.33	0.61	1.19	0.69	1.26	0.67
95% CI	(0.95, 1.85)	(0.46, 0.82)	(0.85, 1.69)	(0.53, 0.90)	(0.99, 1.60)	(0.55, 0.81)
Depemokimab vs. Placebo						
Rate Ratio		0.46		0.58		0.53
95% CI		(0.30, 0.72)		(0.38, 0.89)		(0.39, 0.72)
p-Value		<0.001		0.013		<0.001
% Reduction in Risk		54%		42%		47%
95% CI		(28%, 70%)		(11%, 62%)		(28%, 61%)
p-value for Treatment by Study Interaction						0.481

Note: Analysis performed using a generalised linear model assuming a negative binomial distribution and covariates of treatment group, exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted FEV1. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate. Note: Percentage reduction in annual rate is calculated as (1-rate ratio)*100.
t_e_rate_exac_p_analy.sas 08JUL2025 17:22

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.21
Forest Plot of Annualised Rate of Clinically Significant Exacerbations over 52 Weeks



/mnt/code/gvd/prod/tfl/f_e_forest_exac_ar.sas 08JUL2025 17:27

2.2 Asthma-Exazerbation (Jahresrate) - Klinisch signifikante Exazerbationen, die einen Krankenhausaufenthalt und/oder Behandlung in einer Notfallambulanz erfordern

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 1 of 2
Data as of 29APR2024

Table 27.12
Analysis of Annualised Rate of Exacerbations Requiring Hospitalisation and/or
Emergency Department (ED) Visit over 52 Weeks

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n	71	132	68	158
Annualised Exacerbation Rate	0.00	0.00	0.09	0.05
95% CI	(0.00, Non-Est)	(0.00, Non-Est)	(0.03, 0.25)	(0.02, 0.11)
Depemokimab vs. Placebo				
Rate Ratio		1.05		0.51
95% CI		(0.07, 14.74)		(0.14, 1.87)
p-Value		0.973		0.314
% Reduction in Risk		-5%		49%
95% CI		(-1374%, 93%)		(-87%, 86%)
p-value for Treatment by Study Interaction				

Note: Analysis performed using a generalised linear model assuming a negative binomial distribution and covariates of treatment group, exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted FEV1.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Percentage reduction in annual rate is calculated as (1-rate ratio)*100.
Note: The unrounded annualised exacerbation rate estimates for SWIFT-1 are 0.000382 on Placebo and 0.0004 on Depemokimab.
t_e_rate_exac_hed_analy.sas 08JUL2025 17:22

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 2 of 2
Data as of 29APR2024


Table 27.12
Analysis of Annualised Rate of Exacerbations Requiring Hospitalisation and/or
Emergency Department (ED) Visit over 52 Weeks

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n	139	290
Annualised Exacerbation Rate	0.05	0.03
95% CI	(0.02, 0.13)	(0.01, 0.06)
Depemokimab vs. Placebo		
Rate Ratio		0.51
95% CI		(0.16, 1.66)
p-Value		0.266
% Reduction in Risk		49%
95% CI		(-66%, 84%)
p-value for Treatment by Study Interaction		0.834

Note: Analysis performed using a generalised linear model assuming a negative binomial distribution and covariates of treatment group, exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted FEV1. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate. Note: Percentage reduction in annual rate is calculated as (1-rate ratio)*100. Note: The unrounded annualised exacerbation rate estimates for SWIFT-1 are 0.000382 on Placebo and 0.0004 on Depemokimab.
t_e_rate_exac_hed_analy.sas 08JUL2025 17:22

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.22
Forest Plot of Annualised Rate of Clinically Significant Exacerbations Requiring Hospitalisation and/or
Emergency Department (ED) Visit over 52 Weeks



/mnt/code/gvd/prod/tfl/f_e_forest_exac_hosp_ar.sas 08JUL2025 17:27

2.3 Asthma-Exazerbation (Zeit bis zur ersten Exazerbation) - Klinisch signifikante Exazerbationen

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 1 of 3
Data as of 29APR2024

Table 27.9
Analysis of Time to First Clinically Significant Exacerbation

	SWIFT-1	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)
n	71	132
First Clinically Significant Exacerbation	35 (49%)	51 (39%)
Subjects Censored	36 (51%)	81 (61%)
Adjusted Probability of Event by Week 52 (%)	50%	39%
95% CI	(39%, 62%)	(32%, 48%)
Depemokimab 100 mg SC vs Placebo		
Hazard Ratio		0.66
95% CI		(0.43, 1.03)
p-Value		0.068
% Reduction in Risk		34%
95% CI		(-3%, 57%)
p-value for Treatment by Study Interaction		

Note: Probability of having event (prior to Day 365) and 95% CI are taken from the Kaplan-Meier estimates.
Note: Hazard ratio and 95% CI are from a Cox proportional hazards model with covariates of treatment group, study (206713 or 213744), exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted FEV1.
Note: Percentage reduction in risk is calculated as (1-hazard ratio)*100.
Note: The analysis only includes data up to Week 52 visit or Withdrawal.
t_e_tte_exac_analy.sas 08JUL2025 17:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 2 of 3
Data as of 29APR2024

Table 27.9
Analysis of Time to First Clinically Significant Exacerbation

	SWIFT-2	
	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n	68	158
First Clinically Significant Exacerbation	38 (56%)	60 (38%)
Subjects Censored	30 (44%)	98 (62%)
Adjusted Probability of Event by Week 52 (%)	56%	38%
95% CI	(45%, 68%)	(31%, 46%)
Depemokimab 100 mg SC vs Placebo		
Hazard Ratio		0.58
95% CI		(0.38, 0.88)
p-Value		0.011
% Reduction in Risk		42%
95% CI		(12%, 62%)
p-value for Treatment by Study Interaction		

Note: Probability of having event (prior to Day 365) and 95% CI are taken from the Kaplan-Meier estimates.
Note: Hazard ratio and 95% CI are from a Cox proportional hazards model with covariates of treatment group, study (206713 or 213744), exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted FEV1.
Note: Percentage reduction in risk is calculated as (1-hazard ratio)*100.
Note: The analysis only includes data up to Week 52 visit or Withdrawal.
t_e_tte_exac_analy.sas 08JUL2025 17:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 3 of 3
Data as of 29APR2024

Table 27.9
Analysis of Time to First Clinically Significant Exacerbation


	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n	139	290
First Clinically Significant Exacerbation	73 (53%)	111 (38%)
Subjects Censored	66 (47%)	179 (62%)
Adjusted Probability of Event by Week 52 (%)	53%	39%
95% CI	(45%, 61%)	(33%, 45%)
Depemokimab 100 mg SC vs Placebo		
Hazard Ratio		0.62
95% CI		(0.46, 0.83)
p-Value		0.002
% Reduction in Risk		38%
95% CI		(17%, 54%)
p-value for Treatment by Study Interaction		0.856

Note: Probability of having event (prior to Day 365) and 95% CI are taken from the Kaplan-Meier estimates.
Note: Hazard ratio and 95% CI are from a Cox proportional hazards model with covariates of treatment group, study (206713 or 213744), exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted FEV1.
Note: Percentage reduction in risk is calculated as (1-hazard ratio)*100.
Note: The analysis only includes data up to Week 52 visit or Withdrawal.
t_e_tte_exac_analy.sas 08JUL2025 17:21

Page 1 of 3
 Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
 Population: FAS - High-dose ICS Subgroup
 Study: 217780 (Pooled)

Figure 27.17
 Kaplan-Meier Plot of Time to First Clinically Significant Exacerbation




Note: Shaded areas represent 95% confidence intervals.
 f_e_km_exac.sas 10JUL2025 08:32

Page 2 of 3
 Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
 Population: FAS - High-dose ICS Subgroup
 Study: 206713 (SWIFT-1)

Figure 27.17
 Kaplan-Meier Plot of Time to First Clinically Significant Exacerbation




Note: Shaded areas represent 95% confidence intervals.
 f_e_km_exac.sas 10JUL2025 08:32

Page 3 of 3
Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup
Study: 213744 (SWIFT-2)


Figure 27.17
Kaplan-Meier Plot of Time to First Clinically Significant Exacerbation



Note: Shaded areas represent 95% confidence intervals.
f_e_km_exac.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.18
Forest Plot of Time to First Clinically Significant Exacerbation



/mnt/code/gvd/prod/tfl/f_e_forest_exac.sas 08JUL2025 17:26

2.4 Asthma-Exazerbation (Zeit bis zur ersten Exazerbation) - Klinisch signifikante Exazerbationen, die einen Krankenhausaufenthalt und/oder Behandlung in einer Notfallambulanz erfordern

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 1 of 3
Data as of 29APR2024

Table 27.10
Analysis of Time to First Clinically Significant Exacerbation Requiring Hospitalisation and/or ED Visit

	SWIFT-1	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)
n	71	132
First Clinically Significant Exacerbation	2 (3%)	3 (2%)
Subjects Censored	69 (97%)	129 (98%)
Adjusted Probability of Event by Week 52 (%)	3%	2%
95% CI	(1%, 11%)	(1%, 7%)
Depemokimab 100 mg SC vs Placebo		
Hazard Ratio		0.61
95% CI		(0.08, 4.57)
p-Value		0.635
% Reduction in Risk		39%
95% CI		(-357%, 92%)
p-value for Treatment by Study Interaction		

Note: Probability of having event (prior to Day 365) and 95% CI are taken from the Kaplan-Meier estimates.
Note: Hazard ratio and 95% CI are from a Cox proportional hazards model with covariates of treatment group, study (206713 or 213744), exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted FEV1.
Note: Percentage reduction in risk is calculated as (1-hazard ratio)*100.
Note: The analysis only includes data up to Week 52 visit or Withdrawal.
t_e_tte_hed_analy.sas 08JUL2025 17:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 2 of 3
Data as of 29APR2024

Table 27.10
Analysis of Time to First Clinically Significant Exacerbation Requiring Hospitalisation and/or ED Visit

	SWIFT-2	
	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n	68	158
First Clinically Significant Exacerbation	7 (10%)	8 (5%)
Subjects Censored	61 (90%)	150 (95%)
Adjusted Probability of Event by Week 52 (%)	10%	5%
95% CI	(5%, 20%)	(2%, 9%)
Depemokimab 100 mg SC vs Placebo		
Hazard Ratio		0.40
95% CI		(0.14, 1.18)
p-Value		0.096
% Reduction in Risk		60%
95% CI		(-18%, 87%)
p-value for Treatment by Study Interaction		

Note: Probability of having event (prior to Day 365) and 95% CI are taken from the Kaplan-Meier estimates.
Note: Hazard ratio and 95% CI are from a Cox proportional hazards model with covariates of treatment group, study (206713 or 213744), exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted FEV1.
Note: Percentage reduction in risk is calculated as (1-hazard ratio)*100.
Note: The analysis only includes data up to Week 52 visit or Withdrawal.
t_e_tte_hed_analy.sas 08JUL2025 17:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 3 of 3
Data as of 29APR2024

Table 27.10
Analysis of Time to First Clinically Significant Exacerbation Requiring Hospitalisation and/or ED Visit


	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n	139	290
First Clinically Significant Exacerbation	9 (6%)	11 (4%)
Subjects Censored	130 (94%)	279 (96%)
Adjusted Probability of Event by Week 52 (%)	7%	4%
95% CI	(3%, 12%)	(2%, 6%)
Depemokimab 100 mg SC vs Placebo		
Hazard Ratio		0.52
95% CI		(0.21, 1.31)
p-Value		0.167
% Reduction in Risk		48%
95% CI		(-31%, 79%)
p-value for Treatment by Study Interaction		0.570

Note: Probability of having event (prior to Day 365) and 95% CI are taken from the Kaplan-Meier estimates.
Note: Hazard ratio and 95% CI are from a Cox proportional hazards model with covariates of treatment group, study (206713 or 213744), exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted FEV1.
Note: Percentage reduction in risk is calculated as (1-hazard ratio)*100.
Note: The analysis only includes data up to Week 52 visit or Withdrawal.
t_e_tte_hed_analy.sas 08JUL2025 17:21

Page 1 of 3
 Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
 Population: FAS - High-dose ICS Subgroup
 Study: 217780 (Pooled)

Figure 27.19
 Kaplan-Meier Plot of Time to First Clinically Significant Exacerbation
 Requiring Hospitalisation and/or ED Visit




Note: Shaded areas represent 95% confidence intervals.
 f_e_km_exac_hosp.sas 10JUL2025 08:33

Page 2 of 3
 Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
 Population: FAS - High-dose ICS Subgroup
 Study: 206713 (SWIFT-1)

Figure 27.19
 Kaplan-Meier Plot of Time to First Clinically Significant Exacerbation
 Requiring Hospitalisation and/or ED Visit




Note: Shaded areas represent 95% confidence intervals.
 f_e_km_exac_hosp.sas 10JUL2025 08:33

Page 3 of 3
 Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
 Population: FAS - High-dose ICS Subgroup
 Study: 213744 (SWIFT-2)


Figure 27.19
 Kaplan-Meier Plot of Time to First Clinically Significant Exacerbation
 Requiring Hospitalisation and/or ED Visit



Note: Shaded areas represent 95% confidence intervals.
 f_e_km_exac_hosp.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.20
Forest Plot of Time to First Clinically Significant Exacerbation Requiring Hospitalisation and/or ED Visit



/mnt/code/gvd/prod/tfl/f_e_forest_exac_hosp.sas 08JUL2025 17:26

2.5 Asthma-Exazerbation (Anzahl der Tage mit OCS)

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 1 of 2
Data as of 29APR2024

Table 27.13
Analysis of Total Number of Days with Oral Corticosteroids Associated with an Exacerbation
Requiring OCS per Subject

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n	35	50	37	60
LS Mean	20.71	12.88	14.44	11.43
95% CI	(13.88, 30.90)	(8.62, 19.24)	(10.54, 19.78)	(8.80, 14.86)
Depemokimab vs. Placebo				
Ratio		0.62		0.79
95% CI		(0.44, 0.88)		(0.54, 1.16)
p-value		0.008		0.228
p-value for Treatment by Study Interaction				

Note: Analysis performed using a general linear model assuming normal distribution, with the response variable log-transformed and covariates of treatment group, exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted FEV1.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Only subjects who received OCS due to an exacerbation are included in the analysis.
t_e_ocs_analy.sas 08JUL2025 17:23

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 2 of 2
Data as of 29APR2024


Table 27.13
Analysis of Total Number of Days with Oral Corticosteroids Associated with an Exacerbation
Requiring OCS per Subject

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n	72	110
LS Mean	17.43	12.29
95% CI	(13.78, 22.03)	(9.95, 15.17)
Depemokimab vs. Placebo		
Ratio		0.71
95% CI		(0.55, 0.91)
p-value		0.008
p-value for Treatment by Study Interaction		0.360

Note: Analysis performed using a general linear model assuming normal distribution, with the response variable log-transformed and covariates of treatment group, exacerbation history (2, 3, 4+), geographical region and baseline pre-bronchodilator percent predicted FEV1.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Only subjects who received OCS due to an exacerbation are included in the analysis.
t_e_ocs_analy.sas 08JUL2025 17:23

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.27
Forest Plot of Analysis of Total Number of Days with Oral Corticosteroids Associated
with an Exacerbation Requiring OCS per Subject



Note: Only subjects who received OCS due to an exacerbation are included in the analysis.
/mnt/code/gvd/prod/tfl/f_e_forest_exac_ocs.sas 07OCT2025 08:41

2.6 ACQ-5 - Veränderung im Vergleich zu Baseline

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 1 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 2

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	70	127	67	147
LS Mean (SE)	2.17 (0.101)	1.98 (0.075)	1.58 (0.102)	1.54 (0.068)
LS Mean Change (SE)	-0.31 (0.101)	-0.51 (0.075)	-0.73 (0.102)	-0.78 (0.068)
Depemokimab vs. Placebo				
Difference		-0.20		-0.05
95% CI		(-0.45, 0.05)		(-0.29, 0.19)
p-value		0.118		0.701
Corrected Hedges g		-0.23		-0.06
95% CI		(-0.53, 0.06)		(-0.35, 0.23)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 2

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	137	274
LS Mean (SE)	1.88 (0.072)	1.74 (0.050)
LS Mean Change (SE)	-0.52 (0.072)	-0.65 (0.050)
Depemokimab vs. Placebo		
Difference		-0.13
95% CI		(-0.31, 0.04)
p-value		0.130
Corrected Hedges g		
95% CI		(-0.37, 0.05)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 3 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 4

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	69	126	67	148
LS Mean (SE)	2.16 (0.105)	1.76 (0.077)	1.73 (0.111)	1.35 (0.074)
LS Mean Change (SE)	-0.32 (0.105)	-0.72 (0.077)	-0.59 (0.111)	-0.96 (0.074)
Depemokimab vs. Placebo				
Difference		-0.40		-0.38
95% CI		(-0.65, -0.14)		(-0.64, -0.11)
p-value		0.003		0.006
Corrected Hedges g		-0.46		-0.42
95% CI		(-0.75, -0.16)		(-0.71, -0.12)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 4

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	136	274
LS Mean (SE)	1.94 (0.076)	1.54 (0.053)
LS Mean Change (SE)	-0.46 (0.076)	-0.85 (0.053)
Depemokimab vs. Placebo		
Difference		-0.39
95% CI		(-0.58, -0.21)
p-value		<0.001
Corrected Hedges g		-0.44
95% CI		(-0.65, -0.24)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 5 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 8

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	67	123	68	149
LS Mean (SE)	1.93 (0.120)	1.69 (0.088)	1.70 (0.120)	1.33 (0.080)
LS Mean Change (SE)	-0.55 (0.120)	-0.80 (0.088)	-0.62 (0.120)	-0.98 (0.080)
Depemokimab vs. Placebo				
Difference		-0.24		-0.37
95% CI		(-0.54, 0.05)		(-0.65, -0.08)
p-value		0.104		0.012
Corrected Hedges g		-0.25		-0.37
95% CI		(-0.55, 0.05)		(-0.66, -0.08)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 8

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	135	272
LS Mean (SE)	1.81 (0.085)	1.50 (0.059)
LS Mean Change (SE)	-0.59 (0.085)	-0.89 (0.059)
Depemokimab vs. Placebo		
Difference		-0.31
95% CI		(-0.51, -0.10)
p-value		0.004
Corrected Hedges g		
95% CI		(-0.52, -0.11)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 7 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 12

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	67	125	66	149
LS Mean (SE)	1.77 (0.132)	1.70 (0.097)	1.59 (0.124)	1.33 (0.082)
LS Mean Change (SE)	-0.71 (0.132)	-0.78 (0.097)	-0.73 (0.124)	-0.98 (0.082)
Depemokimab vs. Placebo				
Difference		-0.07		-0.26
95% CI		(-0.39, 0.25)		(-0.55, 0.04)
p-value		0.668		0.087
Corrected Hedges g		-0.06		-0.25
95% CI		(-0.36, 0.23)		(-0.55, 0.04)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 12

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	133	274
LS Mean (SE)	1.67 (0.090)	1.51 (0.063)
LS Mean Change (SE)	-0.72 (0.090)	-0.89 (0.063)
Depemokimab vs. Placebo		
Difference		-0.16
95% CI		(-0.38, 0.05)
p-value		0.138
Corrected Hedges g		
95% CI		(-0.36, 0.05)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 9 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 16

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	68	121	65	148
LS Mean (SE)	1.59 (0.125)	1.74 (0.093)	1.54 (0.123)	1.34 (0.081)
LS Mean Change (SE)	-0.89 (0.125)	-0.75 (0.093)	-0.77 (0.123)	-0.98 (0.081)
Depemokimab vs. Placebo				
Difference		0.14		-0.21
95% CI		(-0.16, 0.45)		(-0.50, 0.08)
p-value		0.360		0.160
Corrected Hedges g		0.14		-0.21
95% CI		(-0.16, 0.44)		(-0.50, 0.08)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 16

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	133	269
LS Mean (SE)	1.56 (0.088)	1.53 (0.061)
LS Mean Change (SE)	-0.84 (0.088)	-0.87 (0.061)
Depemokimab vs. Placebo		
Difference		-0.03
95% CI		(-0.24, 0.18)
p-value		0.780
Corrected Hedges g		-0.03
95% CI		(-0.24, 0.18)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 11 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 20

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	65	120	66	147
LS Mean (SE)	1.72 (0.124)	1.72 (0.091)	1.66 (0.127)	1.31 (0.084)
LS Mean Change (SE)	-0.76 (0.124)	-0.76 (0.091)	-0.65 (0.127)	-1.01 (0.084)
Depemokimab vs. Placebo				
Difference		0.00		-0.35
95% CI		(-0.30, 0.31)		(-0.66, -0.05)
p-value		0.998		0.023
Corrected Hedges g				
95% CI		(-0.30, 0.30)		(-0.64, -0.05)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 20

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	131	267
LS Mean (SE)	1.69 (0.090)	1.50 (0.063)
LS Mean Change (SE)	-0.71 (0.090)	-0.89 (0.063)
Depemokimab vs. Placebo		
Difference		-0.19
95% CI		(-0.40, 0.03)
p-value		0.090
Corrected Hedges g		-0.18
95% CI		(-0.39, 0.03)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 13 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 24

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	66	121	64	142
LS Mean (SE)	1.67 (0.130)	1.76 (0.096)	1.63 (0.121)	1.41 (0.081)
LS Mean Change (SE)	-0.81 (0.130)	-0.72 (0.096)	-0.69 (0.121)	-0.91 (0.081)
Depemokimab vs. Placebo				
Difference		0.09		-0.22
95% CI		(-0.23, 0.41)		(-0.51, 0.07)
p-value		0.578		0.135
Corrected Hedges g				
95% CI		(-0.21, 0.39)		(-0.52, 0.07)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 24

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	130	263
LS Mean (SE)	1.65 (0.089)	1.58 (0.062)
LS Mean Change (SE)	-0.75 (0.089)	-0.82 (0.062)
Depemokimab vs. Placebo		
Difference		-0.07
95% CI		(-0.28, 0.14)
p-value		0.511
Corrected Hedges g		
95% CI		(-0.28, 0.14)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 15 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 26

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	65	122	68	147
LS Mean (SE)	1.89 (0.138)	1.77 (0.101)	1.65 (0.122)	1.47 (0.082)
LS Mean Change (SE)	-0.59 (0.138)	-0.71 (0.101)	-0.66 (0.122)	-0.85 (0.082)
Depemokimab vs. Placebo				
Difference		-0.12		-0.19
95% CI		(-0.45, 0.22)		(-0.48, 0.10)
p-value		0.496		0.205
Corrected Hedges g		-0.10		-0.19
95% CI		(-0.41, 0.20)		(-0.48, 0.10)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 26

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	133	269
LS Mean (SE)	1.76 (0.091)	1.61 (0.064)
LS Mean Change (SE)	-0.64 (0.091)	-0.78 (0.064)
Depemokimab vs. Placebo		
Difference		-0.15
95% CI		(-0.37, 0.07)
p-value		0.190
Corrected Hedges g		-0.14
95% CI		(-0.35, 0.07)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 17 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 28

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	60	122	66	144
LS Mean (SE)	1.76 (0.136)	1.65 (0.099)	1.54 (0.118)	1.23 (0.079)
LS Mean Change (SE)	-0.73 (0.136)	-0.84 (0.099)	-0.78 (0.118)	-1.08 (0.079)
Depemokimab vs. Placebo				
Difference		-0.11		-0.31
95% CI		(-0.44, 0.22)		(-0.59, -0.02)
p-value		0.511		0.035
Corrected Hedges g		-0.10		-0.32
95% CI		(-0.41, 0.21)		(-0.61, -0.03)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 28

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	126	266
LS Mean (SE)	1.64 (0.090)	1.43 (0.062)
LS Mean Change (SE)	-0.76 (0.090)	-0.97 (0.062)
Depemokimab vs. Placebo		
Difference		-0.21
95% CI		(-0.43, 0.00)
p-value		0.054
Corrected Hedges g		
95% CI		(-0.42, 0.00)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 19 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 32

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	65	117	66	142
LS Mean (SE)	1.70 (0.132)	1.61 (0.097)	1.64 (0.114)	1.24 (0.076)
LS Mean Change (SE)	-0.78 (0.132)	-0.87 (0.097)	-0.68 (0.114)	-1.08 (0.076)
Depemokimab vs. Placebo				
Difference		-0.09		-0.40
95% CI		(-0.42, 0.23)		(-0.67, -0.13)
p-value		0.569		0.005
Corrected Hedges g		-0.09		-0.43
95% CI		(-0.39, 0.21)		(-0.73, -0.14)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 32

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	131	259
LS Mean (SE)	1.67 (0.087)	1.41 (0.061)
LS Mean Change (SE)	-0.73 (0.087)	-0.98 (0.061)
Depemokimab vs. Placebo		
Difference		-0.25
95% CI		(-0.46, -0.04)
p-value		0.019
Corrected Hedges g		
95% CI		(-0.47, -0.04)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 36

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	62	120	66	144
LS Mean (SE)	1.71 (0.133)	1.50 (0.097)	1.50 (0.116)	1.21 (0.077)
LS Mean Change (SE)	-0.77 (0.133)	-0.98 (0.097)	-0.81 (0.116)	-1.11 (0.077)
Depemokimab vs. Placebo				
Difference		-0.21		-0.29
95% CI		(-0.53, 0.12)		(-0.57, -0.02)
p-value		0.215		0.039
Corrected Hedges g		-0.19		-0.31
95% CI		(-0.50, 0.11)		(-0.60, -0.02)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 36

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	128	264
LS Mean (SE)	1.60 (0.088)	1.35 (0.061)
LS Mean Change (SE)	-0.79 (0.088)	-1.04 (0.061)
Depemokimab vs. Placebo		
Difference		-0.25
95% CI		(-0.46, -0.04)
p-value		0.022
Corrected Hedges g		-0.25
95% CI		(-0.46, -0.04)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 23 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 40

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	64	118	66	140
LS Mean (SE)	1.67 (0.132)	1.65 (0.097)	1.34 (0.121)	1.41 (0.081)
LS Mean Change (SE)	-0.82 (0.132)	-0.83 (0.097)	-0.98 (0.121)	-0.91 (0.081)
Depemokimab vs. Placebo				
Difference		-0.02		0.07
95% CI		(-0.34, 0.31)		(-0.22, 0.36)
p-value		0.916		0.640
Corrected Hedges g		-0.02		0.07
95% CI		(-0.32, 0.29)		(-0.22, 0.36)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 40

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	130	258
LS Mean (SE)	1.49 (0.089)	1.52 (0.062)
LS Mean Change (SE)	-0.91 (0.089)	-0.87 (0.062)
Depemokimab vs. Placebo		
Difference		0.03
95% CI		(-0.18, 0.25)
p-value		0.756
Corrected Hedges g		0.03
95% CI		(-0.18, 0.24)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 25 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 44

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	62	119	62	139
LS Mean (SE)	1.65 (0.128)	1.72 (0.093)	1.47 (0.133)	1.39 (0.088)
LS Mean Change (SE)	-0.84 (0.128)	-0.76 (0.093)	-0.85 (0.133)	-0.93 (0.088)
Depemokimab vs. Placebo				
Difference		0.08		-0.08
95% CI		(-0.24, 0.39)		(-0.39, 0.24)
p-value		0.637		0.625
Corrected Hedges g		0.07		-0.08
95% CI		(-0.23, 0.38)		(-0.37, 0.22)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 44

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	124	258
LS Mean (SE)	1.55 (0.092)	1.54 (0.064)
LS Mean Change (SE)	-0.85 (0.092)	-0.85 (0.064)
Depemokimab vs. Placebo		
Difference		-0.01
95% CI		(-0.23, 0.21)
p-value		0.954
Corrected Hedges g		
95% CI		(-0.22, 0.21)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 27 of 30
Data as of 29APR2024

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 48

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	63	122	64	141
LS Mean (SE)	1.73 (0.128)	1.66 (0.093)	1.60 (0.134)	1.33 (0.090)
LS Mean Change (SE)	-0.75 (0.128)	-0.82 (0.093)	-0.71 (0.134)	-0.98 (0.090)
Depemokimab vs. Placebo				
Difference		-0.07		-0.27
95% CI		(-0.38, 0.24)		(-0.59, 0.05)
p-value		0.651		0.098
Corrected Hedges g		-0.07		-0.25
95% CI		(-0.37, 0.23)		(-0.55, 0.04)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 48

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	127	263
LS Mean (SE)	1.66 (0.093)	1.48 (0.064)
LS Mean Change (SE)	-0.73 (0.093)	-0.92 (0.064)
Depemokimab vs. Placebo		
Difference		-0.18
95% CI		(-0.41, 0.04)
p-value		0.107
Corrected Hedges g		
95% CI		(-0.39, 0.04)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 52

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	61	120	66	140
LS Mean (SE)	1.61 (0.124)	1.73 (0.090)	1.58 (0.130)	1.45 (0.088)
LS Mean Change (SE)	-0.88 (0.124)	-0.75 (0.090)	-0.74 (0.130)	-0.87 (0.088)
Depemokimab vs. Placebo				
Difference		0.12		-0.13
95% CI		(-0.18, 0.43)		(-0.44, 0.18)
p-value		0.424		0.407
Corrected Hedges g		0.13		-0.12
95% CI		(-0.18, 0.43)		(-0.42, 0.17)
p-value for Treatment by Study Interaction				

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.3
Analysis of Change from Baseline in ACQ-5 Score

Visit: Week 52

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	127	260
LS Mean (SE)	1.59 (0.090)	1.59 (0.063)
LS Mean Change (SE)	-0.80 (0.090)	-0.81 (0.063)
Depemokimab vs. Placebo		
Difference		-0.01
95% CI		(-0.22, 0.21)
p-value		0.953
Corrected Hedges g		-0.01
95% CI		(-0.22, 0.21)
p-value for Treatment by Study Interaction		0.864


[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ACQ-5 score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline ACQ-5 score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_acq_analy.sas 08JUL2025 14:07

Page 1 of 3
Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.5
Line Plot of Analysis of Change from Baseline in ACQ-5 Score

Study: SWIFT-1




f_e_acq_analy_line.sas 08JUL2025 17:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.5
Line Plot of Analysis of Change from Baseline in ACQ-5 Score

Study: SWIFT-2




f_e_acq_analy_line.sas 08JUL2025 17:24

Protocol: 217780 Depemokimab GVD Asthma
 Population: FAS - High-dose ICS Subgroup

Figure 27.5
 Line Plot of Analysis of Change from Baseline in ACQ-5 Score


Study: SWIFT-1 & SWIFT-2



f_e_acq_analy_line.sas 08JUL2025 17:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.6
Forest Plot of Analysis of Change from Baseline in ACQ-5 Score at Week 52



Note: Analysis performed using a repeated measures model with covariates as per corresponding analysis table.
No. of Subjects is the number of subjects with analysable data for one or more timepoints for the two treatment groups of interest.
/mnt/code/gvd/prod/tf/f_e_acq_forest_chg.sas 08JUL2025 17:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 2 of 16
Data as of 29APR2024

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 2		
n	139	290
Responder [1]	42 (30%)	93 (32%)
Non-responder	97 (70%)	197 (68%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.09 (0.69, 1.74)
Unadjusted Relative Risk (Exact 95% CI)		1.06 (0.79, 1.56)
Risk Difference (%) (Exact 95% CI)		1.9 (-7.9, 11.1)
z-test p-value		0.699
Logistic Regression Model		
Odds Ratio (95% CI)		1.07 (0.67, 1.71)
p-value		0.791
Poisson Regression Model		
Relative Risk (95% CI)		1.06 (0.80, 1.41)
p-value		0.675

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 3 of 16
Data as of 29APR2024

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 4				
n	71	132	68	158
Responder [1]	16 (23%)	45 (34%)	21 (31%)	74 (47%)
Non-responder	55 (77%)	87 (66%)	47 (69%)	84 (53%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.78 (0.88, 3.70)		1.97 (1.04, 3.80)
Unadjusted Relative Risk (Exact 95% CI)		1.51 (0.93, 2.80)		1.52 (1.00, 2.57)
Risk Difference (%) (Exact 95% CI)		11.6 (-2.5, 23.8)		16.0 (0.3, 28.9)
z-test p-value		0.087		0.026
Logistic Regression Model				
Odds Ratio (95% CI)		1.85 (0.92, 3.72)		2.20 (1.15, 4.21)
p-value		0.085		0.018
Poisson Regression Model				
Relative Risk (95% CI)		1.48 (0.94, 2.34)		1.55 (1.07, 2.24)
p-value		0.089		0.020

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 4 of 16
Data as of 29APR2024

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 4		
n	139	290
Responder [1]	37 (27%)	119 (41%)
Non-responder	102 (73%)	171 (59%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.92 (1.21, 3.08)
Unadjusted Relative Risk (Exact 95% CI)		1.54 (1.11, 2.21)
Risk Difference (%) (Exact 95% CI)		14.4 (3.0, 23.5)
z-test p-value		0.004
Logistic Regression Model		
Odds Ratio (95% CI)		2.01 (1.27, 3.19)
p-value		0.004
Poisson Regression Model		
Relative Risk (95% CI)		1.53 (1.15, 2.04)
p-value		0.004

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 5 of 16
Data as of 29APR2024

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 8				
n	71	132	68	158
Responder [1]	19 (27%)	47 (36%)	26 (38%)	73 (46%)
Non-responder	52 (73%)	85 (64%)	42 (62%)	85 (54%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.51 (0.77, 3.04)		1.39 (0.75, 2.60)
Unadjusted Relative Risk (Exact 95% CI)		1.33 (0.86, 2.25)		1.21 (0.86, 1.85)
Risk Difference (%) (Exact 95% CI)		8.8 (-5.3, 21.7)		8.0 (-6.6, 21.6)
z-test p-value		0.200		0.269
Logistic Regression Model				
Odds Ratio (95% CI)		1.64 (0.81, 3.29)		1.50 (0.80, 2.83)
p-value		0.166		0.210
Poisson Regression Model				
Relative Risk (95% CI)		1.34 (0.87, 2.05)		1.23 (0.88, 1.73)
p-value		0.181		0.233

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 6 of 16
Data as of 29APR2024

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 8		
n	139	290
Responder [1]	45 (32%)	120 (41%)
Non-responder	94 (68%)	170 (59%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.47 (0.95, 2.32)
Unadjusted Relative Risk (Exact 95% CI)		1.28 (0.97, 1.76)
Risk Difference (%) (Exact 95% CI)		9.0 (-1.2, 18.5)
z-test p-value		0.073
Logistic Regression Model		
Odds Ratio (95% CI)		1.54 (0.97, 2.44)
p-value		0.066
Poisson Regression Model		
Relative Risk (95% CI)		1.27 (0.98, 1.66)
p-value		0.075

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 7 of 16
Data as of 29APR2024

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 12				
n	71	132	68	158
Responder [1]	22 (31%)	52 (39%)	26 (38%)	73 (46%)
Non-responder	49 (69%)	80 (61%)	42 (62%)	85 (54%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.45 (0.75, 2.82)		1.39 (0.75, 2.60)
Unadjusted Relative Risk (Exact 95% CI)		1.27 (0.86, 2.02)		1.21 (0.86, 1.85)
Risk Difference (%) (Exact 95% CI)		8.4 (-5.9, 21.7)		8.0 (-6.6, 21.6)
z-test p-value		0.236		0.269
Logistic Regression Model				
Odds Ratio (95% CI)		1.54 (0.79, 3.01)		1.51 (0.81, 2.82)
p-value		0.209		0.199
Poisson Regression Model				
Relative Risk (95% CI)		1.27 (0.85, 1.89)		1.23 (0.87, 1.73)
p-value		0.244		0.235

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 8 of 16
Data as of 29APR2024

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 12		
n	139	290
Responder [1]	48 (35%)	125 (43%)
Non-responder	91 (65%)	165 (57%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.44 (0.93, 2.24)
Unadjusted Relative Risk (Exact 95% CI)		1.25 (0.96, 1.68)
Risk Difference (%) (Exact 95% CI)		8.6 (-1.6, 18.2)
z-test p-value		0.091
Logistic Regression Model		
Odds Ratio (95% CI)		1.49 (0.95, 2.35)
p-value		0.083
Poisson Regression Model		
Relative Risk (95% CI)		1.24 (0.96, 1.61)
p-value		0.101

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 9 of 16
Data as of 29APR2024

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 26				
n	71	132	68	158
Responder [1]	23 (32%)	47 (36%)	23 (34%)	62 (39%)
Non-responder	48 (68%)	85 (64%)	45 (66%)	96 (61%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.15 (0.60, 2.24)		1.26 (0.67, 2.41)
Unadjusted Relative Risk (Exact 95% CI)		1.10 (0.74, 1.76)		1.16 (0.80, 1.85)
Risk Difference (%) (Exact 95% CI)		3.2 (-11.0, 16.6)		5.4 (-8.9, 18.7)
z-test p-value		0.647		0.441
Logistic Regression Model				
Odds Ratio (95% CI)		1.14 (0.60, 2.16)		1.31 (0.68, 2.54)
p-value		0.690		0.414
Poisson Regression Model				
Relative Risk (95% CI)		1.08 (0.73, 1.61)		1.18 (0.82, 1.69)
p-value		0.695		0.379

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 10 of 16
Data as of 29APR2024

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 26		
n	139	290
Responder [1]	46 (33%)	109 (38%)
Non-responder	93 (67%)	181 (62%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.22 (0.78, 1.91)
Unadjusted Relative Risk (Exact 95% CI)		1.14 (0.86, 1.58)
Risk Difference (%) (Exact 95% CI)		4.5 (-5.5, 13.9)
z-test p-value		0.365
Logistic Regression Model		
Odds Ratio (95% CI)		1.20 (0.76, 1.90)
p-value		0.437
Poisson Regression Model		
Relative Risk (95% CI)		1.13 (0.86, 1.48)
p-value		0.375

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 11 of 16
Data as of 29APR2024

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 28				
n	71	132	68	158
Responder [1]	24 (34%)	53 (40%)	28 (41%)	78 (49%)
Non-responder	47 (66%)	79 (60%)	40 (59%)	80 (51%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.31 (0.69, 2.52)		1.39 (0.75, 2.59)
Unadjusted Relative Risk (Exact 95% CI)		1.19 (0.81, 1.86)		1.20 (0.88, 1.77)
Risk Difference (%) (Exact 95% CI)		6.3 (-8.1, 19.9)		8.2 (-6.6, 22.2)
z-test p-value		0.374		0.258
Logistic Regression Model				
Odds Ratio (95% CI)		1.32 (0.70, 2.50)		1.55 (0.81, 2.95)
p-value		0.390		0.181
Poisson Regression Model				
Relative Risk (95% CI)		1.18 (0.80, 1.74)		1.22 (0.88, 1.69)
p-value		0.405		0.237

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 28		
n	139	290
Responder [1]	52 (37%)	131 (45%)
Non-responder	87 (63%)	159 (55%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.38 (0.89, 2.14)
Unadjusted Relative Risk (Exact 95% CI)		1.21 (0.94, 1.61)
Risk Difference (%) (Exact 95% CI)		7.8 (-2.5, 17.6)
z-test p-value		0.129
Logistic Regression Model		
Odds Ratio (95% CI)		1.41 (0.90, 2.21)
p-value		0.133
Poisson Regression Model		
Relative Risk (95% CI)		1.20 (0.94, 1.54)
p-value		0.151

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 13 of 16
Data as of 29APR2024

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 40				
n	71	132	68	158
Responder [1]	28 (39%)	46 (35%)	32 (47%)	66 (42%)
Non-responder	43 (61%)	86 (65%)	36 (53%)	92 (58%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.82 (0.44, 1.56)		0.81 (0.44, 1.49)
Unadjusted Relative Risk (Exact 95% CI)		0.88 (0.61, 1.38)		0.89 (0.65, 1.32)
Risk Difference (%) (Exact 95% CI)		-4.6 (-18.9, 9.3)		-5.3 (-19.6, 9.2)
z-test p-value		0.518		0.463
Logistic Regression Model				
Odds Ratio (95% CI)		0.78 (0.42, 1.47)		0.83 (0.44, 1.55)
p-value		0.445		0.557
Poisson Regression Model				
Relative Risk (95% CI)		0.88 (0.60, 1.28)		0.90 (0.66, 1.24)
p-value		0.506		0.533

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 40		
n	139	290
Responder [1]	60 (43%)	112 (39%)
Non-responder	79 (57%)	178 (61%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		0.83 (0.54, 1.28)
Unadjusted Relative Risk (Exact 95% CI)		0.89 (0.71, 1.18)
Risk Difference (%) (Exact 95% CI)		-4.5 (-14.6, 5.5)
z-test p-value		0.369
Logistic Regression Model		
Odds Ratio (95% CI)		0.79 (0.51, 1.23)
p-value		0.307
Poisson Regression Model		
Relative Risk (95% CI)		0.89 (0.70, 1.14)
p-value		0.347

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 15 of 16
Data as of 29APR2024

Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 52				
n	71	132	68	158
Responder [1]	30 (42%)	45 (34%)	24 (35%)	66 (42%)
Non-responder	41 (58%)	87 (66%)	44 (65%)	92 (58%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.71 (0.38, 1.34)		1.32 (0.70, 2.49)
Unadjusted Relative Risk (Exact 95% CI)		0.81 (0.56, 1.21)		1.18 (0.83, 1.87)
Risk Difference (%) (Exact 95% CI)		-8.2 (-22.5, 5.9)		6.5 (-8.1, 19.9)
z-test p-value		0.251		0.362
Logistic Regression Model				
Odds Ratio (95% CI)		0.66 (0.35, 1.24)		1.38 (0.73, 2.62)
p-value		0.194		0.319
Poisson Regression Model				
Relative Risk (95% CI)		0.81 (0.56, 1.17)		1.20 (0.84, 1.71)
p-value		0.253		0.308
p-value for Treatment by Study Interaction				

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 16 of 16
Data as of 29APR2024


Table 27.4
Analysis of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 52		
n	139	290
Responder [1]	54 (39%)	111 (38%)
Non-responder	85 (61%)	179 (62%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		0.98 (0.63, 1.51)
Unadjusted Relative Risk (Exact 95% CI)		0.99 (0.77, 1.33)
Risk Difference (%) (Exact 95% CI)		-0.6 (-10.7, 9.2)
z-test p-value		0.910
Logistic Regression Model		
Odds Ratio (95% CI)		0.95 (0.61, 1.49)
p-value		0.816
Poisson Regression Model		
Relative Risk (95% CI)		0.98 (0.76, 1.26)
p-value		0.877
p-value for Treatment by Study Interaction		0.884

[1] Response is defined as a reduction in ACQ-5 score of at least 0.9 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ACQ-5 score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: Weeks 6, 20, 24, 32, 36, 44 and 48 have been excluded and AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_acq.sas 08JUL2025 17:28

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup


Figure 27.7
Forest Plot of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)
(odds ratios)



No. of Subjects is the number of subjects with non-missing baseline covariates.
/mnt/code/gvd/prod/tf/f_e_acq_forest_or.sas 10JUL2025 08:34

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.8
Forest Plot of Proportion of Responders according to ACQ-5 Score
(responder defined as achieving ≥ 0.9 -point reduction from baseline)
(relative risks)



No. of Subjects is the number of subjects with non-missing baseline covariates.
/mnt/code/gvd/prod/tf/f_e_acq_forest_rr.sas 10JUL2025 08:34

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 2 of 10
Data as of 29APR2024

Table 27.15
Analysis of Proportion of Responders according to PGI-C
(responder defined as achieving categories of "much better" or "a little better")

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 12		
n	139	290
Responder [1]	87 (63%)	211 (73%)
Non-responder	52 (37%)	79 (27%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.60 (1.01, 2.51)
Unadjusted Relative Risk (Exact 95% CI)		1.16 (1.00, 1.40)
Risk Difference (%) (Exact 95% CI)		10.2 (0.0, 20.0)
z-test p-value		0.033
Logistic Regression Model		
Odds Ratio (95% CI)		1.49 (0.95, 2.33)
p-value		0.082
Poisson Regression Model		
Relative Risk (95% CI)		1.13 (0.98, 1.31)
p-value		0.082

[1] Response is defined as reporting "much better" or "a little better" on the PGI-C scale compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgic.sas 08JUL2025 23:55

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 3 of 10
Data as of 29APR2024

Table 27.15
Analysis of Proportion of Responders according to PGI-C
(responder defined as achieving categories of "much better" or "a little better")

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 20				
n	71	132	68	158
Responder [1]	42 (59%)	84 (64%)	41 (60%)	125 (79%)
Non-responder	29 (41%)	48 (36%)	27 (40%)	33 (21%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.21 (0.64, 2.27)		2.49 (1.28, 4.84)
Unadjusted Relative Risk (Exact 95% CI)		1.08 (0.86, 1.45)		1.31 (1.03, 1.72)
Risk Difference (%) (Exact 95% CI)		4.5 (-9.6, 18.9)		18.8 (4.2, 32.5)
z-test p-value		0.531		0.004
Logistic Regression Model				
Odds Ratio (95% CI)		1.19 (0.63, 2.24)		2.58 (1.33, 4.99)
p-value		0.597		0.006
Poisson Regression Model				
Relative Risk (95% CI)		1.05 (0.84, 1.32)		1.32 (1.09, 1.58)
p-value		0.656		0.005

[1] Response is defined as reporting "much better" or "a little better" on the PGI-C scale compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgic.sas 08JUL2025 23:55

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.15
Analysis of Proportion of Responders according to PGI-C
(responder defined as achieving categories of "much better" or "a little better")

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 20		
n	139	290
Responder [1]	83 (60%)	209 (72%)
Non-responder	56 (40%)	81 (28%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.74 (1.11, 2.72)
Unadjusted Relative Risk (Exact 95% CI)		1.21 (1.01, 1.47)
Risk Difference (%) (Exact 95% CI)		12.4 (2.0, 22.2)
z-test p-value		0.011
Logistic Regression Model		
Odds Ratio (95% CI)		1.70 (1.09, 2.67)
p-value		0.021
Poisson Regression Model		
Relative Risk (95% CI)		1.19 (1.03, 1.38)
p-value		0.017

[1] Response is defined as reporting "much better" or "a little better" on the PGI-C scale compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgic.sas 08JUL2025 23:55

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 5 of 10
Data as of 29APR2024

Table 27.15
Analysis of Proportion of Responders according to PGI-C
(responder defined as achieving categories of "much better" or "a little better")

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 26				
n	71	132	68	158
Responder [1]	43 (61%)	86 (65%)	47 (69%)	122 (77%)
Non-responder	28 (39%)	46 (35%)	21 (31%)	36 (23%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.22 (0.64, 2.30)		1.51 (0.76, 2.98)
Unadjusted Relative Risk (Exact 95% CI)		1.08 (0.87, 1.44)		1.12 (0.94, 1.41)
Risk Difference (%) (Exact 95% CI)		4.6 (-9.3, 18.9)		8.1 (-4.4, 21.6)
z-test p-value		0.518		0.199
Logistic Regression Model				
Odds Ratio (95% CI)		1.23 (0.65, 2.34)		1.62 (0.83, 3.12)
p-value		0.526		0.154
Poisson Regression Model				
Relative Risk (95% CI)		1.06 (0.85, 1.33)		1.13 (0.95, 1.35)
p-value		0.598		0.173

[1] Response is defined as reporting "much better" or "a little better" on the PGI-C scale compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgic.sas 08JUL2025 23:55

Table 27.15
Analysis of Proportion of Responders according to PGI-C
(responder defined as achieving categories of "much better" or "a little better")

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 26		
n	139	290
Responder [1]	90 (65%)	208 (72%)
Non-responder	49 (35%)	82 (28%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.38 (0.87, 2.17)
Unadjusted Relative Risk (Exact 95% CI)		1.11 (0.96, 1.32)
Risk Difference (%) (Exact 95% CI)		7.0 (-2.5, 16.8)
z-test p-value		0.143
Logistic Regression Model		
Odds Ratio (95% CI)		1.38 (0.88, 2.18)
p-value		0.158
Poisson Regression Model		
Relative Risk (95% CI)		1.11 (0.96, 1.28)
p-value		0.156

[1] Response is defined as reporting "much better" or "a little better" on the PGI-C scale compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgic.sas 08JUL2025 23:55

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 7 of 10
Data as of 29APR2024

Table 27.15
Analysis of Proportion of Responders according to PGI-C
(responder defined as achieving categories of "much better" or "a little better")

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 40				
n	71	132	68	158
Responder [1]	47 (66%)	86 (65%)	51 (75%)	114 (72%)
Non-responder	24 (34%)	46 (35%)	17 (25%)	44 (28%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.95 (0.49, 1.83)		0.86 (0.42, 1.72)
Unadjusted Relative Risk (Exact 95% CI)		0.98 (0.80, 1.26)		0.96 (0.82, 1.20)
Risk Difference (%) (Exact 95% CI)		-1.0 (-14.5, 13.2)		-2.8 (-14.9, 10.6)
z-test p-value		0.882		0.659
Logistic Regression Model				
Odds Ratio (95% CI)		0.95 (0.49, 1.84)		0.89 (0.45, 1.77)
p-value		0.884		0.743
Poisson Regression Model				
Relative Risk (95% CI)		0.98 (0.78, 1.22)		0.98 (0.82, 1.16)
p-value		0.833		0.783

[1] Response is defined as reporting "much better" or "a little better" on the PGI-C scale compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgic.sas 08JUL2025 23:55

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.15
Analysis of Proportion of Responders according to PGI-C
(responder defined as achieving categories of "much better" or "a little better")

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 40		
n	139	290
Responder [1]	98 (71%)	200 (69%)
Non-responder	41 (29%)	90 (31%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		0.93 (0.58, 1.48)
Unadjusted Relative Risk (Exact 95% CI)		0.98 (0.86, 1.15)
Risk Difference (%) (Exact 95% CI)		-1.5 (-10.7, 8.2)
z-test p-value		0.747
Logistic Regression Model		
Odds Ratio (95% CI)		0.92 (0.58, 1.47)
p-value		0.727
Poisson Regression Model		
Relative Risk (95% CI)		0.98 (0.85, 1.12)
p-value		0.740

[1] Response is defined as reporting "much better" or "a little better" on the PGI-C scale compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgic.sas 08JUL2025 23:55

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 9 of 10
Data as of 29APR2024

Table 27.15
Analysis of Proportion of Responders according to PGI-C
(responder defined as achieving categories of "much better" or "a little better")

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 52				
n	71	132	68	158
Responder [1]	45 (63%)	83 (63%)	49 (72%)	113 (72%)
Non-responder	26 (37%)	49 (37%)	19 (28%)	45 (28%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.98 (0.51, 1.85)		0.97 (0.49, 1.90)
Unadjusted Relative Risk (Exact 95% CI)		0.99 (0.80, 1.29)		0.99 (0.84, 1.25)
Risk Difference (%) (Exact 95% CI)		-0.5 (-14.2, 13.9)		-0.5 (-13.0, 13.2)
z-test p-value		0.944		0.935
Logistic Regression Model				
Odds Ratio (95% CI)		0.97 (0.51, 1.85)		0.94 (0.49, 1.83)
p-value		0.934		0.861
Poisson Regression Model				
Relative Risk (95% CI)		0.99 (0.79, 1.23)		0.99 (0.83, 1.18)
p-value		0.907		0.880
p-value for Treatment by Study Interaction				

[1] Response is defined as reporting "much better" or "a little better" on the PGI-C scale compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgic.sas 08JUL2025 23:55

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.15
Analysis of Proportion of Responders according to PGI-C
(responder defined as achieving categories of "much better" or "a little better")


	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 52		
n	139	290
Responder [1]	94 (68%)	196 (68%)
Non-responder	45 (32%)	94 (32%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.00 (0.63, 1.57)
Unadjusted Relative Risk (Exact 95% CI)		1.00 (0.87, 1.18)
Risk Difference (%) (Exact 95% CI)		0.0 (-9.4, 9.8)
z-test p-value		0.994
Logistic Regression Model		
Odds Ratio (95% CI)		0.95 (0.61, 1.50)
p-value		0.833
Poisson Regression Model		
Relative Risk (95% CI)		0.99 (0.86, 1.14)
p-value		0.853
p-value for Treatment by Study Interaction		0.592

[1] Response is defined as reporting "much better" or "a little better" on the PGI-C scale compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgic.sas 08JUL2025 23:55

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup


Figure 27.25
Forest Plot of Proportion of Responders according to PGI-C
(responder defined as achieving categories of "much better" or "a little better")
(odds ratios)



No. of Subjects is the number of subjects with non-missing baseline covariates.
/mnt/code/gvd/prod/tf/f_e_resp_pgic_or.sas 10JUL2025 08:35

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.26
Forest Plot of Proportion of Responders according to PGI-C
(responder defined as achieving categories of "much better" or "a little better")
(relative risks)



No. of Subjects is the number of subjects with non-missing baseline covariates.
/mnt/code/gvd/prod/tf/f_e_resp_pgi_c_rr.sas 10JUL2025 08:35

2.9 PGI-S - Responderanalyse

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 1 of 10
Data as of 29APR2024

Table 27.14
Analysis of Proportion of Responders according to PGI-S
(responder defined as achieving reduction in symptoms from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 12				
n	71	132	68	158
Responder [1]	31 (44%)	58 (44%)	30 (44%)	73 (46%)
Non-responder	40 (56%)	74 (56%)	38 (56%)	85 (54%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.01 (0.54, 1.89)		1.09 (0.59, 2.01)
Unadjusted Relative Risk (Exact 95% CI)		1.01 (0.73, 1.49)		1.05 (0.77, 1.51)
Risk Difference (%) (Exact 95% CI)		0.3 (-14.3, 14.5)		2.1 (-12.5, 16.4)
z-test p-value		0.970		0.773
Logistic Regression Model				
Odds Ratio (95% CI)		1.00 (0.52, 1.93)		1.01 (0.53, 1.90)
p-value		0.998		0.980
Poisson Regression Model				
Relative Risk (95% CI)		1.00 (0.72, 1.39)		1.03 (0.75, 1.41)
p-value		0.988		0.853

[1] Response is defined as achieving reduction in symptoms on the PGI-S scale compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history, (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note:AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgis.sas 08JUL2025 23:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 2 of 10
Data as of 29APR2024

Table 27.14
Analysis of Proportion of Responders according to PGI-S
(responder defined as achieving reduction in symptoms from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 12		
n	139	290
Responder [1]	61 (44%)	131 (45%)
Non-responder	78 (56%)	159 (55%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.05 (0.69, 1.62)
Unadjusted Relative Risk (Exact 95% CI)		1.03 (0.82, 1.34)
Risk Difference (%) (Exact 95% CI)		1.3 (-9.0, 11.4)
z-test p-value		0.802
Logistic Regression Model		
Odds Ratio (95% CI)		0.99 (0.63, 1.56)
p-value		0.978
Poisson Regression Model		
Relative Risk (95% CI)		1.01 (0.81, 1.27)
p-value		0.909

[1] Response is defined as achieving reduction in symptoms on the PGI-S scale compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history, (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note:AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgis.sas 08JUL2025 23:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 3 of 10
Data as of 29APR2024

Table 27.14
Analysis of Proportion of Responders according to PGI-S
(responder defined as achieving reduction in symptoms from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 20				
n	71	132	68	158
Responder [1]	24 (34%)	56 (42%)	28 (41%)	74 (47%)
Non-responder	47 (66%)	76 (58%)	40 (59%)	84 (53%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.44 (0.76, 2.77)		1.26 (0.68, 2.34)
Unadjusted Relative Risk (Exact 95% CI)		1.26 (0.87, 1.97)		1.14 (0.83, 1.69)
Risk Difference (%) (Exact 95% CI)		8.6 (-5.9, 22.1)		5.7 (-8.9, 19.6)
z-test p-value		0.231		0.433
Logistic Regression Model				
Odds Ratio (95% CI)		1.52 (0.76, 3.01)		1.20 (0.62, 2.33)
p-value		0.233		0.587
Poisson Regression Model				
Relative Risk (95% CI)		1.24 (0.87, 1.78)		1.12 (0.81, 1.55)
p-value		0.235		0.498

[1] Response is defined as achieving reduction in symptoms on the PGI-S scale compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history, (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note:AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgis.sas 08JUL2025 23:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 4 of 10
Data as of 29APR2024

Table 27.14
Analysis of Proportion of Responders according to PGI-S
(responder defined as achieving reduction in symptoms from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 20		
n	139	290
Responder [1]	52 (37%)	130 (45%)
Non-responder	87 (63%)	160 (55%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.36 (0.88, 2.11)
Unadjusted Relative Risk (Exact 95% CI)		1.20 (0.94, 1.59)
Risk Difference (%) (Exact 95% CI)		7.4 (-2.9, 17.2)
z-test p-value		0.146
Logistic Regression Model		
Odds Ratio (95% CI)		1.34 (0.84, 2.14)
p-value		0.219
Poisson Regression Model		
Relative Risk (95% CI)		1.18 (0.93, 1.50)
p-value		0.177

[1] Response is defined as achieving reduction in symptoms on the PGI-S scale compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history, (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note:AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgis.sas 08JUL2025 23:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 5 of 10
Data as of 29APR2024

Table 27.14
Analysis of Proportion of Responders according to PGI-S
(responder defined as achieving reduction in symptoms from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 26				
n	71	132	68	158
Responder [1]	29 (41%)	55 (42%)	29 (43%)	71 (45%)
Non-responder	42 (59%)	77 (58%)	39 (57%)	87 (55%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.03 (0.55, 1.95)		1.10 (0.60, 2.04)
Unadjusted Relative Risk (Exact 95% CI)		1.02 (0.73, 1.55)		1.05 (0.77, 1.54)
Risk Difference (%) (Exact 95% CI)		0.8 (-13.7, 14.9)		2.3 (-12.3, 16.4)
z-test p-value		0.910		0.751
Logistic Regression Model				
Odds Ratio (95% CI)		1.03 (0.54, 1.96)		1.01 (0.53, 1.96)
p-value		0.929		0.967
Poisson Regression Model				
Relative Risk (95% CI)		1.01 (0.72, 1.42)		1.04 (0.75, 1.43)
p-value		0.938		0.831

[1] Response is defined as achieving reduction in symptoms on the PGI-S scale compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history, (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note:AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgis.sas 08JUL2025 23:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 6 of 10
Data as of 29APR2024

Table 27.14
Analysis of Proportion of Responders according to PGI-S
(responder defined as achieving reduction in symptoms from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 26		
n	139	290
Responder [1]	58 (42%)	126 (43%)
Non-responder	81 (58%)	164 (57%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.07 (0.70, 1.65)
Unadjusted Relative Risk (Exact 95% CI)		1.04 (0.83, 1.38)
Risk Difference (%) (Exact 95% CI)		1.7 (-8.5, 11.7)
z-test p-value		0.736
Logistic Regression Model		
Odds Ratio (95% CI)		1.01 (0.64, 1.59)
p-value		0.962
Poisson Regression Model		
Relative Risk (95% CI)		1.02 (0.81, 1.29)
p-value		0.842

[1] Response is defined as achieving reduction in symptoms on the PGI-S scale compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history, (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note:AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgis.sas 08JUL2025 23:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 7 of 10
Data as of 29APR2024

Table 27.14
Analysis of Proportion of Responders according to PGI-S
(responder defined as achieving reduction in symptoms from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 40				
n	71	132	68	158
Responder [1]	26 (37%)	57 (43%)	27 (40%)	69 (44%)
Non-responder	45 (63%)	75 (57%)	41 (60%)	89 (56%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.32 (0.70, 2.50)		1.18 (0.64, 2.20)
Unadjusted Relative Risk (Exact 95% CI)		1.18 (0.83, 1.79)		1.10 (0.79, 1.64)
Risk Difference (%) (Exact 95% CI)		6.6 (-7.9, 20.3)		4.0 (-10.6, 17.7)
z-test p-value		0.365		0.581
Logistic Regression Model				
Odds Ratio (95% CI)		1.40 (0.71, 2.78)		1.10 (0.57, 2.15)
p-value		0.334		0.770
Poisson Regression Model				
Relative Risk (95% CI)		1.16 (0.82, 1.64)		1.08 (0.78, 1.51)
p-value		0.400		0.631

[1] Response is defined as achieving reduction in symptoms on the PGI-S scale compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history, (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note:AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgis.sas 08JUL2025 23:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 8 of 10
Data as of 29APR2024

Table 27.14
Analysis of Proportion of Responders according to PGI-S
(responder defined as achieving reduction in symptoms from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 40		
n	139	290
Responder [1]	53 (38%)	126 (43%)
Non-responder	86 (62%)	164 (57%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.25 (0.81, 1.93)
Unadjusted Relative Risk (Exact 95% CI)		1.14 (0.89, 1.57)
Risk Difference (%) (Exact 95% CI)		5.3 (-4.9, 15.1)
z-test p-value		0.296
Logistic Regression Model		
Odds Ratio (95% CI)		1.22 (0.77, 1.96)
p-value		0.397
Poisson Regression Model		
Relative Risk (95% CI)		1.12 (0.88, 1.42)
p-value		0.343

[1] Response is defined as achieving reduction in symptoms on the PGI-S scale compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history, (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note:AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgis.sas 08JUL2025 23:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 9 of 10
Data as of 29APR2024

Table 27.14
Analysis of Proportion of Responders according to PGI-S
(responder defined as achieving reduction in symptoms from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 52				
n	71	132	68	158
Responder [1]	30 (42%)	54 (41%)	26 (38%)	68 (43%)
Non-responder	41 (58%)	78 (59%)	42 (62%)	90 (57%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.95 (0.51, 1.78)		1.22 (0.66, 2.29)
Unadjusted Relative Risk (Exact 95% CI)		0.97 (0.69, 1.45)		1.13 (0.80, 1.72)
Risk Difference (%) (Exact 95% CI)		-1.3 (-15.8, 12.8)		4.8 (-9.8, 18.5)
z-test p-value		0.853		0.502
Logistic Regression Model				
Odds Ratio (95% CI)		0.92 (0.48, 1.77)		1.15 (0.61, 2.20)
p-value		0.811		0.664
Poisson Regression Model				
Relative Risk (95% CI)		0.96 (0.69, 1.34)		1.11 (0.79, 1.55)
p-value		0.814		0.559
p-value for Treatment by Study Interaction				

[1] Response is defined as achieving reduction in symptoms on the PGI-S scale compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history, (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note:AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgis.sas 08JUL2025 23:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup


Table 27.14
Analysis of Proportion of Responders according to PGI-S
(responder defined as achieving reduction in symptoms from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 52		
n	139	290
Responder [1]	56 (40%)	122 (42%)
Non-responder	83 (60%)	168 (58%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.08 (0.70, 1.66)
Unadjusted Relative Risk (Exact 95% CI)		1.04 (0.82, 1.40)
Risk Difference (%) (Exact 95% CI)		1.8 (-8.4, 11.7)
z-test p-value		0.727
Logistic Regression Model		
Odds Ratio (95% CI)		1.01 (0.64, 1.59)
p-value		0.958
Poisson Regression Model		
Relative Risk (95% CI)		1.03 (0.81, 1.30)
p-value		0.828
p-value for Treatment by Study Interaction		0.866

[1] Response is defined as achieving reduction in symptoms on the PGI-S scale compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history, (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline PGI-S score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note:AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_pgis.sas 08JUL2025 23:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup


Figure 27.23
Forest Plot of Proportion of Responders according to PGI-S
(responder defined as achieving reduction in symptoms from baseline)
(odds ratios)



No. of Subjects is the number of subjects with non-missing baseline covariates.
/mnt/code/gvd/prod/tf/f_e_resp_pgis_or.sas 10JUL2025 08:34

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.24
Forest Plot of Proportion of Responders according to PGI-S
(responder defined as achieving reduction in symptoms from baseline)
(relative risks)



No. of Subjects is the number of subjects with non-missing baseline covariates.
/mnt/code/gvd/prod/tf/f_e_resp_pgis_rr.sas 10JUL2025 08:35

2.10 ADSD - Veränderung im Vergleich zu Baseline

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 1 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 1

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	64	121	65	149
LS Mean (SE)	2.36 (0.152)	2.19 (0.111)	1.99 (0.131)	1.81 (0.086)
LS Mean Change (SE)	-0.37 (0.152)	-0.53 (0.111)	-0.29 (0.131)	-0.47 (0.086)
Depemokimab vs. Placebo				
Difference		-0.17		-0.17
95% CI		(-0.54, 0.20)		(-0.48, 0.14)
p-value		0.378		0.271
Corrected Hedges g		-0.14		-0.16
95% CI		(-0.44, 0.17)		(-0.46, 0.13)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 2 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 1

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	129	270
LS Mean (SE)	2.17 (0.067)	1.98 (0.046)
LS Mean Change (SE)	-0.31 (0.067)	-0.50 (0.046)
Depemokimab vs. Placebo		
Difference		-0.19
95% CI		(-0.35, -0.03)
p-value		0.021
Corrected Hedges g		
95% CI		(-0.46, -0.04)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 2

Page 3 of 52
Data as of 29APR2024

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	65	119	66	152
LS Mean (SE)	2.16 (0.152)	2.05 (0.111)	1.80 (0.131)	1.52 (0.086)
LS Mean Change (SE)	-0.57 (0.152)	-0.68 (0.111)	-0.48 (0.131)	-0.76 (0.086)
Depemokimab vs. Placebo				
Difference		-0.11		-0.29
95% CI		(-0.48, 0.26)		(-0.59, 0.02)
p-value		0.564		0.071
Corrected Hedges g		-0.09		-0.27
95% CI		(-0.39, 0.21)		(-0.56, 0.02)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 2

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	131	271
LS Mean (SE)	1.98 (0.081)	1.76 (0.056)
LS Mean Change (SE)	-0.51 (0.081)	-0.73 (0.056)
Depemokimab vs. Placebo		
Difference		-0.22
95% CI		(-0.41, -0.03)
p-value		0.027
Corrected Hedges g		
95% CI		(-0.45, -0.03)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 3

Page 5 of 52
Data as of 29APR2024

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	64	119	65	146
LS Mean (SE)	2.12 (0.152)	1.90 (0.111)	1.78 (0.131)	1.40 (0.086)
LS Mean Change (SE)	-0.60 (0.152)	-0.83 (0.111)	-0.50 (0.131)	-0.88 (0.086)
Depemokimab vs. Placebo				
Difference		-0.23		-0.38
95% CI		(-0.60, 0.14)		(-0.69, -0.07)
p-value		0.232		0.017
Corrected Hedges g		-0.19		-0.36
95% CI		(-0.49, 0.12)		(-0.66, -0.07)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 6 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 3

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	129	265
LS Mean (SE)	1.95 (0.087)	1.62 (0.060)
LS Mean Change (SE)	-0.53 (0.087)	-0.86 (0.060)
Depemokimab vs. Placebo		
Difference		-0.33
95% CI		(-0.54, -0.12)
p-value		0.002
Corrected Hedges g		
95% CI		(-0.55, -0.13)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
 Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
 Table 27.7
 Page 7 of 52
 Data as of 29APR2024

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 4

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	63	117	65	150
LS Mean (SE)	2.05 (0.152)	1.83 (0.111)	1.86 (0.131)	1.28 (0.086)
LS Mean Change (SE)	-0.68 (0.152)	-0.90 (0.111)	-0.41 (0.131)	-1.00 (0.086)
Depemokimab vs. Placebo				
Difference		-0.22		-0.59
95% CI		(-0.59, 0.15)		(-0.90, -0.28)
p-value		0.241		<0.001
Corrected Hedges g		-0.18		-0.56
95% CI		(-0.49, 0.12)		(-0.85, -0.26)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.

t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 8 of 52
Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 4

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	128	267
LS Mean (SE)	1.95 (0.092)	1.52 (0.064)
LS Mean Change (SE)	-0.53 (0.092)	-0.96 (0.064)
Depemokimab vs. Placebo		
Difference		-0.43
95% CI		(-0.65, -0.21)
p-value		<0.001
Corrected Hedges g		-0.41
95% CI		(-0.62, -0.20)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma

Page 9 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 5

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	60	119	66	148
LS Mean (SE)	2.07 (0.152)	1.73 (0.111)	1.80 (0.131)	1.24 (0.086)
LS Mean Change (SE)	-0.65 (0.152)	-0.99 (0.111)	-0.48 (0.131)	-1.03 (0.086)
Depemokimab vs. Placebo				
Difference		-0.35		-0.56
95% CI		(-0.72, 0.03)		(-0.87, -0.25)
p-value		0.068		<0.001
Corrected Hedges g		-0.29		-0.53
95% CI		(-0.60, 0.02)		(-0.82, -0.23)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.

t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 10 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 5

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	126	267
LS Mean (SE)	1.93 (0.097)	1.46 (0.067)
LS Mean Change (SE)	-0.55 (0.097)	-1.02 (0.067)
Depemokimab vs. Placebo		
Difference		-0.47
95% CI		(-0.71, -0.24)
p-value		<0.001
Corrected Hedges g		
95% CI		(-0.64, -0.22)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 6

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	60	116	66	146
LS Mean (SE)	2.04 (0.152)	1.62 (0.111)	1.80 (0.131)	1.22 (0.086)
LS Mean Change (SE)	-0.68 (0.152)	-1.10 (0.111)	-0.48 (0.131)	-1.05 (0.086)
Depemokimab vs. Placebo				
Difference		-0.41		-0.57
95% CI		(-0.78, -0.04)		(-0.88, -0.26)
p-value		0.029		<0.001
Corrected Hedges g		-0.35		-0.54
95% CI		(-0.66, -0.03)		(-0.84, -0.25)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 12 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 6

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	126	262
LS Mean (SE)	1.91 (0.102)	1.40 (0.070)
LS Mean Change (SE)	-0.57 (0.102)	-1.08 (0.070)
Depemokimab vs. Placebo		
Difference		-0.51
95% CI		(-0.75, -0.26)
p-value		<0.001
Corrected Hedges g		
95% CI		-0.44 (-0.66, -0.23)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 13 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 7

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	63	114	65	146
LS Mean (SE)	1.99 (0.151)	1.70 (0.111)	1.80 (0.131)	1.21 (0.086)
LS Mean Change (SE)	-0.74 (0.151)	-1.02 (0.111)	-0.48 (0.131)	-1.07 (0.086)
Depemokimab vs. Placebo				
Difference		-0.29		-0.59
95% CI		(-0.66, 0.08)		(-0.90, -0.28)
p-value		0.128		<0.001
Corrected Hedges g		-0.24		-0.56
95% CI		(-0.55, 0.07)		(-0.86, -0.27)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 7

Page 14 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	128	260
LS Mean (SE)	1.89 (0.105)	1.42 (0.073)
LS Mean Change (SE)	-0.59 (0.105)	-1.06 (0.073)
Depemokimab vs. Placebo		
Difference		-0.47
95% CI		(-0.72, -0.22)
p-value		<0.001
Corrected Hedges g		-0.40
95% CI		(-0.61, -0.19)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSND) - High-dose ICS Subgroup

Page 15 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 8

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	60	116	63	147
LS Mean (SE)	1.88 (0.151)	1.71 (0.111)	1.73 (0.132)	1.14 (0.086)
LS Mean Change (SE)	-0.84 (0.151)	-1.01 (0.111)	-0.55 (0.132)	-1.14 (0.086)
Depemokimab vs. Placebo				
Difference		-0.17		-0.59
95% CI		(-0.54, 0.20)		(-0.90, -0.28)
p-value		0.357		<0.001
Corrected Hedges g		-0.15		-0.56
95% CI		(-0.46, 0.17)		(-0.86, -0.26)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 8

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	123	263
LS Mean (SE)	1.81 (0.107)	1.39 (0.074)
LS Mean Change (SE)	-0.67 (0.107)	-1.09 (0.074)
Depemokimab vs. Placebo		
Difference		-0.42
95% CI		(-0.67, -0.16)
p-value		0.002
Corrected Hedges g		-0.35
95% CI		(-0.56, -0.13)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 17 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 9

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	60	114	62	144
LS Mean (SE)	1.84 (0.152)	1.68 (0.112)	1.72 (0.132)	1.14 (0.087)
LS Mean Change (SE)	-0.88 (0.152)	-1.04 (0.112)	-0.56 (0.132)	-1.13 (0.087)
Depemokimab vs. Placebo				
Difference		-0.16		-0.57
95% CI		(-0.53, 0.21)		(-0.89, -0.26)
p-value		0.408		<0.001
Corrected Hedges g		-0.13		-0.55
95% CI		(-0.44, 0.18)		(-0.85, -0.25)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 18 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 9

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	122	258
LS Mean (SE)	1.78 (0.106)	1.38 (0.073)
LS Mean Change (SE)	-0.70 (0.106)	-1.10 (0.073)
Depemokimab vs. Placebo		
Difference		-0.40
95% CI		(-0.65, -0.15)
p-value		0.003
Corrected Hedges g		
95% CI		(-0.56, -0.12)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 19 of 52
Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 10

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	61	112	61	141
LS Mean (SE)	1.77 (0.152)	1.64 (0.112)	1.67 (0.133)	1.12 (0.087)
LS Mean Change (SE)	-0.95 (0.152)	-1.09 (0.112)	-0.60 (0.133)	-1.16 (0.087)
Depemokimab vs. Placebo				
Difference		-0.13		-0.55
95% CI		(-0.50, 0.24)		(-0.87, -0.24)
p-value		0.486		<0.001
Corrected Hedges g		-0.11		-0.53
95% CI		(-0.42, 0.20)		(-0.84, -0.23)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.

t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 20 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 10

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	122	253
LS Mean (SE)	1.72 (0.109)	1.35 (0.076)
LS Mean Change (SE)	-0.76 (0.109)	-1.13 (0.076)
Depemokimab vs. Placebo		
Difference		-0.37
95% CI		(-0.64, -0.11)
p-value		0.006
Corrected Hedges g		
95% CI		(-0.53, -0.09)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 21 of 52
Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 11

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	61	113	63	139
LS Mean (SE)	1.79 (0.153)	1.65 (0.112)	1.62 (0.132)	1.09 (0.087)
LS Mean Change (SE)	-0.93 (0.153)	-1.07 (0.112)	-0.66 (0.132)	-1.19 (0.087)
Depemokimab vs. Placebo				
Difference		-0.13		-0.53
95% CI		(-0.51, 0.24)		(-0.84, -0.22)
p-value		0.479		<0.001
Corrected Hedges g		-0.11		-0.51
95% CI		(-0.42, 0.20)		(-0.82, -0.21)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 11

Page 22 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	124	252
LS Mean (SE)	1.70 (0.110)	1.34 (0.076)
LS Mean Change (SE)	-0.78 (0.110)	-1.14 (0.076)
Depemokimab vs. Placebo		
Difference		-0.36
95% CI		(-0.63, -0.10)
p-value		0.007
Corrected Hedges g		-0.30
95% CI		(-0.52, -0.08)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma

Page 23 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 12

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	58	115	64	147
LS Mean (SE)	1.73 (0.153)	1.69 (0.112)	1.65 (0.132)	1.06 (0.087)
LS Mean Change (SE)	-0.99 (0.153)	-1.03 (0.112)	-0.63 (0.132)	-1.21 (0.087)
Depemokimab vs. Placebo				
Difference		-0.04		-0.58
95% CI		(-0.41, 0.33)		(-0.90, -0.27)
p-value		0.836		<0.001
Corrected Hedges g		-0.03		-0.55
95% CI		(-0.35, 0.28)		(-0.85, -0.25)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.

t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 24 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 12

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	122	262
LS Mean (SE)	1.69 (0.113)	1.34 (0.078)
LS Mean Change (SE)	-0.79 (0.113)	-1.14 (0.078)
Depemokimab vs. Placebo		
Difference		-0.35
95% CI		(-0.62, -0.08)
p-value		0.012
Corrected Hedges g		
95% CI		(-0.49, -0.06)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 25 of 52
Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 13

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	59	108	64	143
LS Mean (SE)	1.75 (0.154)	1.65 (0.112)	1.64 (0.132)	1.09 (0.087)
LS Mean Change (SE)	-0.98 (0.154)	-1.07 (0.112)	-0.64 (0.132)	-1.19 (0.087)
Depemokimab vs. Placebo				
Difference		-0.09		-0.55
95% CI		(-0.47, 0.28)		(-0.86, -0.24)
p-value		0.626		<0.001
Corrected Hedges g		-0.08		-0.53
95% CI		(-0.40, 0.24)		(-0.82, -0.23)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.

t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 13

Page 26 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	123	251
LS Mean (SE)	1.69 (0.110)	1.34 (0.076)
LS Mean Change (SE)	-0.79 (0.110)	-1.14 (0.076)
Depemokimab vs. Placebo		
Difference		-0.35
95% CI		(-0.62, -0.09)
p-value		0.010
Corrected Hedges g		-0.29
95% CI		(-0.51, -0.07)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSd) - High-dose ICS Subgroup
Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 14

Page 27 of 52
Data as of 29APR2024

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	62	109	62	139
LS Mean (SE)	1.73 (0.153)	1.75 (0.113)	1.61 (0.132)	1.10 (0.087)
LS Mean Change (SE)	-0.99 (0.153)	-0.97 (0.113)	-0.67 (0.132)	-1.18 (0.087)
Depemokimab vs. Placebo				
Difference		0.02		-0.51
95% CI		(-0.35, 0.40)		(-0.82, -0.19)
p-value		0.916		0.002
Corrected Hedges g		0.02		-0.49
95% CI		(-0.29, 0.33)		(-0.79, -0.19)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSd score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSd score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 14

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	124	248
LS Mean (SE)	1.67 (0.114)	1.39 (0.079)
LS Mean Change (SE)	-0.81 (0.114)	-1.09 (0.079)
Depemokimab vs. Placebo		
Difference		-0.28
95% CI		(-0.56, -0.01)
p-value		0.043
Corrected Hedges g		-0.23
95% CI		(-0.44, -0.01)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma

Page 29 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 15

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	61	109	63	143
LS Mean (SE)	1.73 (0.154)	1.73 (0.113)	1.55 (0.132)	1.11 (0.087)
LS Mean Change (SE)	-1.00 (0.154)	-1.00 (0.113)	-0.72 (0.132)	-1.17 (0.087)
Depemokimab vs. Placebo				
Difference		0.00		-0.44
95% CI		(-0.38, 0.38)		(-0.76, -0.13)
p-value		1.000		0.006
Corrected Hedges g		0.00		-0.43
95% CI		(-0.31, 0.31)		(-0.72, -0.13)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.

t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma

Page 30 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 15

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	124	252
LS Mean (SE)	1.65 (0.115)	1.38 (0.080)
LS Mean Change (SE)	-0.84 (0.115)	-1.10 (0.080)
Depemokimab vs. Placebo		
Difference		-0.27
95% CI		(-0.54, 0.01)
p-value		0.058
Corrected Hedges g		
95% CI		(-0.43, 0.01)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.

t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 31 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 16

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	55	94	55	127
LS Mean (SE)	1.59 (0.154)	1.72 (0.114)	1.54 (0.133)	1.14 (0.087)
LS Mean Change (SE)	-1.13 (0.154)	-1.00 (0.114)	-0.73 (0.133)	-1.14 (0.087)
Depemokimab vs. Placebo				
Difference		0.13		-0.40
95% CI		(-0.25, 0.51)		(-0.72, -0.09)
p-value		0.507		0.012
Corrected Hedges g		0.11		-0.41
95% CI		(-0.22, 0.45)		(-0.73, -0.09)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 32 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 16

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	110	221
LS Mean (SE)	1.57 (0.112)	1.39 (0.078)
LS Mean Change (SE)	-0.91 (0.112)	-1.09 (0.078)
Depemokimab vs. Placebo		
Difference		-0.18
95% CI		(-0.45, 0.09)
p-value		0.190
Corrected Hedges g		
95% CI		(-0.38, 0.07)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 20

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	49	90	53	120
LS Mean (SE)	1.55 (0.156)	1.65 (0.115)	1.49 (0.134)	1.07 (0.088)
LS Mean Change (SE)	-1.17 (0.156)	-1.07 (0.115)	-0.79 (0.134)	-1.21 (0.088)
Depemokimab vs. Placebo				
Difference		0.10		-0.42
95% CI		(-0.29, 0.48)		(-0.73, -0.10)
p-value		0.625		0.010
Corrected Hedges g		0.09		-0.43
95% CI		(-0.26, 0.43)		(-0.76, -0.10)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 20

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	102	210
LS Mean (SE)	1.54 (0.111)	1.32 (0.077)
LS Mean Change (SE)	-0.95 (0.111)	-1.16 (0.077)
Depemokimab vs. Placebo		
Difference		-0.22
95% CI		(-0.48, 0.05)
p-value		0.114
Corrected Hedges g		
95% CI		(-0.43, 0.05)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 35 of 52
Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 24

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	49	92	53	115
LS Mean (SE)	1.63 (0.156)	1.60 (0.116)	1.56 (0.134)	1.08 (0.088)
LS Mean Change (SE)	-1.10 (0.156)	-1.12 (0.116)	-0.72 (0.134)	-1.19 (0.088)
Depemokimab vs. Placebo				
Difference		-0.03		-0.48
95% CI		(-0.41, 0.36)		(-0.79, -0.16)
p-value		0.892		0.004
Corrected Hedges g		-0.02		-0.50
95% CI		(-0.37, 0.32)		(-0.83, -0.17)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.

t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 36 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 24

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	102	207
LS Mean (SE)	1.59 (0.111)	1.30 (0.077)
LS Mean Change (SE)	-0.89 (0.111)	-1.18 (0.077)
Depemokimab vs. Placebo		
Difference		-0.29
95% CI		(-0.56, -0.03)
p-value		0.032
Corrected Hedges g		
95% CI		(-0.50, -0.02)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
 Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 37 of 52
 Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 26

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	51	90	56	116
LS Mean (SE)	1.61 (0.157)	1.60 (0.116)	1.44 (0.133)	1.14 (0.088)
LS Mean Change (SE)	-1.11 (0.157)	-1.13 (0.116)	-0.83 (0.133)	-1.14 (0.088)
Depemokimab vs. Placebo				
Difference		-0.01		-0.31
95% CI		(-0.40, 0.37)		(-0.62, 0.01)
p-value		0.944		0.058
Corrected Hedges g		-0.01		-0.32
95% CI		(-0.36, 0.33)		(-0.64, 0.01)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.

t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 38 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 26

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	107	206
LS Mean (SE)	1.51 (0.112)	1.33 (0.078)
LS Mean Change (SE)	-0.97 (0.112)	-1.15 (0.078)
Depemokimab vs. Placebo		
Difference		-0.18
95% CI		(-0.45, 0.09)
p-value		0.189
Corrected Hedges g		
95% CI		-0.16 (-0.39, 0.08)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 39 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 28

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	50	97	57	119
LS Mean (SE)	1.50 (0.158)	1.53 (0.116)	1.48 (0.133)	1.02 (0.089)
LS Mean Change (SE)	-1.22 (0.158)	-1.19 (0.116)	-0.80 (0.133)	-1.26 (0.089)
Depemokimab vs. Placebo				
Difference		0.02		-0.46
95% CI		(-0.36, 0.41)		(-0.78, -0.15)
p-value		0.899		0.005
Corrected Hedges g		0.02		-0.47
95% CI		(-0.32, 0.36)		(-0.79, -0.15)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 40 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 28

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	107	216
LS Mean (SE)	1.49 (0.115)	1.23 (0.080)
LS Mean Change (SE)	-0.99 (0.115)	-1.25 (0.080)
Depemokimab vs. Placebo		
Difference		-0.25
95% CI		(-0.53, 0.02)
p-value		0.070
Corrected Hedges g		
95% CI		(-0.45, 0.02)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
 Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 41 of 52
 Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 32

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	46	83	46	106
LS Mean (SE)	1.58 (0.160)	1.55 (0.117)	1.42 (0.135)	0.98 (0.090)
LS Mean Change (SE)	-1.15 (0.160)	-1.17 (0.117)	-0.86 (0.135)	-1.30 (0.090)
Depemokimab vs. Placebo				
Difference		-0.03		-0.44
95% CI		(-0.42, 0.37)		(-0.76, -0.12)
p-value		0.899		0.008
Corrected Hedges g		-0.02		-0.47
95% CI		(-0.38, 0.34)		(-0.82, -0.12)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.

t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 32

Page 42 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	92	189
LS Mean (SE)	1.53 (0.114)	1.20 (0.079)
LS Mean Change (SE)	-0.96 (0.114)	-1.28 (0.079)
Depemokimab vs. Placebo		
Difference		-0.32
95% CI		(-0.60, -0.05)
p-value		0.021
Corrected Hedges g		
95% CI		(-0.30, -0.05)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 43 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 36

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	44	85	48	117
LS Mean (SE)	1.55 (0.162)	1.43 (0.118)	1.44 (0.135)	0.97 (0.090)
LS Mean Change (SE)	-1.18 (0.162)	-1.29 (0.118)	-0.83 (0.135)	-1.31 (0.090)
Depemokimab vs. Placebo				
Difference		-0.11		-0.48
95% CI		(-0.50, 0.28)		(-0.80, -0.16)
p-value		0.580		0.004
Corrected Hedges g		-0.10		-0.49
95% CI		(-0.47, 0.26)		(-0.83, -0.15)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 36

Page 44 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	92	202
LS Mean (SE)	1.48 (0.109)	1.16 (0.075)
LS Mean Change (SE)	-1.00 (0.109)	-1.32 (0.075)
Depemokimab vs. Placebo		
Difference		-0.32
95% CI		(-0.58, -0.06)
p-value		0.017
Corrected Hedges g		-0.30
95% CI		(-0.55, -0.05)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSND) - High-dose ICS Subgroup
Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 40

Page 45 of 52
Data as of 29APR2024

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	48	85	49	112
LS Mean (SE)	1.47 (0.162)	1.54 (0.118)	1.32 (0.135)	1.00 (0.090)
LS Mean Change (SE)	-1.26 (0.162)	-1.18 (0.118)	-0.96 (0.135)	-1.28 (0.090)
Depemokimab vs. Placebo				
Difference		0.08		-0.32
95% CI		(-0.32, 0.47)		(-0.64, 0.00)
p-value		0.709		0.052
Corrected Hedges g		0.07		-0.33
95% CI		(-0.29, 0.42)		(-0.67, 0.00)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 46 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 40

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	97	197
LS Mean (SE)	1.39 (0.107)	1.24 (0.075)
LS Mean Change (SE)	-1.09 (0.107)	-1.24 (0.075)
Depemokimab vs. Placebo		
Difference		-0.16
95% CI		(-0.41, 0.10)
p-value		0.237
Corrected Hedges g		
95% CI		(-0.39, 0.10)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 47 of 52
Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 44

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	47	88	55	110
LS Mean (SE)	1.51 (0.163)	1.55 (0.118)	1.31 (0.134)	1.01 (0.090)
LS Mean Change (SE)	-1.21 (0.163)	-1.17 (0.118)	-0.97 (0.134)	-1.26 (0.090)
Depemokimab vs. Placebo				
Difference		0.04		-0.30
95% CI		(-0.36, 0.43)		(-0.61, 0.02)
p-value		0.855		0.070
Corrected Hedges g		0.03		-0.30
95% CI		(-0.32, 0.39)		(-0.63, 0.02)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.

t_e_adsd_analy.sas 08JUL2025 14:25

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score
Visit: Week 44

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	102	198
LS Mean (SE)	1.38 (0.114)	1.24 (0.079)
LS Mean Change (SE)	-1.11 (0.114)	-1.24 (0.079)
Depemokimab vs. Placebo		
Difference		-0.13
95% CI		(-0.41, 0.14)
p-value		0.340
Corrected Hedges g		-0.12
95% CI		(-0.36, 0.12)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma

Page 49 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 48

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	41	88	50	110
LS Mean (SE)	1.51 (0.165)	1.49 (0.119)	1.43 (0.135)	0.99 (0.091)
LS Mean Change (SE)	-1.21 (0.165)	-1.23 (0.119)	-0.85 (0.135)	-1.29 (0.091)
Depemokimab vs. Placebo				
Difference		-0.02		-0.44
95% CI		(-0.42, 0.38)		(-0.76, -0.12)
p-value		0.907		0.008
Corrected Hedges g		-0.02		-0.46
95% CI		(-0.39, 0.35)		(-0.79, -0.12)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.

t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 50 of 52
Data as of 29APR2024

Table 27.7
Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 48

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	91	198
LS Mean (SE)	1.47 (0.113)	1.20 (0.078)
LS Mean Change (SE)	-1.01 (0.113)	-1.28 (0.078)
Depemokimab vs. Placebo		
Difference		-0.27
95% CI		(-0.54, 0.00)
p-value		0.053
Corrected Hedges g		
95% CI		(-0.49, 0.00)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 52

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	67	123	67	155
n [2]	45	77	47	101
LS Mean (SE)	1.45 (0.166)	1.52 (0.122)	1.35 (0.138)	1.03 (0.093)
LS Mean Change (SE)	-1.28 (0.166)	-1.20 (0.122)	-0.93 (0.138)	-1.25 (0.093)
Depemokimab vs. Placebo				
Difference		0.07		-0.32
95% CI		(-0.33, 0.48)		(-0.65, 0.00)
p-value		0.729		0.053
Corrected Hedges g		0.07		-0.34
95% CI		(-0.30, 0.43)		(-0.69, 0.01)
p-value for Treatment by Study Interaction				

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.
t_e_adsd_analy.sas 08JUL2025 14:25

Protocol: 217780 Depemokimab GVD Asthma

Page 52 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.7

Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Visit: Week 52

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	134	278
n [2]	92	178
LS Mean (SE)	1.39 (0.116)	1.25 (0.081)
LS Mean Change (SE)	-1.10 (0.116)	-1.23 (0.081)
Depemokimab vs. Placebo		
Difference		-0.13
95% CI		(-0.41, 0.15)
p-value		0.356
Corrected Hedges g		
95% CI		(-0.37, 0.13)
p-value for Treatment by Study Interaction		0.967

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ADSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ADSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence for individual SWIFT-1 and SWIFT-2 models.


t_e_adsd_analy.sas 08JUL2025 14:25

Page 1 of 3
 Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
 Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Figure 27.13
 Line Plot of Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Study: SWIFT-1



f_e_atsd_analy_line.sas 08JUL2025 17:25


Page 2 of 3
Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Figure 27.13

Line Plot of Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score

Study: SWIFT-2



f_e_atsd_analy_line.sas 08JUL2025 17:25


Page 3 of 3
Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Figure 27.13

Line Plot of Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score


Study: SWIFT-1 & SWIFT-2



f_e_atsd_analy_line.sas 08JUL2025 17:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Figure 27.14
Forest Plot of Analysis of Change from Baseline in Asthma Daytime Symptom Diary (ADSD) Weekly Mean Score at Week 52



Note: Analysis performed using a repeated measures model with covariates as per corresponding analysis table.
No. of Subjects is the number of subjects with analysable data for one or more timepoints for the two treatment groups of interest.
/mnt/code/gvd/prod/tfl/f_e_atsd_forest_chg.sas 08JUL2025 17:25

2.11 ANSD - Veränderung im Vergleich zu Baseline

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSd) - High-dose ICS Subgroup

Page 1 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSd) Weekly Mean Score
Visit: Week 1

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	56	108	62	142
LS Mean (SE)	2.51 (0.159)	2.34 (0.115)	2.10 (0.138)	1.91 (0.092)
LS Mean Change (SE)	-0.36 (0.159)	-0.53 (0.115)	-0.31 (0.138)	-0.50 (0.092)
Depemokimab vs. Placebo				
Difference		-0.17		-0.19
95% CI		(-0.56, 0.22)		(-0.52, 0.14)
p-value		0.390		0.253
Corrected Hedges g		-0.14		-0.17
95% CI		(-0.46, 0.18)		(-0.47, 0.13)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 1

Page 2 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	118	250
LS Mean (SE)	2.29 (0.105)	2.11 (0.073)
LS Mean Change (SE)	-0.34 (0.105)	-0.52 (0.073)
Depemokimab vs. Placebo		
Difference		-0.18
95% CI		(-0.43, 0.07)
p-value		0.161
Corrected Hedges g		
95% CI		-0.16 (-0.38, 0.06)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 3 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 2

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	55	110	62	138
LS Mean (SE)	2.34 (0.159)	2.17 (0.115)	1.79 (0.138)	1.57 (0.092)
LS Mean Change (SE)	-0.53 (0.159)	-0.71 (0.115)	-0.63 (0.138)	-0.84 (0.092)
Depemokimab vs. Placebo				
Difference		-0.18		-0.22
95% CI		(-0.56, 0.21)		(-0.54, 0.11)
p-value		0.373		0.195
Corrected Hedges g		-0.15		-0.20
95% CI		(-0.47, 0.18)		(-0.50, 0.10)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 2

Page 4 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	117	248
LS Mean (SE)	2.04 (0.105)	1.84 (0.073)
LS Mean Change (SE)	-0.58 (0.105)	-0.78 (0.073)
Depemokimab vs. Placebo		
Difference		-0.20
95% CI		(-0.46, 0.05)
p-value		0.112
Corrected Hedges g		
95% CI		(-0.40, 0.04)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 5 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 3

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	55	110	63	135
LS Mean (SE)	2.33 (0.159)	2.03 (0.115)	1.72 (0.137)	1.45 (0.092)
LS Mean Change (SE)	-0.54 (0.159)	-0.84 (0.115)	-0.69 (0.137)	-0.97 (0.092)
Depemokimab vs. Placebo				
Difference		-0.31		-0.28
95% CI		(-0.69, 0.08)		(-0.60, 0.05)
p-value		0.122		0.098
Corrected Hedges g		-0.25		-0.25
95% CI		(-0.58, 0.07)		(-0.56, 0.05)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 3

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	118	245
LS Mean (SE)	2.01 (0.105)	1.71 (0.073)
LS Mean Change (SE)	-0.62 (0.105)	-0.92 (0.073)
Depemokimab vs. Placebo		
Difference		-0.30
95% CI		(-0.55, -0.05)
p-value		0.020
Corrected Hedges g		
95% CI		(-0.48, -0.04)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 7 of 52
Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 4

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	56	108	60	136
LS Mean (SE)	2.28 (0.159)	1.94 (0.115)	1.87 (0.138)	1.36 (0.092)
LS Mean Change (SE)	-0.59 (0.159)	-0.93 (0.115)	-0.55 (0.138)	-1.06 (0.092)
Depemokimab vs. Placebo				
Difference		-0.35		-0.51
95% CI		(-0.73, 0.04)		(-0.84, -0.18)
p-value		0.080		0.003
Corrected Hedges g		-0.29		-0.47
95% CI		(-0.61, 0.04)		(-0.78, -0.16)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 8 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 4

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	116	244
LS Mean (SE)	2.06 (0.105)	1.62 (0.073)
LS Mean Change (SE)	-0.56 (0.105)	-1.01 (0.073)
Depemokimab vs. Placebo		
Difference		-0.44
95% CI		(-0.69, -0.19)
p-value		<0.001
Corrected Hedges g		
95% CI		(-0.39, -0.16)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 5

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	54	107	60	136
LS Mean (SE)	2.31 (0.159)	1.81 (0.115)	1.81 (0.138)	1.30 (0.093)
LS Mean Change (SE)	-0.57 (0.159)	-1.07 (0.115)	-0.61 (0.138)	-1.12 (0.093)
Depemokimab vs. Placebo				
Difference		-0.50		-0.51
95% CI		(-0.89, -0.11)		(-0.84, -0.18)
p-value		0.012		0.003
Corrected Hedges g		-0.42		-0.47
95% CI		(-0.75, -0.09)		(-0.78, -0.17)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 10 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 5

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	114	243
LS Mean (SE)	2.04 (0.105)	1.52 (0.073)
LS Mean Change (SE)	-0.58 (0.105)	-1.10 (0.073)
Depemokimab vs. Placebo		
Difference		-0.52
95% CI		(-0.77, -0.26)
p-value		<0.001
Corrected Hedges g		
95% CI		(-0.68, -0.23)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 11 of 52
Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 6

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	53	105	60	134
LS Mean (SE)	2.21 (0.160)	1.75 (0.116)	1.84 (0.138)	1.31 (0.093)
LS Mean Change (SE)	-0.66 (0.160)	-1.12 (0.116)	-0.58 (0.138)	-1.11 (0.093)
Depemokimab vs. Placebo				
Difference		-0.46		-0.53
95% CI		(-0.85, -0.07)		(-0.86, -0.20)
p-value		0.020		0.002
Corrected Hedges g		-0.39		-0.49
95% CI		(-0.72, -0.06)		(-0.80, -0.18)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 12 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 6

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	113	239
LS Mean (SE)	2.01 (0.106)	1.51 (0.073)
LS Mean Change (SE)	-0.61 (0.106)	-1.12 (0.073)
Depemokimab vs. Placebo		
Difference		-0.51
95% CI		(-0.76, -0.25)
p-value		<0.001
Corrected Hedges g		
95% CI		-0.45 (-0.67, -0.22)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 7

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	53	104	60	133
LS Mean (SE)	2.14 (0.160)	1.82 (0.116)	1.91 (0.139)	1.28 (0.093)
LS Mean Change (SE)	-0.73 (0.160)	-1.05 (0.116)	-0.50 (0.139)	-1.14 (0.093)
Depemokimab vs. Placebo				
Difference		-0.32		-0.63
95% CI		(-0.71, 0.07)		(-0.96, -0.31)
p-value		0.107		<0.001
Corrected Hedges g		-0.27		-0.59
95% CI		(-0.60, 0.06)		(-0.90, -0.28)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 14 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 7

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	113	237
LS Mean (SE)	2.02 (0.106)	1.52 (0.074)
LS Mean Change (SE)	-0.61 (0.106)	-1.10 (0.074)
Depemokimab vs. Placebo		
Difference		-0.50
95% CI		(-0.75, -0.25)
p-value		<0.001
Corrected Hedges g		
95% CI		(-0.67, -0.21)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 15 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 8

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	52	103	57	132
LS Mean (SE)	2.07 (0.160)	1.82 (0.116)	1.77 (0.139)	1.21 (0.093)
LS Mean Change (SE)	-0.81 (0.160)	-1.05 (0.116)	-0.65 (0.139)	-1.21 (0.093)
Depemokimab vs. Placebo				
Difference		-0.24		-0.56
95% CI		(-0.63, 0.15)		(-0.89, -0.23)
p-value		0.222		<0.001
Corrected Hedges g		-0.21		-0.52
95% CI		(-0.54, 0.13)		(-0.84, -0.21)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 16 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 8

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	109	235
LS Mean (SE)	1.90 (0.106)	1.48 (0.074)
LS Mean Change (SE)	-0.72 (0.106)	-1.14 (0.074)
Depemokimab vs. Placebo		
Difference		-0.43
95% CI		(-0.68, -0.17)
p-value		0.002
Corrected Hedges g		
95% CI		(-0.38, -0.15)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 17 of 52
Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 9

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	52	103	59	129
LS Mean (SE)	2.06 (0.160)	1.83 (0.116)	1.76 (0.140)	1.21 (0.094)
LS Mean Change (SE)	-0.82 (0.160)	-1.04 (0.116)	-0.66 (0.140)	-1.20 (0.094)
Depemokimab vs. Placebo				
Difference		-0.23		-0.55
95% CI		(-0.62, 0.16)		(-0.88, -0.22)
p-value		0.258		0.002
Corrected Hedges g		-0.19		-0.51
95% CI		(-0.53, 0.14)		(-0.82, -0.20)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 9

Page 18 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	111	232
LS Mean (SE)	1.89 (0.106)	1.48 (0.074)
LS Mean Change (SE)	-0.73 (0.106)	-1.14 (0.074)
Depemokimab vs. Placebo		
Difference		-0.41
95% CI		(-0.67, -0.16)
p-value		0.002
Corrected Hedges g		-0.36
95% CI		(-0.59, -0.14)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 19 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 10

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	52	102	58	127
LS Mean (SE)	1.93 (0.161)	1.80 (0.116)	1.75 (0.140)	1.17 (0.094)
LS Mean Change (SE)	-0.94 (0.161)	-1.07 (0.116)	-0.66 (0.140)	-1.24 (0.094)
Depemokimab vs. Placebo				
Difference		-0.13		-0.58
95% CI		(-0.52, 0.26)		(-0.91, -0.25)
p-value		0.514		<0.001
Corrected Hedges g		-0.11		-0.55
95% CI		(-0.44, 0.22)		(-0.86, -0.23)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 20 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 10

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	110	229
LS Mean (SE)	1.83 (0.107)	1.45 (0.074)
LS Mean Change (SE)	-0.79 (0.107)	-1.17 (0.074)
Depemokimab vs. Placebo		
Difference		-0.38
95% CI		(-0.64, -0.13)
p-value		0.004
Corrected Hedges g		
95% CI		(-0.57, -0.11)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 21 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 11

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	53	100	57	131
LS Mean (SE)	1.96 (0.161)	1.79 (0.117)	1.64 (0.140)	1.16 (0.094)
LS Mean Change (SE)	-0.92 (0.161)	-1.08 (0.117)	-0.78 (0.140)	-1.26 (0.094)
Depemokimab vs. Placebo				
Difference		-0.16		-0.48
95% CI		(-0.55, 0.23)		(-0.81, -0.15)
p-value		0.417		0.005
Corrected Hedges g		-0.14		-0.45
95% CI		(-0.47, 0.20)		(-0.76, -0.13)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 11

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	110	231
LS Mean (SE)	1.79 (0.107)	1.44 (0.074)
LS Mean Change (SE)	-0.84 (0.107)	-1.18 (0.074)
Depemokimab vs. Placebo		
Difference		-0.35
95% CI		(-0.60, -0.09)
p-value		0.008
Corrected Hedges g		
95% CI		(-0.54, -0.08)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 23 of 52
Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 12

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	51	100	57	130
LS Mean (SE)	1.84 (0.162)	1.78 (0.117)	1.72 (0.141)	1.12 (0.094)
LS Mean Change (SE)	-1.04 (0.162)	-1.10 (0.117)	-0.70 (0.141)	-1.29 (0.094)
Depemokimab vs. Placebo				
Difference		-0.06		-0.59
95% CI		(-0.45, 0.33)		(-0.92, -0.26)
p-value		0.761		<0.001
Corrected Hedges g		-0.05		-0.55
95% CI		(-0.39, 0.29)		(-0.87, -0.24)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 12

Page 24 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	108	230
LS Mean (SE)	1.77 (0.107)	1.41 (0.074)
LS Mean Change (SE)	-0.85 (0.107)	-1.21 (0.074)
Depemokimab vs. Placebo		
Difference		-0.36
95% CI		(-0.62, -0.10)
p-value		0.007
Corrected Hedges g		-0.32
95% CI		(-0.55, -0.09)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 25 of 52
Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 13

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	51	97	55	125
LS Mean (SE)	1.87 (0.162)	1.83 (0.117)	1.72 (0.141)	1.14 (0.094)
LS Mean Change (SE)	-1.01 (0.162)	-1.04 (0.117)	-0.70 (0.141)	-1.27 (0.094)
Depemokimab vs. Placebo				
Difference		-0.03		-0.58
95% CI		(-0.43, 0.36)		(-0.91, -0.24)
p-value		0.873		<0.001
Corrected Hedges g		-0.03		-0.55
95% CI		(-0.37, 0.31)		(-0.87, -0.23)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 13

Page 26 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	106	222
LS Mean (SE)	1.78 (0.107)	1.45 (0.074)
LS Mean Change (SE)	-0.84 (0.107)	-1.18 (0.074)
Depemokimab vs. Placebo		
Difference		-0.34
95% CI		(-0.60, -0.08)
p-value		0.010
Corrected Hedges g		-0.31
95% CI		(-0.54, -0.07)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 27 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 14

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	55	96	56	128
LS Mean (SE)	1.88 (0.162)	1.94 (0.118)	1.68 (0.141)	1.15 (0.094)
LS Mean Change (SE)	-0.99 (0.162)	-0.93 (0.118)	-0.74 (0.141)	-1.26 (0.094)
Depemokimab vs. Placebo				
Difference		0.06		-0.52
95% CI		(-0.34, 0.45)		(-0.86, -0.19)
p-value		0.772		0.003
Corrected Hedges g		0.05		-0.49
95% CI		(-0.28, 0.38)		(-0.81, -0.18)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 14

Page 28 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	111	224
LS Mean (SE)	1.77 (0.107)	1.50 (0.074)
LS Mean Change (SE)	-0.85 (0.107)	-1.12 (0.074)
Depemokimab vs. Placebo		
Difference		-0.27
95% CI		(-0.53, -0.02)
p-value		0.038
Corrected Hedges g		-0.24
95% CI		(-0.47, -0.01)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 29 of 52
Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 15

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	52	95	57	129
LS Mean (SE)	1.88 (0.163)	1.89 (0.118)	1.59 (0.140)	1.12 (0.094)
LS Mean Change (SE)	-1.00 (0.163)	-0.98 (0.118)	-0.82 (0.140)	-1.29 (0.094)
Depemokimab vs. Placebo				
Difference		0.02		-0.47
95% CI		(-0.38, 0.41)		(-0.80, -0.14)
p-value		0.938		0.006
Corrected Hedges g		0.01		-0.44
95% CI		(-0.32, 0.35)		(-0.75, -0.12)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 15

Page 30 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	109	224
LS Mean (SE)	1.72 (0.107)	1.46 (0.075)
LS Mean Change (SE)	-0.90 (0.107)	-1.16 (0.075)
Depemokimab vs. Placebo		
Difference		-0.27
95% CI		(-0.52, -0.01)
p-value		0.044
Corrected Hedges g		
95% CI		(-0.47, -0.01)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 31 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 16

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	44	82	47	104
LS Mean (SE)	1.75 (0.165)	1.84 (0.119)	1.54 (0.142)	1.14 (0.095)
LS Mean Change (SE)	-1.12 (0.165)	-1.03 (0.119)	-0.88 (0.142)	-1.27 (0.095)
Depemokimab vs. Placebo				
Difference		0.09		-0.40
95% CI		(-0.31, 0.49)		(-0.73, -0.06)
p-value		0.666		0.022
Corrected Hedges g		0.08		-0.41
95% CI		(-0.29, 0.45)		(-0.75, -0.06)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 32 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 16

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	91	186
LS Mean (SE)	1.64 (0.109)	1.45 (0.075)
LS Mean Change (SE)	-0.98 (0.109)	-1.17 (0.075)
Depemokimab vs. Placebo		
Difference		-0.19
95% CI		(-0.45, 0.07)
p-value		0.152
Corrected Hedges g		
95% CI		(-0.44, 0.07)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
 Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 33 of 52
 Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 20

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	37	75	48	105
LS Mean (SE)	1.76 (0.168)	1.79 (0.121)	1.58 (0.142)	1.14 (0.095)
LS Mean Change (SE)	-1.12 (0.168)	-1.09 (0.121)	-0.84 (0.142)	-1.27 (0.095)
Depemokimab vs. Placebo				
Difference		0.03		-0.43
95% CI		(-0.38, 0.44)		(-0.77, -0.10)
p-value		0.892		0.012
Corrected Hedges g		0.03		-0.44
95% CI		(-0.37, 0.42)		(-0.78, -0.09)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 34 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 20

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	85	180
LS Mean (SE)	1.66 (0.110)	1.43 (0.076)
LS Mean Change (SE)	-0.96 (0.110)	-1.20 (0.076)
Depemokimab vs. Placebo		
Difference		-0.24
95% CI		(-0.50, 0.02)
p-value		0.076
Corrected Hedges g		
95% CI		(-0.49, 0.03)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 35 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 24

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	37	81	46	100
LS Mean (SE)	1.77 (0.169)	1.73 (0.121)	1.76 (0.143)	1.15 (0.096)
LS Mean Change (SE)	-1.11 (0.169)	-1.14 (0.121)	-0.66 (0.143)	-1.27 (0.096)
Depemokimab vs. Placebo				
Difference		-0.04		-0.61
95% CI		(-0.45, 0.37)		(-0.95, -0.27)
p-value		0.858		<0.001
Corrected Hedges g		-0.03		-0.63
95% CI		(-0.42, 0.35)		(-0.99, -0.28)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 24

Page 36 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	83	181
LS Mean (SE)	1.77 (0.110)	1.40 (0.076)
LS Mean Change (SE)	-0.86 (0.110)	-1.22 (0.076)
Depemokimab vs. Placebo		
Difference		-0.36
95% CI		(-0.63, -0.10)
p-value		0.008
Corrected Hedges g		-0.35
95% CI		(-0.62, -0.09)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 37 of 52
Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 26

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	41	82	48	98
LS Mean (SE)	1.71 (0.169)	1.75 (0.121)	1.57 (0.143)	1.15 (0.097)
LS Mean Change (SE)	-1.16 (0.169)	-1.12 (0.121)	-0.85 (0.143)	-1.27 (0.097)
Depemokimab vs. Placebo				
Difference		0.04		-0.42
95% CI		(-0.37, 0.45)		(-0.76, -0.08)
p-value		0.858		0.016
Corrected Hedges g		0.03		-0.43
95% CI		(-0.34, 0.41)		(-0.78, -0.08)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 26

Page 38 of 52
Data as of 29APR2024

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	89	180
LS Mean (SE)	1.64 (0.111)	1.42 (0.077)
LS Mean Change (SE)	-0.99 (0.111)	-1.21 (0.077)
Depemokimab vs. Placebo		
Difference		-0.22
95% CI		(-0.49, 0.04)
p-value		0.103
Corrected Hedges g		
95% CI		-0.21 (-0.47, 0.04)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 39 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 28

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	39	83	45	101
LS Mean (SE)	1.61 (0.172)	1.68 (0.122)	1.57 (0.145)	1.06 (0.098)
LS Mean Change (SE)	-1.26 (0.172)	-1.19 (0.122)	-0.85 (0.145)	-1.36 (0.098)
Depemokimab vs. Placebo				
Difference		0.07		-0.51
95% CI		(-0.35, 0.48)		(-0.85, -0.16)
p-value		0.748		0.004
Corrected Hedges g		0.06		-0.51
95% CI		(-0.32, 0.44)		(-0.87, -0.16)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 40 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 28

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	84	184
LS Mean (SE)	1.59 (0.112)	1.33 (0.077)
LS Mean Change (SE)	-1.03 (0.112)	-1.29 (0.077)
Depemokimab vs. Placebo		
Difference		-0.26
95% CI		(-0.52, 0.01)
p-value		0.062
Corrected Hedges g		
95% CI		-0.24 (-0.50, 0.01)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 41 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 32

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	38	64	39	91
LS Mean (SE)	1.76 (0.174)	1.62 (0.124)	1.61 (0.147)	1.02 (0.099)
LS Mean Change (SE)	-1.11 (0.174)	-1.25 (0.124)	-0.80 (0.147)	-1.39 (0.099)
Depemokimab vs. Placebo				
Difference		-0.14		-0.59
95% CI		(-0.56, 0.28)		(-0.94, -0.24)
p-value		0.519		<0.001
Corrected Hedges g		-0.13		-0.63
95% CI		(-0.54, 0.27)		(-1.01, -0.24)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 42 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 32

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	77	155
LS Mean (SE)	1.69 (0.114)	1.29 (0.079)
LS Mean Change (SE)	-0.93 (0.114)	-1.34 (0.079)
Depemokimab vs. Placebo		
Difference		-0.40
95% CI		(-0.67, -0.13)
p-value		0.004
Corrected Hedges g		
95% CI		(-0.68, -0.13)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 43 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 36

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	33	69	42	96
LS Mean (SE)	1.63 (0.178)	1.60 (0.125)	1.54 (0.148)	1.02 (0.099)
LS Mean Change (SE)	-1.24 (0.178)	-1.27 (0.125)	-0.88 (0.148)	-1.39 (0.099)
Depemokimab vs. Placebo				
Difference		-0.03		-0.52
95% CI		(-0.46, 0.39)		(-0.87, -0.17)
p-value		0.878		0.004
Corrected Hedges g		-0.03		-0.53
95% CI		(-0.45, 0.38)		(-0.90, -0.16)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 44 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 36

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	75	165
LS Mean (SE)	1.58 (0.115)	1.28 (0.079)
LS Mean Change (SE)	-1.04 (0.115)	-1.34 (0.079)
Depemokimab vs. Placebo		
Difference		-0.30
95% CI		(-0.57, -0.02)
p-value		0.033
Corrected Hedges g		
95% CI		(-0.57, -0.02)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 45 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 40

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	36	72	41	94
LS Mean (SE)	1.50 (0.179)	1.63 (0.125)	1.43 (0.148)	1.04 (0.100)
LS Mean Change (SE)	-1.37 (0.179)	-1.24 (0.125)	-0.99 (0.148)	-1.38 (0.100)
Depemokimab vs. Placebo				
Difference		0.13		-0.39
95% CI		(-0.30, 0.56)		(-0.74, -0.04)
p-value		0.567		0.030
Corrected Hedges g		0.12		-0.40
95% CI		(-0.28, 0.52)		(-0.77, -0.03)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Page 46 of 52
Data as of 29APR2024
Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 40

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	77	166
LS Mean (SE)	1.47 (0.116)	1.30 (0.079)
LS Mean Change (SE)	-1.15 (0.116)	-1.32 (0.079)
Depemokimab vs. Placebo		
Difference		-0.17
95% CI		(-0.44, 0.11)
p-value		0.231
Corrected Hedges g		-0.16
95% CI		(-0.44, 0.11)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
Visit: Week 44

Page 47 of 52
Data as of 29APR2024

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	36	65	46	89
LS Mean (SE)	1.55 (0.181)	1.62 (0.127)	1.47 (0.148)	1.06 (0.102)
LS Mean Change (SE)	-1.32 (0.181)	-1.26 (0.127)	-0.95 (0.148)	-1.36 (0.102)
Depemokimab vs. Placebo				
Difference		0.06		-0.42
95% CI		(-0.37, 0.50)		(-0.77, -0.06)
p-value		0.775		0.022
Corrected Hedges g		0.06		-0.42
95% CI		(-0.35, 0.47)		(-0.78, -0.06)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 48 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 44

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	82	154
LS Mean (SE)	1.51 (0.116)	1.31 (0.080)
LS Mean Change (SE)	-1.11 (0.116)	-1.32 (0.080)
Depemokimab vs. Placebo		
Difference		-0.21
95% CI		(-0.48, 0.07)
p-value		0.144
Corrected Hedges g		
95% CI		(-0.47, 0.07)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 49 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 48

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	26	66	42	86
LS Mean (SE)	1.50 (0.187)	1.61 (0.128)	1.51 (0.149)	1.03 (0.103)
LS Mean Change (SE)	-1.37 (0.187)	-1.26 (0.128)	-0.91 (0.149)	-1.39 (0.103)
Depemokimab vs. Placebo				
Difference		0.11		-0.48
95% CI		(-0.33, 0.56)		(-0.83, -0.12)
p-value		0.623		0.009
Corrected Hedges g		0.11		-0.50
95% CI		(-0.35, 0.56)		(-0.87, -0.12)

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 50 of 52
Data as of 29APR2024

Table 27.5
Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 48

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	68	152
LS Mean (SE)	1.51 (0.118)	1.29 (0.081)
LS Mean Change (SE)	-1.11 (0.118)	-1.34 (0.081)
Depemokimab vs. Placebo		
Difference		-0.22
95% CI		(-0.51, 0.06)
p-value		0.121
Corrected Hedges g		
95% CI		(-0.51, 0.06)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: AR(1) covariance structure used to enable convergence
t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma

Page 51 of 52

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.5

Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Visit: Week 52

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	60	111	65	143
n [2]	33	59	43	87
LS Mean (SE)	1.50 (0.188)	1.65 (0.132)	1.48 (0.151)	1.11 (0.104)
LS Mean Change (SE)	-1.37 (0.188)	-1.23 (0.132)	-0.94 (0.151)	-1.30 (0.104)
Depemokimab vs. Placebo				
Difference		0.15		-0.36
95% CI		(-0.30, 0.60)		(-0.72, 0.00)
p-value		0.523		0.050
Corrected Hedges g		0.14		-0.37
95% CI		(-0.29, 0.57)		(-0.73, 0.00)
p-value for Treatment by Study Interaction				

[1] Number of subjects with analysable data for one or more timepoints.

[2] Number of subjects with analysable data at the given timepoint.

Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: AR(1) covariance structure used to enable convergence

t_e_ansd_analy.sas 08JUL2025 14:21

Protocol: 217780 Depemokimab GVD Asthma
 Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
 Page 52 of 52
 Data as of 29APR2024
 Table 27.5
 Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score
 Visit: Week 52

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
n [1]	125	254
n [2]	76	146
LS Mean (SE)	1.49 (0.120)	1.35 (0.083)
LS Mean Change (SE)	-1.13 (0.120)	-1.27 (0.083)
Depemokimab vs. Placebo		
Difference		-0.14
95% CI		(-0.42, 0.15)
p-value		0.342
Corrected Hedges g		-0.14
95% CI		(-0.41, 0.14)
p-value for Treatment by Study Interaction		0.099


[1] Number of subjects with analysable data for one or more timepoints.
 [2] Number of subjects with analysable data at the given timepoint.
 Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline ANSD score, baseline pre-bronchodilator percent predicted FEV1, study (206713 or 213744), visit, visit by baseline ANSD score and visit by treatment group. For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
 Note: AR(1) covariance structure used to enable convergence
 t_e_ansd_analy.sas 08JUL2025 14:21

Page 1 of 3
Data as of 29APR2024


Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Figure 27.9
Line Plot of Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score

Study: SWIFT-1



f_e_ansd_analy_line.sas 08JUL2025 17:24




Page 3 of 3
Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Figure 27.9
Line Plot of Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score


Study: SWIFT-1 & SWIFT-2



f_e_ansd_analy_line.sas 08JUL2025 17:24

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSd) - High-dose ICS Subgroup

Figure 27.10
Forest Plot of Analysis of Change from Baseline in Asthma Nighttime Symptom Diary (ANSd) Weekly Mean Score at Week 52



Note: Analysis performed using a repeated measures model with covariates as per corresponding analysis table.
No. of Subjects is the number of subjects with analysable data for one or more timepoints for the two treatment groups of interest.
/mnt/code/gvd/prod/tfl/f_e_ansd_forest_chg.sas 08JUL2025 17:24

2.12 ADSD - Responderanalyse

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 1 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 2				
n	67	124	68	158
Responder [1]	9 (13%)	25 (20%)	5 (7%)	33 (21%)
Non-responder	58 (87%)	99 (80%)	63 (93%)	125 (79%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.63 (0.68, 4.23)		3.33 (1.20, 11.40)
Unadjusted Relative Risk (Exact 95% CI)		1.50 (0.76, 3.90)		2.84 (1.02, 14.39)
Risk Difference (%) (Exact 95% CI)		6.7 (-5.4, 17.2)		13.5 (1.3, 22.2)
z-test p-value		0.247		0.013
Logistic Regression Model				
Odds Ratio (95% CI)		1.78 (0.76, 4.20)		5.48 (1.82, 16.45)
p-value		0.185		0.003
Poisson Regression Model				
Relative Risk (95% CI)		1.62 (0.80, 3.26)		2.93 (1.27, 6.74)
p-value		0.179		0.012

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 2		
n	135	282
Responder [1]	14 (10%)	58 (21%)
Non-responder	121 (90%)	224 (79%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		2.24 (1.17, 4.52)
Unadjusted Relative Risk (Exact 95% CI)		1.98 (1.01, 4.74)
Risk Difference (%) (Exact 95% CI)		10.2 (0.7, 17.0)
z-test p-value		0.010
Logistic Regression Model		
Odds Ratio (95% CI)		2.66 (1.40, 5.05)
p-value		0.003
Poisson Regression Model		
Relative Risk (95% CI)		2.06 (1.21, 3.50)
p-value		0.008

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 3 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 3				
n	67	124	68	158
Responder [1]	12 (18%)	26 (21%)	6 (9%)	38 (24%)
Non-responder	55 (82%)	98 (79%)	62 (91%)	120 (76%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.22 (0.54, 2.86)		3.27 (1.27, 9.95)
Unadjusted Relative Risk (Exact 95% CI)		1.17 (0.64, 2.37)		2.73 (1.02, 10.04)
Risk Difference (%) (Exact 95% CI)		3.1 (-9.8, 14.3)		15.2 (1.6, 24.4)
z-test p-value		0.614		0.009
Logistic Regression Model				
Odds Ratio (95% CI)		1.34 (0.60, 3.00)		5.93 (2.04, 17.24)
p-value		0.482		0.002
Poisson Regression Model				
Relative Risk (95% CI)		1.28 (0.70, 2.35)		2.81 (1.36, 5.82)
p-value		0.427		0.006

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 4 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 3		
n	135	282
Responder [1]	18 (13%)	64 (23%)
Non-responder	117 (87%)	218 (77%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.91 (1.06, 3.58)
Unadjusted Relative Risk (Exact 95% CI)		1.70 (1.00, 3.24)
Risk Difference (%) (Exact 95% CI)		9.4 (0.3, 16.7)
z-test p-value		0.025
Logistic Regression Model		
Odds Ratio (95% CI)		2.31 (1.26, 4.24)
p-value		0.007
Poisson Regression Model		
Relative Risk (95% CI)		1.78 (1.12, 2.81)
p-value		0.014

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 4				
n	67	124	68	158
Responder [1]	13 (19%)	31 (25%)	3 (4%)	45 (28%)
Non-responder	54 (81%)	93 (75%)	65 (96%)	113 (72%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.38 (0.64, 3.14)		8.63 (2.59, 44.81)
Unadjusted Relative Risk (Exact 95% CI)		1.29 (0.73, 2.50)		6.46 (2.23, 54.06)
Risk Difference (%) (Exact 95% CI)		5.6 (-7.7, 17.5)		24.1 (13.7, 32.6)
z-test p-value		0.381		<0.001
Logistic Regression Model				
Odds Ratio (95% CI)		1.59 (0.72, 3.53)		18.56 (5.12, 67.30)
p-value		0.250		<0.001
Poisson Regression Model				
Relative Risk (95% CI)		1.42 (0.80, 2.52)		6.56 (2.24, 19.16)
p-value		0.233		<0.001

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 4		
n	135	282
Responder [1]	16 (12%)	76 (27%)
Non-responder	119 (88%)	206 (73%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		2.74 (1.50, 5.27)
Unadjusted Relative Risk (Exact 95% CI)		2.27 (1.37, 5.30)
Risk Difference (%) (Exact 95% CI)		15.1 (5.8, 22.4)
z-test p-value		<0.001
Logistic Regression Model		
Odds Ratio (95% CI)		3.54 (1.90, 6.58)
p-value		<0.001
Poisson Regression Model		
Relative Risk (95% CI)		2.36 (1.46, 3.83)
p-value		<0.001

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 7 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 5				
n	67	124	68	158
Responder [1]	16 (24%)	34 (27%)	5 (7%)	40 (25%)
Non-responder	51 (76%)	90 (73%)	63 (93%)	118 (75%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.20 (0.58, 2.57)		4.27 (1.57, 14.49)
Unadjusted Relative Risk (Exact 95% CI)		1.15 (0.69, 2.06)		3.44 (1.42, 14.39)
Risk Difference (%) (Exact 95% CI)		3.5 (-10.2, 16.0)		18.0 (5.2, 26.9)
z-test p-value		0.596		0.002
Logistic Regression Model				
Odds Ratio (95% CI)		1.38 (0.64, 2.94)		7.66 (2.55, 23.01)
p-value		0.410		<0.001
Poisson Regression Model				
Relative Risk (95% CI)		1.26 (0.76, 2.09)		3.53 (1.56, 7.96)
p-value		0.368		0.003

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma

Page 8 of 50

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.8

Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 5		
n	135	282
Responder [1]	21 (16%)	74 (26%)
Non-responder	114 (84%)	208 (74%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.93 (1.11, 3.48)
Unadjusted Relative Risk (Exact 95% CI)		1.69 (1.01, 2.97)
Risk Difference (%) (Exact 95% CI)		10.7 (0.7, 18.4)
z-test p-value		0.015
Logistic Regression Model		
Odds Ratio (95% CI)		2.39 (1.34, 4.28)
p-value		0.004
Poisson Regression Model		
Relative Risk (95% CI)		1.76 (1.15, 2.68)
p-value		0.009

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 9 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 6				
n	67	124	68	158
Responder [1]	16 (24%)	42 (34%)	6 (9%)	47 (30%)
Non-responder	51 (76%)	82 (66%)	62 (91%)	111 (70%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.63 (0.80, 3.44)		4.38 (1.72, 13.17)
Unadjusted Relative Risk (Exact 95% CI)		1.42 (0.88, 2.53)		3.37 (1.53, 14.39)
Risk Difference (%) (Exact 95% CI)		10.0 (-4.1, 22.8)		20.9 (8.4, 30.6)
z-test p-value		0.152		<0.001
Logistic Regression Model				
Odds Ratio (95% CI)		1.96 (0.93, 4.13)		7.88 (2.81, 22.05)
p-value		0.078		<0.001
Poisson Regression Model				
Relative Risk (95% CI)		1.54 (0.95, 2.50)		3.42 (1.61, 7.30)
p-value		0.079		0.002

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 6		
n	135	282
Responder [1]	22 (16%)	89 (32%)
Non-responder	113 (84%)	193 (68%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		2.37 (1.38, 4.19)
Unadjusted Relative Risk (Exact 95% CI)		1.94 (1.25, 3.48)
Risk Difference (%) (Exact 95% CI)		15.3 (5.2, 23.3)
z-test p-value		<0.001
Logistic Regression Model		
Odds Ratio (95% CI)		3.08 (1.75, 5.44)
p-value		<0.001
Poisson Regression Model		
Relative Risk (95% CI)		2.00 (1.35, 2.98)
p-value		<0.001

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 11 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 7				
n	67	124	68	158
Responder [1]	17 (25%)	38 (31%)	7 (10%)	41 (26%)
Non-responder	50 (75%)	86 (69%)	61 (90%)	117 (74%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.30 (0.64, 2.72)		3.05 (1.25, 8.52)
Unadjusted Relative Risk (Exact 95% CI)		1.21 (0.75, 2.14)		2.52 (1.02, 6.87)
Risk Difference (%) (Exact 95% CI)		5.3 (-8.9, 18.1)		15.7 (1.6, 25.3)
z-test p-value		0.443		0.009
Logistic Regression Model				
Odds Ratio (95% CI)		1.50 (0.71, 3.16)		4.85 (1.81, 13.00)
p-value		0.289		0.002
Poisson Regression Model				
Relative Risk (95% CI)		1.32 (0.82, 2.14)		2.58 (1.26, 5.29)
p-value		0.255		0.010

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma

Page 12 of 50

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.8

Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 7		
n	135	282
Responder [1]	24 (18%)	79 (28%)
Non-responder	111 (82%)	203 (72%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.80 (1.06, 3.14)
Unadjusted Relative Risk (Exact 95% CI)		1.58 (1.00, 2.66)
Risk Difference (%) (Exact 95% CI)		10.2 (0.3, 18.3)
z-test p-value		0.024
Logistic Regression Model		
Odds Ratio (95% CI)		2.20 (1.26, 3.86)
p-value		0.006
Poisson Regression Model		
Relative Risk (95% CI)		1.64 (1.11, 2.43)
p-value		0.014

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 13 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 8				
n	67	124	68	158
Responder [1]	20 (30%)	37 (30%)	5 (7%)	43 (27%)
Non-responder	47 (70%)	87 (70%)	63 (93%)	115 (73%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.00 (0.50, 2.03)		4.71 (1.73, 15.93)
Unadjusted Relative Risk (Exact 95% CI)		1.00 (0.64, 1.76)		3.70 (1.53, 14.39)
Risk Difference (%) (Exact 95% CI)		0.0 (-14.3, 13.3)		19.9 (7.3, 29.0)
z-test p-value		0.999		<0.001
Logistic Regression Model				
Odds Ratio (95% CI)		1.07 (0.53, 2.16)		8.81 (2.89, 26.84)
p-value		0.861		<0.001
Poisson Regression Model				
Relative Risk (95% CI)		1.08 (0.69, 1.68)		3.79 (1.68, 8.53)
p-value		0.740		0.002

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 8		
n	135	282
Responder [1]	25 (19%)	80 (28%)
Non-responder	110 (81%)	202 (72%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.74 (1.03, 3.02)
Unadjusted Relative Risk (Exact 95% CI)		1.53 (1.00, 2.52)
Risk Difference (%) (Exact 95% CI)		9.9 (0.3, 18.0)
z-test p-value		0.031
Logistic Regression Model		
Odds Ratio (95% CI)		2.07 (1.20, 3.57)
p-value		0.010
Poisson Regression Model		
Relative Risk (95% CI)		1.59 (1.09, 2.32)
p-value		0.018

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 15 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 9				
n	67	124	68	158
Responder [1]	20 (30%)	38 (31%)	6 (9%)	44 (28%)
Non-responder	47 (70%)	86 (69%)	62 (91%)	114 (72%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.04 (0.52, 2.11)		3.99 (1.56, 12.04)
Unadjusted Relative Risk (Exact 95% CI)		1.03 (0.65, 1.77)		3.16 (1.42, 14.39)
Risk Difference (%) (Exact 95% CI)		0.8 (-13.6, 14.1)		19.0 (7.1, 28.5)
z-test p-value		0.910		0.002
Logistic Regression Model				
Odds Ratio (95% CI)		1.13 (0.55, 2.34)		7.71 (2.60, 22.84)
p-value		0.742		<0.001
Poisson Regression Model				
Relative Risk (95% CI)		1.12 (0.73, 1.72)		3.25 (1.62, 6.52)
p-value		0.588		<0.001

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV₁, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 9		
n	135	282
Responder [1]	26 (19%)	82 (29%)
Non-responder	109 (81%)	200 (71%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.72 (1.02, 2.95)
Unadjusted Relative Risk (Exact 95% CI)		1.51 (1.00, 2.43)
Risk Difference (%) (Exact 95% CI)		9.8 (0.0, 18.1)
z-test p-value		0.033
Logistic Regression Model		
Odds Ratio (95% CI)		2.10 (1.20, 3.66)
p-value		0.009
Poisson Regression Model		
Relative Risk (95% CI)		1.57 (1.10, 2.26)
p-value		0.014

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 17 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 10				
n	67	124	68	158
Responder [1]	20 (30%)	34 (27%)	7 (10%)	46 (29%)
Non-responder	47 (70%)	90 (73%)	61 (90%)	112 (71%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.89 (0.44, 1.82)		3.58 (1.48, 9.93)
Unadjusted Relative Risk (Exact 95% CI)		0.92 (0.58, 1.61)		2.83 (1.32, 8.72)
Risk Difference (%) (Exact 95% CI)		-2.4 (-16.6, 10.8)		18.8 (5.2, 28.7)
z-test p-value		0.722		0.003
Logistic Regression Model				
Odds Ratio (95% CI)		0.91 (0.45, 1.86)		6.11 (2.25, 16.57)
p-value		0.801		<0.001
Poisson Regression Model				
Relative Risk (95% CI)		0.99 (0.64, 1.54)		2.89 (1.49, 5.59)
p-value		0.975		0.002

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 10		
n	135	282
Responder [1]	27 (20%)	80 (28%)
Non-responder	108 (80%)	202 (72%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.58 (0.95, 2.71)
Unadjusted Relative Risk (Exact 95% CI)		1.42 (0.97, 2.21)
Risk Difference (%) (Exact 95% CI)		8.4 (-1.0, 16.7)
z-test p-value		0.068
Logistic Regression Model		
Odds Ratio (95% CI)		1.82 (1.07, 3.11)
p-value		0.029
Poisson Regression Model		
Relative Risk (95% CI)		1.47 (1.03, 2.10)
p-value		0.036

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 11				
n	67	124	68	158
Responder [1]	22 (33%)	37 (30%)	7 (10%)	42 (27%)
Non-responder	45 (67%)	87 (70%)	61 (90%)	116 (73%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.87 (0.44, 1.74)		3.16 (1.29, 8.79)
Unadjusted Relative Risk (Exact 95% CI)		0.91 (0.59, 1.51)		2.58 (1.18, 7.21)
Risk Difference (%) (Exact 95% CI)		-3.0 (-17.5, 10.6)		16.3 (1.6, 26.0)
z-test p-value		0.669		0.007
Logistic Regression Model				
Odds Ratio (95% CI)		0.89 (0.44, 1.81)		4.57 (1.77, 11.83)
p-value		0.742		0.002
Poisson Regression Model				
Relative Risk (95% CI)		0.99 (0.66, 1.49)		2.62 (1.29, 5.32)
p-value		0.959		0.008

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 11		
n	135	282
Responder [1]	29 (21%)	79 (28%)
Non-responder	106 (79%)	203 (72%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.42 (0.86, 2.40)
Unadjusted Relative Risk (Exact 95% CI)		1.30 (0.90, 2.00)
Risk Difference (%) (Exact 95% CI)		6.5 (-2.8, 15.0)
z-test p-value		0.155
Logistic Regression Model		
Odds Ratio (95% CI)		1.59 (0.94, 2.69)
p-value		0.084
Poisson Regression Model		
Relative Risk (95% CI)		1.35 (0.95, 1.91)
p-value		0.094

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 12				
n	67	124	68	158
Responder [1]	20 (30%)	40 (32%)	8 (12%)	52 (33%)
Non-responder	47 (70%)	84 (68%)	60 (88%)	106 (67%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.12 (0.56, 2.26)		3.68 (1.59, 9.53)
Unadjusted Relative Risk (Exact 95% CI)		1.08 (0.70, 1.79)		2.80 (1.39, 7.31)
Risk Difference (%) (Exact 95% CI)		2.4 (-12.0, 15.8)		21.1 (7.3, 31.3)
z-test p-value		0.733		<0.001
Logistic Regression Model				
Odds Ratio (95% CI)		1.21 (0.59, 2.47)		6.06 (2.41, 15.23)
p-value		0.603		<0.001
Poisson Regression Model				
Relative Risk (95% CI)		1.17 (0.77, 1.79)		2.82 (1.46, 5.45)
p-value		0.458		0.003

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 12		
n	135	282
Responder [1]	28 (21%)	92 (33%)
Non-responder	107 (79%)	190 (67%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.85 (1.12, 3.13)
Unadjusted Relative Risk (Exact 95% CI)		1.57 (1.01, 2.49)
Risk Difference (%) (Exact 95% CI)		11.9 (1.5, 20.4)
z-test p-value		0.013
Logistic Regression Model		
Odds Ratio (95% CI)		2.23 (1.32, 3.77)
p-value		0.003
Poisson Regression Model		
Relative Risk (95% CI)		1.62 (1.14, 2.30)
p-value		0.008

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 13				
n	67	124	68	158
Responder [1]	21 (31%)	36 (29%)	8 (12%)	51 (32%)
Non-responder	46 (69%)	88 (71%)	60 (88%)	107 (68%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.90 (0.45, 1.81)		3.57 (1.54, 9.27)
Unadjusted Relative Risk (Exact 95% CI)		0.93 (0.59, 1.59)		2.74 (1.36, 7.05)
Risk Difference (%) (Exact 95% CI)		-2.3 (-16.6, 11.1)		20.5 (6.2, 30.6)
z-test p-value		0.740		0.002
Logistic Regression Model				
Odds Ratio (95% CI)		0.91 (0.45, 1.85)		6.21 (2.38, 16.19)
p-value		0.804		<0.001
Poisson Regression Model				
Relative Risk (95% CI)		1.00 (0.65, 1.53)		2.78 (1.49, 5.20)
p-value		>0.999		0.002

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 13		
n	135	282
Responder [1]	29 (21%)	87 (31%)
Non-responder	106 (79%)	195 (69%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.63 (0.99, 2.74)
Unadjusted Relative Risk (Exact 95% CI)		1.44 (0.99, 2.19)
Risk Difference (%) (Exact 95% CI)		9.4 (-0.2, 17.9)
z-test p-value		0.046
Logistic Regression Model		
Odds Ratio (95% CI)		1.90 (1.13, 3.22)
p-value		0.017
Poisson Regression Model		
Relative Risk (95% CI)		1.48 (1.05, 2.09)
p-value		0.024

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 25 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 14				
n	67	124	68	158
Responder [1]	21 (31%)	35 (28%)	10 (15%)	48 (30%)
Non-responder	46 (69%)	89 (72%)	58 (85%)	110 (70%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.86 (0.43, 1.75)		2.53 (1.15, 6.01)
Unadjusted Relative Risk (Exact 95% CI)		0.90 (0.58, 1.53)		2.07 (1.02, 6.43)
Risk Difference (%) (Exact 95% CI)		-3.1 (-17.5, 10.2)		15.7 (0.7, 26.2)
z-test p-value		0.652		0.014
Logistic Regression Model				
Odds Ratio (95% CI)		0.87 (0.43, 1.74)		3.52 (1.51, 8.19)
p-value		0.691		0.004
Poisson Regression Model				
Relative Risk (95% CI)		0.96 (0.63, 1.47)		2.08 (1.17, 3.70)
p-value		0.867		0.013

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma

Page 26 of 50

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.8

Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 14		
n	135	282
Responder [1]	31 (23%)	83 (29%)
Non-responder	104 (77%)	199 (71%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.40 (0.85, 2.34)
Unadjusted Relative Risk (Exact 95% CI)		1.28 (0.90, 1.96)
Risk Difference (%) (Exact 95% CI)		6.5 (-3.0, 15.2)
z-test p-value		0.166
Logistic Regression Model		
Odds Ratio (95% CI)		1.54 (0.93, 2.55)
p-value		0.092
Poisson Regression Model		
Relative Risk (95% CI)		1.32 (0.94, 1.84)
p-value		0.108

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup
Page 27 of 50
Data as of 29APR2024
Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 15				
n	67	124	68	158
Responder [1]	20 (30%)	37 (30%)	10 (15%)	49 (31%)
Non-responder	47 (70%)	87 (70%)	58 (85%)	109 (69%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.00 (0.50, 2.03)		2.61 (1.19, 6.19)
Unadjusted Relative Risk (Exact 95% CI)		1.00 (0.64, 1.76)		2.11 (1.02, 6.43)
Risk Difference (%) (Exact 95% CI)		0.0 (-14.3, 13.3)		16.3 (1.6, 26.9)
z-test p-value		0.999		0.011
Logistic Regression Model				
Odds Ratio (95% CI)		1.05 (0.52, 2.15)		3.75 (1.59, 8.86)
p-value		0.888		0.003
Poisson Regression Model				
Relative Risk (95% CI)		1.08 (0.71, 1.65)		2.13 (1.20, 3.79)
p-value		0.705		0.011

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 15		
n	135	282
Responder [1]	30 (22%)	86 (30%)
Non-responder	105 (78%)	196 (70%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.54 (0.93, 2.57)
Unadjusted Relative Risk (Exact 95% CI)		1.37 (0.96, 2.12)
Risk Difference (%) (Exact 95% CI)		8.3 (-1.3, 16.9)
z-test p-value		0.078
Logistic Regression Model		
Odds Ratio (95% CI)		1.76 (1.05, 2.95)
p-value		0.032
Poisson Regression Model		
Relative Risk (95% CI)		1.42 (1.01, 1.98)
p-value		0.043

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSO) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSO Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 16				
n	67	124	68	158
Responder [1]	20 (30%)	27 (22%)	11 (16%)	40 (25%)
Non-responder	47 (70%)	97 (78%)	57 (84%)	118 (75%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.65 (0.32, 1.37)		1.76 (0.81, 4.08)
Unadjusted Relative Risk (Exact 95% CI)		0.73 (0.44, 1.27)		1.57 (0.87, 4.03)
Risk Difference (%) (Exact 95% CI)		-8.1 (-21.9, 4.8)		9.1 (-3.6, 19.7)
z-test p-value		0.217		0.132
Logistic Regression Model				
Odds Ratio (95% CI)		0.65 (0.31, 1.35)		2.16 (0.91, 5.14)
p-value		0.244		0.081
Poisson Regression Model				
Relative Risk (95% CI)		0.79 (0.49, 1.27)		1.61 (0.95, 2.72)
p-value		0.329		0.077

[1] Response is defined as a reduction in ADSO score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSO score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adso.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 16		
n	135	282
Responder [1]	31 (23%)	67 (24%)
Non-responder	104 (77%)	215 (76%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.05 (0.63, 1.76)
Unadjusted Relative Risk (Exact 95% CI)		1.03 (0.72, 1.58)
Risk Difference (%) (Exact 95% CI)		0.8 (-8.4, 9.2)
z-test p-value		0.858
Logistic Regression Model		
Odds Ratio (95% CI)		1.10 (0.65, 1.86)
p-value		0.735
Poisson Regression Model		
Relative Risk (95% CI)		1.08 (0.76, 1.52)
p-value		0.678

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 20				
n	67	124	68	158
Responder [1]	20 (30%)	31 (25%)	10 (15%)	38 (24%)
Non-responder	47 (70%)	93 (75%)	58 (85%)	120 (76%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.78 (0.39, 1.62)		1.84 (0.82, 4.42)
Unadjusted Relative Risk (Exact 95% CI)		0.84 (0.52, 1.46)		1.64 (0.88, 4.79)
Risk Difference (%) (Exact 95% CI)		-4.9 (-18.9, 8.2)		9.3 (-3.2, 19.6)
z-test p-value		0.470		0.116
Logistic Regression Model				
Odds Ratio (95% CI)		0.81 (0.39, 1.65)		2.38 (0.96, 5.88)
p-value		0.555		0.061
Poisson Regression Model				
Relative Risk (95% CI)		0.90 (0.57, 1.43)		1.69 (1.01, 2.84)
p-value		0.663		0.046

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 20		
n	135	282
Responder [1]	30 (22%)	69 (24%)
Non-responder	105 (78%)	213 (76%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.13 (0.68, 1.92)
Unadjusted Relative Risk (Exact 95% CI)		1.10 (0.76, 1.67)
Risk Difference (%) (Exact 95% CI)		2.2 (-7.0, 10.6)
z-test p-value		0.615
Logistic Regression Model		
Odds Ratio (95% CI)		1.22 (0.72, 2.08)
p-value		0.457
Poisson Regression Model		
Relative Risk (95% CI)		1.15 (0.80, 1.63)
p-value		0.452

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 33 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 24				
n	67	124	68	158
Responder [1]	18 (27%)	32 (26%)	8 (12%)	36 (23%)
Non-responder	49 (73%)	92 (74%)	60 (88%)	122 (77%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.95 (0.46, 1.99)		2.21 (0.93, 5.84)
Unadjusted Relative Risk (Exact 95% CI)		0.96 (0.59, 1.76)		1.94 (0.96, 6.43)
Risk Difference (%) (Exact 95% CI)		-1.1 (-14.9, 11.7)		11.0 (-1.0, 20.7)
z-test p-value		0.874		0.055
Logistic Regression Model				
Odds Ratio (95% CI)		1.03 (0.50, 2.14)		2.68 (1.13, 6.32)
p-value		0.938		0.025
Poisson Regression Model				
Relative Risk (95% CI)		1.04 (0.64, 1.68)		1.95 (1.00, 3.79)
p-value		0.875		0.050

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 34 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 24		
n	135	282
Responder [1]	26 (19%)	68 (24%)
Non-responder	109 (81%)	214 (76%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.33 (0.78, 2.31)
Unadjusted Relative Risk (Exact 95% CI)		1.25 (0.84, 1.98)
Risk Difference (%) (Exact 95% CI)		4.9 (-4.1, 12.9)
z-test p-value		0.268
Logistic Regression Model		
Odds Ratio (95% CI)		1.47 (0.87, 2.48)
p-value		0.155
Poisson Regression Model		
Relative Risk (95% CI)		1.29 (0.87, 1.90)
p-value		0.205

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSO) - High-dose ICS Subgroup

Page 35 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSO Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 26				
n	67	124	68	158
Responder [1]	19 (28%)	31 (25%)	11 (16%)	38 (24%)
Non-responder	48 (72%)	93 (75%)	57 (84%)	120 (76%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.84 (0.41, 1.75)		1.64 (0.75, 3.82)
Unadjusted Relative Risk (Exact 95% CI)		0.88 (0.54, 1.57)		1.49 (0.82, 3.71)
Risk Difference (%) (Exact 95% CI)		-3.4 (-17.3, 9.5)		7.9 (-4.7, 18.4)
z-test p-value		0.615		0.188
Logistic Regression Model				
Odds Ratio (95% CI)		0.91 (0.45, 1.85)		1.94 (0.85, 4.42)
p-value		0.793		0.114
Poisson Regression Model				
Relative Risk (95% CI)		0.94 (0.59, 1.50)		1.51 (0.86, 2.65)
p-value		0.796		0.149

[1] Response is defined as a reduction in ADSO score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV₁, baseline ADSO score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adso.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma

Page 36 of 50

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.8

Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 26		
n	135	282
Responder [1]	30 (22%)	69 (24%)
Non-responder	105 (78%)	213 (76%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.13 (0.68, 1.92)
Unadjusted Relative Risk (Exact 95% CI)		1.10 (0.76, 1.67)
Risk Difference (%) (Exact 95% CI)		2.2 (-7.0, 10.6)
z-test p-value		0.615
Logistic Regression Model		
Odds Ratio (95% CI)		1.23 (0.73, 2.05)
p-value		0.435
Poisson Regression Model		
Relative Risk (95% CI)		1.13 (0.79, 1.62)
p-value		0.494

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 28				
n	67	124	68	158
Responder [1]	19 (28%)	37 (30%)	12 (18%)	40 (25%)
Non-responder	48 (72%)	87 (70%)	56 (82%)	118 (75%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.07 (0.53, 2.21)		1.58 (0.74, 3.57)
Unadjusted Relative Risk (Exact 95% CI)		1.05 (0.66, 1.78)		1.43 (0.82, 3.27)
Risk Difference (%) (Exact 95% CI)		1.5 (-12.8, 14.6)		7.7 (-5.2, 18.5)
z-test p-value		0.831		0.209
Logistic Regression Model				
Odds Ratio (95% CI)		1.22 (0.60, 2.48)		1.86 (0.84, 4.13)
p-value		0.578		0.126
Poisson Regression Model				
Relative Risk (95% CI)		1.13 (0.72, 1.75)		1.45 (0.88, 2.40)
p-value		0.598		0.145

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma

Page 38 of 50

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.8

Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 28		
n	135	282
Responder [1]	31 (23%)	77 (27%)
Non-responder	104 (77%)	205 (73%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.26 (0.76, 2.11)
Unadjusted Relative Risk (Exact 95% CI)		1.19 (0.83, 1.78)
Risk Difference (%) (Exact 95% CI)		4.3 (-5.0, 12.9)
z-test p-value		0.344
Logistic Regression Model		
Odds Ratio (95% CI)		1.40 (0.85, 2.33)
p-value		0.190
Poisson Regression Model		
Relative Risk (95% CI)		1.22 (0.87, 1.72)
p-value		0.250

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 32				
n	67	124	68	158
Responder [1]	15 (22%)	31 (25%)	8 (12%)	36 (23%)
Non-responder	52 (78%)	93 (75%)	60 (88%)	122 (77%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.16 (0.55, 2.52)		2.21 (0.93, 5.84)
Unadjusted Relative Risk (Exact 95% CI)		1.12 (0.65, 2.05)		1.94 (0.96, 6.43)
Risk Difference (%) (Exact 95% CI)		2.6 (-11.0, 14.9)		11.0 (-1.0, 20.7)
z-test p-value		0.688		0.055
Logistic Regression Model				
Odds Ratio (95% CI)		1.37 (0.64, 2.91)		2.95 (1.19, 7.28)
p-value		0.415		0.020
Poisson Regression Model				
Relative Risk (95% CI)		1.20 (0.71, 2.02)		1.97 (1.02, 3.79)
p-value		0.490		0.043

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 32		
n	135	282
Responder [1]	23 (17%)	67 (24%)
Non-responder	112 (83%)	215 (76%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.52 (0.88, 2.69)
Unadjusted Relative Risk (Exact 95% CI)		1.39 (0.91, 2.30)
Risk Difference (%) (Exact 95% CI)		6.7 (-2.1, 14.5)
z-test p-value		0.119
Logistic Regression Model		
Odds Ratio (95% CI)		1.77 (1.02, 3.07)
p-value		0.042
Poisson Regression Model		
Relative Risk (95% CI)		1.44 (0.95, 2.17)
p-value		0.085

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 41 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 36				
n	67	124	68	158
Responder [1]	17 (25%)	28 (23%)	11 (16%)	43 (27%)
Non-responder	50 (75%)	96 (77%)	57 (84%)	115 (73%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.86 (0.41, 1.84)		1.94 (0.90, 4.48)
Unadjusted Relative Risk (Exact 95% CI)		0.89 (0.53, 1.71)		1.68 (0.94, 4.55)
Risk Difference (%) (Exact 95% CI)		-2.8 (-16.5, 9.6)		11.0 (-1.8, 21.7)
z-test p-value		0.665		0.075
Logistic Regression Model				
Odds Ratio (95% CI)		0.97 (0.47, 2.02)		2.69 (1.14, 6.35)
p-value		0.941		0.025
Poisson Regression Model				
Relative Risk (95% CI)		0.95 (0.58, 1.56)		1.72 (0.98, 3.00)
p-value		0.838		0.058

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 36		
n	135	282
Responder [1]	28 (21%)	71 (25%)
Non-responder	107 (79%)	211 (75%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.29 (0.77, 2.20)
Unadjusted Relative Risk (Exact 95% CI)		1.21 (0.83, 1.90)
Risk Difference (%) (Exact 95% CI)		4.4 (-4.7, 12.7)
z-test p-value		0.320
Logistic Regression Model		
Odds Ratio (95% CI)		1.46 (0.86, 2.47)
p-value		0.159
Poisson Regression Model		
Relative Risk (95% CI)		1.25 (0.87, 1.81)
p-value		0.229

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 43 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 40				
n	67	124	68	158
Responder [1]	19 (28%)	25 (20%)	12 (18%)	37 (23%)
Non-responder	48 (72%)	99 (80%)	56 (82%)	121 (77%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.64 (0.30, 1.36)		1.43 (0.66, 3.24)
Unadjusted Relative Risk (Exact 95% CI)		0.71 (0.42, 1.27)		1.33 (0.75, 2.91)
Risk Difference (%) (Exact 95% CI)		-8.2 (-21.9, 4.8)		5.8 (-7.0, 16.5)
z-test p-value		0.200		0.335
Logistic Regression Model				
Odds Ratio (95% CI)		0.68 (0.31, 1.47)		1.66 (0.74, 3.72)
p-value		0.328		0.215
Poisson Regression Model				
Relative Risk (95% CI)		0.79 (0.48, 1.30)		1.35 (0.81, 2.23)
p-value		0.358		0.249

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma

Page 44 of 50

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.8

Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 40		
n	135	282
Responder [1]	31 (23%)	62 (22%)
Non-responder	104 (77%)	220 (78%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		0.95 (0.57, 1.60)
Unadjusted Relative Risk (Exact 95% CI)		0.96 (0.66, 1.54)
Risk Difference (%) (Exact 95% CI)		-1.0 (-10.2, 7.4)
z-test p-value		0.823
Logistic Regression Model		
Odds Ratio (95% CI)		1.00 (0.59, 1.70)
p-value		0.990
Poisson Regression Model		
Relative Risk (95% CI)		1.00 (0.70, 1.42)
p-value		0.985

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSO) - High-dose ICS Subgroup

Page 45 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSO Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 44				
n	67	124	68	158
Responder [1]	16 (24%)	34 (27%)	9 (13%)	40 (25%)
Non-responder	51 (76%)	90 (73%)	59 (87%)	118 (75%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.20 (0.58, 2.57)		2.22 (0.97, 5.55)
Unadjusted Relative Risk (Exact 95% CI)		1.15 (0.69, 2.06)		1.91 (0.98, 6.31)
Risk Difference (%) (Exact 95% CI)		3.5 (-10.2, 16.0)		12.1 (-0.6, 22.2)
z-test p-value		0.596		0.044
Logistic Regression Model				
Odds Ratio (95% CI)		1.48 (0.70, 3.13)		2.94 (1.25, 6.92)
p-value		0.309		0.014
Poisson Regression Model				
Relative Risk (95% CI)		1.25 (0.77, 2.02)		1.92 (1.02, 3.64)
p-value		0.361		0.045

[1] Response is defined as a reduction in ADSO score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV₁, baseline ADSO score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adso.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma

Page 46 of 50

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.8

Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 44		
n	135	282
Responder [1]	25 (19%)	74 (26%)
Non-responder	110 (81%)	208 (74%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.57 (0.92, 2.72)
Unadjusted Relative Risk (Exact 95% CI)		1.42 (0.95, 2.27)
Risk Difference (%) (Exact 95% CI)		7.7 (-1.5, 15.8)
z-test p-value		0.083
Logistic Regression Model		
Odds Ratio (95% CI)		1.83 (1.07, 3.13)
p-value		0.028
Poisson Regression Model		
Relative Risk (95% CI)		1.46 (0.99, 2.15)
p-value		0.055

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 48				
n	67	124	68	158
Responder [1]	14 (21%)	32 (26%)	9 (13%)	35 (22%)
Non-responder	53 (79%)	92 (74%)	59 (87%)	123 (78%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.32 (0.62, 2.92)		1.87 (0.81, 4.70)
Unadjusted Relative Risk (Exact 95% CI)		1.24 (0.72, 2.37)		1.67 (0.87, 5.70)
Risk Difference (%) (Exact 95% CI)		4.9 (-8.6, 17.1)		8.9 (-3.2, 18.8)
z-test p-value		0.449		0.121
Logistic Regression Model				
Odds Ratio (95% CI)		1.70 (0.76, 3.78)		2.39 (0.99, 5.79)
p-value		0.194		0.054
Poisson Regression Model				
Relative Risk (95% CI)		1.37 (0.81, 2.32)		1.70 (0.88, 3.30)
p-value		0.241		0.113

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 48		
n	135	282
Responder [1]	23 (17%)	67 (24%)
Non-responder	112 (83%)	215 (76%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.52 (0.88, 2.69)
Unadjusted Relative Risk (Exact 95% CI)		1.39 (0.91, 2.30)
Risk Difference (%) (Exact 95% CI)		6.7 (-2.1, 14.5)
z-test p-value		0.119
Logistic Regression Model		
Odds Ratio (95% CI)		1.80 (1.02, 3.16)
p-value		0.043
Poisson Regression Model		
Relative Risk (95% CI)		1.45 (0.97, 2.19)
p-value		0.074

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.
Note: AR(1) covariance structure was used in logistic regression to enable convergence.
t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 49 of 50
Data as of 29APR2024

Table 27.8
Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 52				
n	67	124	68	158
Responder [1]	18 (27%)	29 (23%)	9 (13%)	33 (21%)
Non-responder	49 (73%)	95 (77%)	59 (87%)	125 (79%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.83 (0.40, 1.76)		1.73 (0.75, 4.38)
Unadjusted Relative Risk (Exact 95% CI)		0.87 (0.52, 1.59)		1.58 (0.82, 5.09)
Risk Difference (%) (Exact 95% CI)		-3.5 (-17.3, 9.2)		7.7 (-4.3, 17.5)
z-test p-value		0.595		0.176
Logistic Regression Model				
Odds Ratio (95% CI)		0.93 (0.45, 1.96)		2.25 (0.89, 5.68)
p-value		0.858		0.086
Poisson Regression Model				
Relative Risk (95% CI)		0.95 (0.59, 1.51)		1.63 (0.87, 3.07)
p-value		0.817		0.130
p-value for Treatment by Study Interaction				

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma

Page 50 of 50

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.8

Analysis of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 52		
n	135	282
Responder [1]	27 (20%)	62 (22%)
Non-responder	108 (80%)	220 (78%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.13 (0.66, 1.95)
Unadjusted Relative Risk (Exact 95% CI)		1.10 (0.74, 1.73)
Risk Difference (%) (Exact 95% CI)		2.0 (-6.9, 10.1)
z-test p-value		0.644
Logistic Regression Model		
Odds Ratio (95% CI)		1.23 (0.71, 2.12)
p-value		0.456
Poisson Regression Model		
Relative Risk (95% CI)		1.15 (0.79, 1.66)
p-value		0.473
p-value for Treatment by Study		<0.001
Interaction		

[1] Response is defined as a reduction in ADSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ADSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.


Note: Subjects with missing baseline covariates did not contribute to the modelled estimates.

Note: AR(1) covariance structure was used in logistic regression to enable convergence.

t_e_resp_adsd.sas 10JUL2025 08:32

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup


Figure 27.15
Forest Plot of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)
(odds ratios)



No. of Subjects is the number of subjects with non-missing baseline covariates.
/mnt/code/gvd/prod/tf/f_e_adsd_forest_or.sas 10JUL2025 11:03

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Figure 27.16
Forest Plot of Proportion of Responders according to ADSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)
(relative risks)



No. of Subjects is the number of subjects with non-missing baseline covariates.
/mnt/code/gvd/prod/tf/f_e_adsd_forest_rr.sas 10JUL2025 11:03

2.13 ANSD - Responderanalyse

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 1 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 2				
n	67	124	68	158
Responder [1]	3 (4%)	18 (15%)	7 (10%)	26 (16%)
Non-responder	64 (96%)	106 (85%)	61 (90%)	132 (84%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		3.62 (0.99, 19.84)		1.72 (0.68, 4.94)
Unadjusted Relative Risk (Exact 95% CI)		3.24 (1.00, 18.07)		1.60 (0.75, 6.30)
Risk Difference (%) (Exact 95% CI)		10.0 (0.4, 18.4)		6.2 (-4.9, 15.1)
z-test p-value		0.035		0.229
Logistic Regression Model				
Odds Ratio (95% CI)		3.98 (1.09, 14.57)		2.08 (0.78, 5.58)
p-value		0.037		0.146
Poisson Regression Model				
Relative Risk (95% CI)		3.16 (0.94, 10.65)		1.69 (0.77, 3.73)
p-value		0.064		0.193

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 2 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 2		
n	135	282
Responder [1]	10 (7%)	44 (16%)
Non-responder	125 (93%)	238 (84%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		2.31 (1.10, 5.32)
Unadjusted Relative Risk (Exact 95% CI)		2.11 (1.01, 7.01)
Risk Difference (%) (Exact 95% CI)		8.2 (0.3, 14.2)
z-test p-value		0.020
Logistic Regression Model		
Odds Ratio (95% CI)		2.63 (1.25, 5.51)
p-value		0.011
Poisson Regression Model		
Relative Risk (95% CI)		2.05 (1.07, 3.92)
p-value		0.031

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 3 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 3				
n	67	124	68	158
Responder [1]	4 (6%)	23 (19%)	8 (12%)	34 (22%)
Non-responder	63 (94%)	101 (81%)	60 (88%)	124 (78%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		3.59 (1.14, 14.85)		2.06 (0.86, 5.45)
Unadjusted Relative Risk (Exact 95% CI)		3.11 (1.02, 18.07)		1.83 (0.91, 6.43)
Risk Difference (%) (Exact 95% CI)		12.6 (1.4, 21.7)		9.8 (-2.1, 19.3)
z-test p-value		0.018		0.084
Logistic Regression Model				
Odds Ratio (95% CI)		4.24 (1.31, 13.68)		2.80 (1.08, 7.27)
p-value		0.016		0.035
Poisson Regression Model				
Relative Risk (95% CI)		3.04 (1.07, 8.59)		1.92 (0.97, 3.81)
p-value		0.037		0.061

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 4 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 3		
n	135	282
Responder [1]	12 (9%)	57 (20%)
Non-responder	123 (91%)	225 (80%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		2.60 (1.31, 5.52)
Unadjusted Relative Risk (Exact 95% CI)		2.27 (1.23, 6.89)
Risk Difference (%) (Exact 95% CI)		11.3 (3.1, 17.9)
z-test p-value		0.004
Logistic Regression Model		
Odds Ratio (95% CI)		3.19 (1.58, 6.43)
p-value		0.002
Poisson Regression Model		
Relative Risk (95% CI)		2.21 (1.26, 3.89)
p-value		0.006

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 5 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 4				
n	67	124	68	158
Responder [1]	11 (16%)	27 (22%)	8 (12%)	39 (25%)
Non-responder	56 (84%)	97 (78%)	60 (88%)	119 (75%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.42 (0.62, 3.41)		2.46 (1.04, 6.46)
Unadjusted Relative Risk (Exact 95% CI)		1.33 (0.72, 2.96)		2.10 (1.00, 6.43)
Risk Difference (%) (Exact 95% CI)		5.4 (-7.4, 16.5)		12.9 (0.3, 22.8)
z-test p-value		0.377		0.029
Logistic Regression Model				
Odds Ratio (95% CI)		1.48 (0.63, 3.47)		3.13 (1.30, 7.58)
p-value		0.364		0.012
Poisson Regression Model				
Relative Risk (95% CI)		1.29 (0.71, 2.35)		2.17 (1.07, 4.37)
p-value		0.403		0.032

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 4		
n	135	282
Responder [1]	19 (14%)	66 (23%)
Non-responder	116 (86%)	216 (77%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.87 (1.04, 3.45)
Unadjusted Relative Risk (Exact 95% CI)		1.66 (1.00, 3.05)
Risk Difference (%) (Exact 95% CI)		9.3 (0.3, 16.8)
z-test p-value		0.027
Logistic Regression Model		
Odds Ratio (95% CI)		2.08 (1.16, 3.74)
p-value		0.015
Poisson Regression Model		
Relative Risk (95% CI)		1.61 (1.02, 2.53)
p-value		0.041

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 7 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 5				
n	67	124	68	158
Responder [1]	10 (15%)	30 (24%)	8 (12%)	40 (25%)
Non-responder	57 (85%)	94 (76%)	60 (88%)	118 (75%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.82 (0.79, 4.48)		2.54 (1.08, 6.67)
Unadjusted Relative Risk (Exact 95% CI)		1.62 (0.86, 4.00)		2.15 (1.01, 6.48)
Risk Difference (%) (Exact 95% CI)		9.3 (-3.7, 20.3)		13.6 (0.3, 23.5)
z-test p-value		0.134		0.023
Logistic Regression Model				
Odds Ratio (95% CI)		1.84 (0.79, 4.31)		3.62 (1.42, 9.23)
p-value		0.160		0.008
Poisson Regression Model				
Relative Risk (95% CI)		1.57 (0.86, 2.88)		2.24 (1.12, 4.47)
p-value		0.141		0.023

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 5		
n	135	282
Responder [1]	18 (13%)	70 (25%)
Non-responder	117 (87%)	212 (75%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		2.15 (1.19, 4.01)
Unadjusted Relative Risk (Exact 95% CI)		1.86 (1.01, 3.66)
Risk Difference (%) (Exact 95% CI)		11.5 (2.1, 18.9)
z-test p-value		0.008
Logistic Regression Model		
Odds Ratio (95% CI)		2.52 (1.38, 4.60)
p-value		0.003
Poisson Regression Model		
Relative Risk (95% CI)		1.80 (1.14, 2.84)
p-value		0.012

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 9 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 6				
n	67	124	68	158
Responder [1]	13 (19%)	34 (27%)	8 (12%)	40 (25%)
Non-responder	54 (81%)	90 (73%)	60 (88%)	118 (75%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.57 (0.73, 3.53)		2.54 (1.08, 6.67)
Unadjusted Relative Risk (Exact 95% CI)		1.41 (0.82, 2.88)		2.15 (1.01, 6.48)
Risk Difference (%) (Exact 95% CI)		8.0 (-5.4, 20.1)		13.6 (0.3, 23.5)
z-test p-value		0.220		0.023
Logistic Regression Model				
Odds Ratio (95% CI)		1.58 (0.69, 3.63)		3.28 (1.34, 8.01)
p-value		0.280		0.010
Poisson Regression Model				
Relative Risk (95% CI)		1.38 (0.81, 2.35)		2.22 (1.12, 4.40)
p-value		0.233		0.022

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 6		
n	135	282
Responder [1]	21 (16%)	74 (26%)
Non-responder	114 (84%)	208 (74%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.93 (1.11, 3.48)
Unadjusted Relative Risk (Exact 95% CI)		1.69 (1.01, 2.97)
Risk Difference (%) (Exact 95% CI)		10.7 (0.7, 18.4)
z-test p-value		0.015
Logistic Regression Model		
Odds Ratio (95% CI)		2.28 (1.27, 4.08)
p-value		0.006
Poisson Regression Model		
Relative Risk (95% CI)		1.63 (1.08, 2.48)
p-value		0.022

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 11 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 7				
n	67	124	68	158
Responder [1]	13 (19%)	30 (24%)	10 (15%)	43 (27%)
Non-responder	54 (81%)	94 (76%)	58 (85%)	115 (73%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.33 (0.61, 3.01)		2.17 (0.98, 5.18)
Unadjusted Relative Risk (Exact 95% CI)		1.25 (0.71, 2.38)		1.85 (0.98, 6.04)
Risk Difference (%) (Exact 95% CI)		4.8 (-8.4, 16.6)		12.5 (-0.6, 22.9)
z-test p-value		0.450		0.042
Logistic Regression Model				
Odds Ratio (95% CI)		1.22 (0.55, 2.73)		2.68 (1.18, 6.11)
p-value		0.628		0.019
Poisson Regression Model				
Relative Risk (95% CI)		1.21 (0.71, 2.06)		1.90 (1.04, 3.50)
p-value		0.476		0.038

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 7		
n	135	282
Responder [1]	23 (17%)	73 (26%)
Non-responder	112 (83%)	209 (74%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.70 (0.99, 3.01)
Unadjusted Relative Risk (Exact 95% CI)		1.52 (0.99, 2.59)
Risk Difference (%) (Exact 95% CI)		8.8 (-0.5, 16.8)
z-test p-value		0.045
Logistic Regression Model		
Odds Ratio (95% CI)		1.85 (1.07, 3.20)
p-value		0.029
Poisson Regression Model		
Relative Risk (95% CI)		1.47 (0.99, 2.18)
p-value		0.060

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 13 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 8				
n	67	124	68	158
Responder [1]	15 (22%)	33 (27%)	10 (15%)	44 (28%)
Non-responder	52 (78%)	91 (73%)	58 (85%)	114 (72%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.26 (0.60, 2.73)		2.24 (1.01, 5.34)
Unadjusted Relative Risk (Exact 95% CI)		1.19 (0.71, 2.21)		1.89 (1.00, 6.30)
Risk Difference (%) (Exact 95% CI)		4.2 (-9.4, 16.5)		13.1 (0.3, 23.6)
z-test p-value		0.521		0.034
Logistic Regression Model				
Odds Ratio (95% CI)		1.14 (0.52, 2.50)		2.82 (1.23, 6.46)
p-value		0.741		0.014
Poisson Regression Model				
Relative Risk (95% CI)		1.16 (0.71, 1.90)		1.95 (1.06, 3.57)
p-value		0.563		0.032

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to modelled estimates.

Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.

t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma

Page 14 of 50

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.6

Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 8		
n	135	282
Responder [1]	25 (19%)	77 (27%)
Non-responder	110 (81%)	205 (73%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.65 (0.97, 2.87)
Unadjusted Relative Risk (Exact 95% CI)		1.47 (0.98, 2.40)
Risk Difference (%) (Exact 95% CI)		8.8 (-0.5, 16.9)
z-test p-value		0.051
Logistic Regression Model		
Odds Ratio (95% CI)		1.80 (1.05, 3.10)
p-value		0.033
Poisson Regression Model		
Relative Risk (95% CI)		1.42 (0.97, 2.09)
p-value		0.070

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV₁, baseline ANSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to modelled estimates.

Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.

t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 9				
n	67	124	68	158
Responder [1]	14 (21%)	32 (26%)	12 (18%)	42 (27%)
Non-responder	53 (79%)	92 (74%)	56 (82%)	116 (73%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.32 (0.62, 2.92)		1.69 (0.79, 3.80)
Unadjusted Relative Risk (Exact 95% CI)		1.24 (0.72, 2.37)		1.51 (0.86, 3.52)
Risk Difference (%) (Exact 95% CI)		4.9 (-8.6, 17.1)		8.9 (-4.0, 19.8)
z-test p-value		0.449		0.149
Logistic Regression Model				
Odds Ratio (95% CI)		1.21 (0.55, 2.67)		2.01 (0.91, 4.45)
p-value		0.643		0.084
Poisson Regression Model				
Relative Risk (95% CI)		1.20 (0.72, 2.00)		1.55 (0.90, 2.66)
p-value		0.481		0.111

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma

Page 16 of 50

Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Data as of 29APR2024

Table 27.6

Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 9		
n	135	282
Responder [1]	26 (19%)	74 (26%)
Non-responder	109 (81%)	208 (74%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.49 (0.88, 2.58)
Unadjusted Relative Risk (Exact 95% CI)		1.36 (0.92, 2.13)
Risk Difference (%) (Exact 95% CI)		7.0 (-2.2, 15.2)
z-test p-value		0.119
Logistic Regression Model		
Odds Ratio (95% CI)		1.58 (0.93, 2.71)
p-value		0.094
Poisson Regression Model		
Relative Risk (95% CI)		1.32 (0.91, 1.91)
p-value		0.149

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to modelled estimates.

Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.

t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 17 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 10				
n	67	124	68	158
Responder [1]	16 (24%)	33 (27%)	12 (18%)	44 (28%)
Non-responder	51 (76%)	91 (73%)	56 (82%)	114 (72%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.16 (0.55, 2.48)		1.80 (0.85, 4.04)
Unadjusted Relative Risk (Exact 95% CI)		1.11 (0.67, 1.97)		1.58 (0.90, 3.79)
Risk Difference (%) (Exact 95% CI)		2.7 (-11.1, 15.2)		10.2 (-2.8, 21.1)
z-test p-value		0.680		0.104
Logistic Regression Model				
Odds Ratio (95% CI)		1.03 (0.48, 2.21)		2.09 (0.97, 4.47)
p-value		0.943		0.059
Poisson Regression Model				
Relative Risk (95% CI)		1.08 (0.67, 1.75)		1.62 (0.94, 2.78)
p-value		0.749		0.084

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to modelled estimates.

Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.

t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 10		
n	135	282
Responder [1]	28 (21%)	77 (27%)
Non-responder	107 (79%)	205 (73%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.44 (0.86, 2.44)
Unadjusted Relative Risk (Exact 95% CI)		1.32 (0.90, 2.06)
Risk Difference (%) (Exact 95% CI)		6.6 (-2.8, 14.9)
z-test p-value		0.149
Logistic Regression Model		
Odds Ratio (95% CI)		1.49 (0.89, 2.49)
p-value		0.133
Poisson Regression Model		
Relative Risk (95% CI)		1.27 (0.88, 1.82)
p-value		0.198

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 19 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 11				
n	67	124	68	158
Responder [1]	15 (22%)	31 (25%)	12 (18%)	45 (28%)
Non-responder	52 (78%)	93 (75%)	56 (82%)	113 (72%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.16 (0.55, 2.52)		1.86 (0.88, 4.16)
Unadjusted Relative Risk (Exact 95% CI)		1.12 (0.65, 2.05)		1.61 (0.93, 3.92)
Risk Difference (%) (Exact 95% CI)		2.6 (-11.0, 14.9)		10.8 (-2.3, 21.8)
z-test p-value		0.688		0.086
Logistic Regression Model				
Odds Ratio (95% CI)		1.05 (0.47, 2.34)		2.35 (1.05, 5.27)
p-value		0.910		0.039
Poisson Regression Model				
Relative Risk (95% CI)		1.09 (0.67, 1.78)		1.67 (0.97, 2.85)
p-value		0.727		0.064

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 20 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 11		
n	135	282
Responder [1]	27 (20%)	76 (27%)
Non-responder	108 (80%)	206 (73%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.48 (0.88, 2.53)
Unadjusted Relative Risk (Exact 95% CI)		1.35 (0.92, 2.12)
Risk Difference (%) (Exact 95% CI)		7.0 (-2.3, 15.2)
z-test p-value		0.124
Logistic Regression Model		
Odds Ratio (95% CI)		1.59 (0.92, 2.74)
p-value		0.094
Poisson Regression Model		
Relative Risk (95% CI)		1.30 (0.91, 1.88)
p-value		0.153

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 21 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 12				
n	67	124	68	158
Responder [1]	15 (22%)	33 (27%)	11 (16%)	48 (30%)
Non-responder	52 (78%)	91 (73%)	57 (84%)	110 (70%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.26 (0.60, 2.73)		2.26 (1.05, 5.19)
Unadjusted Relative Risk (Exact 95% CI)		1.19 (0.71, 2.21)		1.88 (1.00, 5.52)
Risk Difference (%) (Exact 95% CI)		4.2 (-9.4, 16.5)		14.2 (0.3, 25.0)
z-test p-value		0.521		0.026
Logistic Regression Model				
Odds Ratio (95% CI)		1.17 (0.53, 2.56)		2.87 (1.29, 6.40)
p-value		0.696		0.010
Poisson Regression Model				
Relative Risk (95% CI)		1.16 (0.71, 1.89)		1.93 (1.09, 3.41)
p-value		0.563		0.025

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 12		
n	135	282
Responder [1]	26 (19%)	81 (29%)
Non-responder	109 (81%)	201 (71%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.69 (1.00, 2.91)
Unadjusted Relative Risk (Exact 95% CI)		1.49 (0.99, 2.39)
Risk Difference (%) (Exact 95% CI)		9.5 (0.0, 17.7)
z-test p-value		0.039
Logistic Regression Model		
Odds Ratio (95% CI)		1.83 (1.07, 3.12)
p-value		0.027
Poisson Regression Model		
Relative Risk (95% CI)		1.44 (0.99, 2.08)
p-value		0.055

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 13				
n	67	124	68	158
Responder [1]	15 (22%)	34 (27%)	11 (16%)	49 (31%)
Non-responder	52 (78%)	90 (73%)	57 (84%)	109 (69%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.31 (0.62, 2.84)		2.33 (1.08, 5.34)
Unadjusted Relative Risk (Exact 95% CI)		1.22 (0.73, 2.27)		1.92 (1.01, 5.74)
Risk Difference (%) (Exact 95% CI)		5.0 (-8.6, 17.4)		14.8 (0.7, 25.7)
z-test p-value		0.448		0.021
Logistic Regression Model				
Odds Ratio (95% CI)		1.24 (0.57, 2.73)		3.32 (1.42, 7.79)
p-value		0.584		0.006
Poisson Regression Model				
Relative Risk (95% CI)		1.19 (0.74, 1.92)		1.98 (1.14, 3.45)
p-value		0.475		0.016

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 24 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 13		
n	135	282
Responder [1]	26 (19%)	83 (29%)
Non-responder	109 (81%)	199 (71%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.75 (1.04, 3.00)
Unadjusted Relative Risk (Exact 95% CI)		1.53 (1.00, 2.47)
Risk Difference (%) (Exact 95% CI)		10.2 (0.3, 18.4)
z-test p-value		0.027
Logistic Regression Model		
Odds Ratio (95% CI)		1.97 (1.14, 3.41)
p-value		0.016
Poisson Regression Model		
Relative Risk (95% CI)		1.48 (1.03, 2.13)
p-value		0.036

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 25 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 14				
n	67	124	68	158
Responder [1]	17 (25%)	26 (21%)	12 (18%)	51 (32%)
Non-responder	50 (75%)	98 (79%)	56 (82%)	107 (68%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.78 (0.37, 1.69)		2.22 (1.06, 4.95)
Unadjusted Relative Risk (Exact 95% CI)		0.83 (0.48, 1.54)		1.83 (1.01, 4.81)
Risk Difference (%) (Exact 95% CI)		-4.4 (-17.9, 8.0)		14.6 (0.3, 25.7)
z-test p-value		0.487		0.025
Logistic Regression Model				
Odds Ratio (95% CI)		0.66 (0.30, 1.46)		2.95 (1.32, 6.60)
p-value		0.302		0.009
Poisson Regression Model				
Relative Risk (95% CI)		0.81 (0.50, 1.31)		1.88 (1.10, 3.22)
p-value		0.385		0.022

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 14		
n	135	282
Responder [1]	29 (21%)	77 (27%)
Non-responder	106 (79%)	205 (73%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.37 (0.83, 2.32)
Unadjusted Relative Risk (Exact 95% CI)		1.27 (0.88, 1.98)
Risk Difference (%) (Exact 95% CI)		5.8 (-3.5, 14.2)
z-test p-value		0.202
Logistic Regression Model		
Odds Ratio (95% CI)		1.42 (0.84, 2.41)
p-value		0.189
Poisson Regression Model		
Relative Risk (95% CI)		1.23 (0.86, 1.75)
p-value		0.255

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 27 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 15				
n	67	124	68	158
Responder [1]	15 (22%)	30 (24%)	11 (16%)	49 (31%)
Non-responder	52 (78%)	94 (76%)	57 (84%)	109 (69%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.11 (0.52, 2.42)		2.33 (1.08, 5.34)
Unadjusted Relative Risk (Exact 95% CI)		1.08 (0.63, 1.97)		1.92 (1.01, 5.74)
Risk Difference (%) (Exact 95% CI)		1.8 (-11.7, 14.1)		14.8 (0.7, 25.7)
z-test p-value		0.780		0.021
Logistic Regression Model				
Odds Ratio (95% CI)		1.04 (0.47, 2.29)		2.91 (1.31, 6.43)
p-value		0.925		0.009
Poisson Regression Model				
Relative Risk (95% CI)		1.05 (0.64, 1.73)		1.97 (1.14, 3.40)
p-value		0.843		0.016

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to modelled estimates.

Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.

t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 15		
n	135	282
Responder [1]	26 (19%)	79 (28%)
Non-responder	109 (81%)	203 (72%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.63 (0.97, 2.81)
Unadjusted Relative Risk (Exact 95% CI)		1.45 (0.98, 2.32)
Risk Difference (%) (Exact 95% CI)		8.8 (-0.5, 17.0)
z-test p-value		0.054
Logistic Regression Model		
Odds Ratio (95% CI)		1.74 (1.02, 2.95)
p-value		0.042
Poisson Regression Model		
Relative Risk (95% CI)		1.40 (0.97, 2.02)
p-value		0.070

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 29 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 16				
n	67	124	68	158
Responder [1]	17 (25%)	27 (22%)	10 (15%)	35 (22%)
Non-responder	50 (75%)	97 (78%)	58 (85%)	123 (78%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.82 (0.39, 1.76)		1.65 (0.73, 3.99)
Unadjusted Relative Risk (Exact 95% CI)		0.86 (0.50, 1.62)		1.51 (0.81, 4.15)
Risk Difference (%) (Exact 95% CI)		-3.6 (-17.1, 8.9)		7.4 (-4.7, 17.7)
z-test p-value		0.573		0.199
Logistic Regression Model				
Odds Ratio (95% CI)		0.73 (0.34, 1.56)		1.95 (0.84, 4.53)
p-value		0.418		0.119
Poisson Regression Model				
Relative Risk (95% CI)		0.83 (0.51, 1.36)		1.56 (0.85, 2.84)
p-value		0.460		0.150

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 16		
n	135	282
Responder [1]	27 (20%)	62 (22%)
Non-responder	108 (80%)	220 (78%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.13 (0.66, 1.95)
Unadjusted Relative Risk (Exact 95% CI)		1.10 (0.74, 1.73)
Risk Difference (%) (Exact 95% CI)		2.0 (-6.9, 10.1)
z-test p-value		0.644
Logistic Regression Model		
Odds Ratio (95% CI)		1.11 (0.65, 1.89)
p-value		0.695
Poisson Regression Model		
Relative Risk (95% CI)		1.06 (0.73, 1.55)
p-value		0.762

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 20				
n	67	124	68	158
Responder [1]	11 (16%)	26 (21%)	11 (16%)	39 (25%)
Non-responder	56 (84%)	98 (79%)	57 (84%)	119 (75%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.35 (0.59, 3.26)		1.70 (0.78, 3.95)
Unadjusted Relative Risk (Exact 95% CI)		1.28 (0.68, 2.78)		1.53 (0.85, 3.87)
Risk Difference (%) (Exact 95% CI)		4.5 (-8.0, 15.6)		8.5 (-4.0, 19.0)
z-test p-value		0.448		0.158
Logistic Regression Model				
Odds Ratio (95% CI)		1.37 (0.58, 3.22)		2.15 (0.92, 5.01)
p-value		0.470		0.078
Poisson Regression Model				
Relative Risk (95% CI)		1.24 (0.69, 2.25)		1.59 (0.94, 2.69)
p-value		0.472		0.087

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 32 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 20		
n	135	282
Responder [1]	22 (16%)	65 (23%)
Non-responder	113 (84%)	217 (77%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.54 (0.88, 2.76)
Unadjusted Relative Risk (Exact 95% CI)		1.41 (0.92, 2.39)
Risk Difference (%) (Exact 95% CI)		6.8 (-2.0, 14.4)
z-test p-value		0.113
Logistic Regression Model		
Odds Ratio (95% CI)		1.66 (0.93, 2.96)
p-value		0.084
Poisson Regression Model		
Relative Risk (95% CI)		1.37 (0.91, 2.05)
p-value		0.129

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 24				
n	67	124	68	158
Responder [1]	12 (18%)	33 (27%)	8 (12%)	35 (22%)
Non-responder	55 (82%)	91 (73%)	60 (88%)	123 (78%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.66 (0.76, 3.83)		2.13 (0.90, 5.64)
Unadjusted Relative Risk (Exact 95% CI)		1.49 (0.84, 3.17)		1.88 (0.94, 6.43)
Risk Difference (%) (Exact 95% CI)		8.7 (-4.8, 20.5)		10.4 (-1.6, 20.0)
z-test p-value		0.177		0.069
Logistic Regression Model				
Odds Ratio (95% CI)		1.75 (0.77, 3.97)		2.65 (1.10, 6.38)
p-value		0.181		0.031
Poisson Regression Model				
Relative Risk (95% CI)		1.44 (0.84, 2.47)		1.94 (0.97, 3.87)
p-value		0.184		0.061

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 34 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 24		
n	135	282
Responder [1]	20 (15%)	68 (24%)
Non-responder	115 (85%)	214 (76%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.83 (1.03, 3.34)
Unadjusted Relative Risk (Exact 95% CI)		1.63 (1.00, 2.90)
Risk Difference (%) (Exact 95% CI)		9.3 (0.3, 16.9)
z-test p-value		0.030
Logistic Regression Model		
Odds Ratio (95% CI)		1.98 (1.12, 3.52)
p-value		0.020
Poisson Regression Model		
Relative Risk (95% CI)		1.57 (1.01, 2.44)
p-value		0.044

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 26				
n	67	124	68	158
Responder [1]	14 (21%)	32 (26%)	12 (18%)	37 (23%)
Non-responder	53 (79%)	92 (74%)	56 (82%)	121 (77%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.32 (0.62, 2.92)		1.43 (0.66, 3.24)
Unadjusted Relative Risk (Exact 95% CI)		1.24 (0.72, 2.37)		1.33 (0.75, 2.91)
Risk Difference (%) (Exact 95% CI)		4.9 (-8.6, 17.1)		5.8 (-7.0, 16.5)
z-test p-value		0.449		0.335
Logistic Regression Model				
Odds Ratio (95% CI)		1.29 (0.59, 2.80)		1.65 (0.75, 3.61)
p-value		0.524		0.213
Poisson Regression Model				
Relative Risk (95% CI)		1.19 (0.73, 1.96)		1.37 (0.78, 2.40)
p-value		0.483		0.281

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 26		
n	135	282
Responder [1]	26 (19%)	69 (24%)
Non-responder	109 (81%)	213 (76%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.36 (0.80, 2.35)
Unadjusted Relative Risk (Exact 95% CI)		1.27 (0.86, 2.02)
Risk Difference (%) (Exact 95% CI)		5.2 (-3.8, 13.3)
z-test p-value		0.236
Logistic Regression Model		
Odds Ratio (95% CI)		1.38 (0.81, 2.34)
p-value		0.234
Poisson Regression Model		
Relative Risk (95% CI)		1.23 (0.84, 1.79)
p-value		0.296

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 28				
n	67	124	68	158
Responder [1]	12 (18%)	32 (26%)	12 (18%)	42 (27%)
Non-responder	55 (82%)	92 (74%)	56 (82%)	116 (73%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.59 (0.72, 3.69)		1.69 (0.79, 3.80)
Unadjusted Relative Risk (Exact 95% CI)		1.44 (0.81, 3.00)		1.51 (0.86, 3.52)
Risk Difference (%) (Exact 95% CI)		7.9 (-5.3, 19.6)		8.9 (-4.0, 19.8)
z-test p-value		0.217		0.149
Logistic Regression Model				
Odds Ratio (95% CI)		1.61 (0.73, 3.54)		2.01 (0.92, 4.39)
p-value		0.238		0.081
Poisson Regression Model				
Relative Risk (95% CI)		1.39 (0.81, 2.38)		1.55 (0.91, 2.63)
p-value		0.235		0.107

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 28		
n	135	282
Responder [1]	24 (18%)	74 (26%)
Non-responder	111 (82%)	208 (74%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.65 (0.96, 2.88)
Unadjusted Relative Risk (Exact 95% CI)		1.48 (0.98, 2.44)
Risk Difference (%) (Exact 95% CI)		8.5 (-1.0, 16.5)
z-test p-value		0.057
Logistic Regression Model		
Odds Ratio (95% CI)		1.70 (1.00, 2.89)
p-value		0.049
Poisson Regression Model		
Relative Risk (95% CI)		1.42 (0.96, 2.10)
p-value		0.076

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 39 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 32				
n	67	124	68	158
Responder [1]	9 (13%)	26 (21%)	10 (15%)	36 (23%)
Non-responder	58 (87%)	98 (79%)	58 (85%)	122 (77%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.71 (0.71, 4.43)		1.71 (0.76, 4.13)
Unadjusted Relative Risk (Exact 95% CI)		1.56 (0.79, 4.15)		1.55 (0.83, 4.36)
Risk Difference (%) (Exact 95% CI)		7.5 (-4.8, 18.1)		8.1 (-4.3, 18.3)
z-test p-value		0.199		0.167
Logistic Regression Model				
Odds Ratio (95% CI)		1.78 (0.74, 4.30)		1.95 (0.87, 4.38)
p-value		0.197		0.108
Poisson Regression Model				
Relative Risk (95% CI)		1.51 (0.78, 2.90)		1.59 (0.87, 2.90)
p-value		0.219		0.130

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 40 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 32		
n	135	282
Responder [1]	19 (14%)	62 (22%)
Non-responder	116 (86%)	220 (78%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.72 (0.96, 3.20)
Unadjusted Relative Risk (Exact 95% CI)		1.56 (0.98, 2.87)
Risk Difference (%) (Exact 95% CI)		7.9 (-0.6, 15.3)
z-test p-value		0.057
Logistic Regression Model		
Odds Ratio (95% CI)		1.79 (1.01, 3.17)
p-value		0.047
Poisson Regression Model		
Relative Risk (95% CI)		1.51 (0.96, 2.36)
p-value		0.075

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 41 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 36				
n	67	124	68	158
Responder [1]	12 (18%)	22 (18%)	12 (18%)	45 (28%)
Non-responder	55 (82%)	102 (82%)	56 (82%)	113 (72%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.99 (0.43, 2.37)		1.86 (0.88, 4.16)
Unadjusted Relative Risk (Exact 95% CI)		0.99 (0.52, 1.98)		1.61 (0.93, 3.92)
Risk Difference (%) (Exact 95% CI)		-0.2 (-12.8, 10.8)		10.8 (-2.3, 21.8)
z-test p-value		0.977		0.086
Logistic Regression Model				
Odds Ratio (95% CI)		0.94 (0.41, 2.12)		2.14 (1.01, 4.57)
p-value		0.877		0.049
Poisson Regression Model				
Relative Risk (95% CI)		0.95 (0.53, 1.73)		1.65 (0.94, 2.90)
p-value		0.877		0.081

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 42 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 36		
n	135	282
Responder [1]	24 (18%)	67 (24%)
Non-responder	111 (82%)	215 (76%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.44 (0.84, 2.54)
Unadjusted Relative Risk (Exact 95% CI)		1.34 (0.88, 2.14)
Risk Difference (%) (Exact 95% CI)		6.0 (-2.8, 13.9)
z-test p-value		0.167
Logistic Regression Model		
Odds Ratio (95% CI)		1.44 (0.85, 2.44)
p-value		0.171
Poisson Regression Model		
Relative Risk (95% CI)		1.29 (0.86, 1.93)
p-value		0.222

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 43 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 40				
n	67	124	68	158
Responder [1]	12 (18%)	26 (21%)	9 (13%)	40 (25%)
Non-responder	55 (82%)	98 (79%)	59 (87%)	118 (75%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.22 (0.54, 2.86)		2.22 (0.97, 5.55)
Unadjusted Relative Risk (Exact 95% CI)		1.17 (0.64, 2.37)		1.91 (0.98, 6.31)
Risk Difference (%) (Exact 95% CI)		3.1 (-9.8, 14.3)		12.1 (-0.6, 22.2)
z-test p-value		0.614		0.044
Logistic Regression Model				
Odds Ratio (95% CI)		1.18 (0.51, 2.75)		2.58 (1.12, 5.96)
p-value		0.704		0.026
Poisson Regression Model				
Relative Risk (95% CI)		1.14 (0.66, 1.96)		1.97 (1.03, 3.74)
p-value		0.633		0.040

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 44 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 40		
n	135	282
Responder [1]	21 (16%)	66 (23%)
Non-responder	114 (84%)	216 (77%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.66 (0.94, 3.00)
Unadjusted Relative Risk (Exact 95% CI)		1.50 (0.97, 2.66)
Risk Difference (%) (Exact 95% CI)		7.8 (-1.0, 15.5)
z-test p-value		0.065
Logistic Regression Model		
Odds Ratio (95% CI)		1.75 (0.99, 3.10)
p-value		0.054
Poisson Regression Model		
Relative Risk (95% CI)		1.45 (0.96, 2.20)
p-value		0.078

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 45 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 44				
n	67	124	68	158
Responder [1]	12 (18%)	25 (20%)	11 (16%)	41 (26%)
Non-responder	55 (82%)	99 (80%)	57 (84%)	117 (74%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.16 (0.51, 2.73)		1.82 (0.84, 4.21)
Unadjusted Relative Risk (Exact 95% CI)		1.13 (0.61, 2.34)		1.60 (0.89, 4.20)
Risk Difference (%) (Exact 95% CI)		2.3 (-10.6, 13.5)		9.8 (-2.9, 20.4)
z-test p-value		0.708		0.110
Logistic Regression Model				
Odds Ratio (95% CI)		1.12 (0.49, 2.58)		2.11 (0.94, 4.73)
p-value		0.781		0.070
Poisson Regression Model				
Relative Risk (95% CI)		1.09 (0.62, 1.93)		1.66 (0.92, 2.96)
p-value		0.766		0.090

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to modelled estimates.

Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.

t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 44		
n	135	282
Responder [1]	23 (17%)	66 (23%)
Non-responder	112 (83%)	216 (77%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.49 (0.86, 2.64)
Unadjusted Relative Risk (Exact 95% CI)		1.37 (0.90, 2.26)
Risk Difference (%) (Exact 95% CI)		6.4 (-2.4, 14.2)
z-test p-value		0.138
Logistic Regression Model		
Odds Ratio (95% CI)		1.53 (0.88, 2.65)
p-value		0.134
Poisson Regression Model		
Relative Risk (95% CI)		1.33 (0.88, 1.99)
p-value		0.173

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 47 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 48				
n	67	124	68	158
Responder [1]	9 (13%)	24 (19%)	13 (19%)	35 (22%)
Non-responder	58 (87%)	100 (81%)	55 (81%)	123 (78%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.55 (0.64, 4.04)		1.20 (0.57, 2.68)
Unadjusted Relative Risk (Exact 95% CI)		1.44 (0.73, 3.65)		1.16 (0.66, 2.39)
Risk Difference (%) (Exact 95% CI)		5.9 (-6.2, 16.3)		3.0 (-9.8, 13.9)
z-test p-value		0.302		0.609
Logistic Regression Model				
Odds Ratio (95% CI)		1.61 (0.66, 3.95)		1.25 (0.59, 2.66)
p-value		0.299		0.561
Poisson Regression Model				
Relative Risk (95% CI)		1.40 (0.71, 2.74)		1.19 (0.68, 2.09)
p-value		0.332		0.546

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.

Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.

For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.

Note: Subjects with missing baseline covariates did not contribute to modelled estimates.

Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.

t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Page 48 of 50
Data as of 29APR2024

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 48		
n	135	282
Responder [1]	22 (16%)	59 (21%)
Non-responder	113 (84%)	223 (79%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.36 (0.77, 2.45)
Unadjusted Relative Risk (Exact 95% CI)		1.28 (0.83, 2.12)
Risk Difference (%) (Exact 95% CI)		4.6 (-4.0, 12.2)
z-test p-value		0.264
Logistic Regression Model		
Odds Ratio (95% CI)		1.35 (0.78, 2.36)
p-value		0.284
Poisson Regression Model		
Relative Risk (95% CI)		1.24 (0.80, 1.90)
p-value		0.332

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=67)	Depemokimab 100 mg SC (N=124)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 52				
n	67	124	68	158
Responder [1]	13 (19%)	22 (18%)	11 (16%)	32 (20%)
Non-responder	54 (81%)	102 (82%)	57 (84%)	126 (80%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.90 (0.40, 2.10)		1.32 (0.59, 3.10)
Unadjusted Relative Risk (Exact 95% CI)		0.91 (0.49, 1.84)		1.25 (0.68, 2.85)
Risk Difference (%) (Exact 95% CI)		-1.7 (-14.5, 9.6)		4.1 (-8.1, 14.4)
z-test p-value		0.778		0.474
Logistic Regression Model				
Odds Ratio (95% CI)		0.84 (0.37, 1.92)		1.40 (0.62, 3.15)
p-value		0.687		0.421
Poisson Regression Model				
Relative Risk (95% CI)		0.88 (0.50, 1.57)		1.30 (0.71, 2.36)
p-value		0.676		0.398
p-value for Treatment by Study Interaction				

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33


Table 27.6
Analysis of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=135)	Depemokimab 100 mg SC (N=282)
Change from baseline at Week 52		
n	135	282
Responder [1]	24 (18%)	54 (19%)
Non-responder	111 (82%)	228 (81%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.10 (0.63, 1.95)
Unadjusted Relative Risk (Exact 95% CI)		1.08 (0.70, 1.77)
Risk Difference (%) (Exact 95% CI)		1.4 (-7.3, 9.0)
z-test p-value		0.737
Logistic Regression Model		
Odds Ratio (95% CI)		1.06 (0.61, 1.84)
p-value		0.838
Poisson Regression Model		
Relative Risk (95% CI)		1.04 (0.69, 1.58)
p-value		0.854
p-value for Treatment by Study Interaction		<0.001

[1] Response is defined as a reduction in ANSD score of at least 1.5 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline ANSD score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used for individual studies data, and Toeplitz for pooled data to enable convergence in logistic regression.
t_e_resp_ansd.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup


Figure 27.11
Forest Plot of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)
(odds ratios)



No. of Subjects is the number of subjects with non-missing baseline covariates.
/mnt/code/gvd/prod/tf/f_e_ansd_forest_or.sas 10JUL2025 11:11

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS (ADSD/ANSD) - High-dose ICS Subgroup

Figure 27.12
Forest Plot of Proportion of Responders according to ANSD Weekly Mean Score
(responder defined as achieving ≥ 1.5 -point reduction from baseline)
(relative risks)



No. of Subjects is the number of subjects with non-missing baseline covariates.
/mnt/code/gvd/prod/tf/f_e_ansd_forest_rr.sas 10JUL2025 11:12

3 Gesundheitsbezogene Lebensqualität
3.1 SGRQ - Veränderung im Vergleich zu Baseline

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 1 of 10
Data as of 29APR2024

Table 27.1
Analysis of Change from Baseline in SGRQ Total Score

Visit: Week 4

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	69	126	67	146
LS Mean (SE)	41.98 (1.747)	38.71 (1.286)	37.04 (1.799)	32.52 (1.200)
LS Mean Change (SE)	-6.56 (1.747)	-9.82 (1.286)	-9.65 (1.799)	-14.18 (1.200)
Depemokimab vs. Placebo				
Difference		-3.26		-4.53
95% CI		(-7.56, 1.03)		(-8.83, -0.23)
p-value		0.136		0.040
Corrected Hedges g		-0.22		-0.31
95% CI		(-0.52, 0.07)		(-0.60, -0.02)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline SGRQ total score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline SGRQ total score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_sgrq_analy.sas 08JUL2025 14:06

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.1
Analysis of Change from Baseline in SGRQ Total Score

Visit: Week 4

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	136	272
LS Mean (SE)	39.44 (1.244)	35.43 (0.871)
LS Mean Change (SE)	-8.13 (1.244)	-12.14 (0.871)
Depemokimab vs. Placebo		
Difference		-4.01
95% CI		(-7.01, -1.01)
p-value		0.009
Corrected Hedges g		-0.28
95% CI		(-0.48, -0.07)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline SGRQ total score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline SGRQ total score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_sgrq_analy.sas 08JUL2025 14:06

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 3 of 10
Data as of 29APR2024

Table 27.1
Analysis of Change from Baseline in SGRQ Total Score

Visit: Week 12

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	67	125	66	148
LS Mean (SE)	39.09 (1.937)	36.55 (1.421)	34.55 (1.947)	30.71 (1.291)
LS Mean Change (SE)	-9.44 (1.937)	-11.98 (1.421)	-12.14 (1.947)	-15.99 (1.291)
Depemokimab vs. Placebo				
Difference		-2.54		-3.84
95% CI		(-7.30, 2.22)		(-8.48, 0.80)
p-value		0.294		0.104
Corrected Hedges g		-0.16		-0.24
95% CI		(-0.46, 0.14)		(-0.53, 0.05)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline SGRQ total score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline SGRQ total score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_sgrq_analy.sas 08JUL2025 14:06

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.1
Analysis of Change from Baseline in SGRQ Total Score

Visit: Week 12

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	133	273
LS Mean (SE)	36.76 (1.372)	33.44 (0.956)
LS Mean Change (SE)	-10.81 (1.372)	-14.13 (0.956)
Depemokimab vs. Placebo		
Difference		-3.32
95% CI		(-6.62, -0.02)
p-value		0.049
Corrected Hedges g		-0.21
95% CI		(-0.42, 0.00)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline SGRQ total score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline SGRQ total score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_sgrq_analy.sas 08JUL2025 14:06

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 5 of 10
Data as of 29APR2024

Table 27.1
Analysis of Change from Baseline in SGRQ Total Score

Visit: Week 26

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	65	122	68	147
LS Mean (SE)	38.14 (2.049)	36.94 (1.501)	35.89 (2.020)	32.63 (1.350)
LS Mean Change (SE)	-10.40 (2.049)	-11.60 (1.501)	-10.81 (2.020)	-14.07 (1.350)
Depemokimab vs. Placebo				
Difference		-1.20		-3.25
95% CI		(-6.22, 3.83)		(-8.08, 1.57)
p-value		0.639		0.185
Corrected Hedges g		-0.07		-0.20
95% CI		(-0.37, 0.23)		(-0.49, 0.09)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline SGRQ total score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline SGRQ total score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_sgrq_analy.sas 08JUL2025 14:06

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.1
Analysis of Change from Baseline in SGRQ Total Score

Visit: Week 26

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	133	269
LS Mean (SE)	36.97 (1.436)	34.66 (1.003)
LS Mean Change (SE)	-10.59 (1.436)	-12.90 (1.003)
Depemokimab vs. Placebo		
Difference		-2.31
95% CI		(-5.77, 1.15)
p-value		0.191
Corrected Hedges g		-0.14
95% CI		(-0.35, 0.07)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline SGRQ total score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline SGRQ total score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_sgrq_analy.sas 08JUL2025 14:06

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 7 of 10
Data as of 29APR2024

Table 27.1
Analysis of Change from Baseline in SGRQ Total Score

Visit: Week 40

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	62	118	66	139
LS Mean (SE)	36.34 (1.962)	33.85 (1.431)	33.08 (2.032)	29.93 (1.366)
LS Mean Change (SE)	-12.19 (1.962)	-14.68 (1.431)	-13.61 (2.032)	-16.77 (1.366)
Depemokimab vs. Placebo				
Difference		-2.49		-3.15
95% CI		(-7.30, 2.31)		(-8.01, 1.71)
p-value		0.308		0.203
Corrected Hedges g		-0.16		-0.19
95% CI		(-0.47, 0.15)		(-0.49, 0.10)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline SGRQ total score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline SGRQ total score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_sgrq_analy.sas 08JUL2025 14:06

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.1
Analysis of Change from Baseline in SGRQ Total Score

Visit: Week 40

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	128	257
LS Mean (SE)	34.70 (1.411)	31.76 (0.987)
LS Mean Change (SE)	-12.87 (1.411)	-15.81 (0.987)
Depemokimab vs. Placebo		
Difference		-2.94
95% CI		(-6.34, 0.46)
p-value		0.090
Corrected Hedges g		-0.18
95% CI		(-0.40, 0.03)

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline SGRQ total score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline SGRQ total score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_sgrq_analy.sas 08JUL2025 14:06

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.1
Analysis of Change from Baseline in SGRQ Total Score

Visit: Week 52

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
n [1]	70	129	68	153
n [2]	61	120	66	140
LS Mean (SE)	35.08 (1.997)	35.34 (1.441)	34.26 (1.926)	31.05 (1.293)
LS Mean Change (SE)	-13.45 (1.997)	-13.19 (1.441)	-12.44 (1.926)	-15.65 (1.293)
Depemokimab vs. Placebo				
Difference		0.26		-3.21
95% CI		(-4.61, 5.14)		(-7.82, 1.39)
p-value		0.916		0.171
Corrected Hedges g		0.02		-0.21
95% CI		(-0.29, 0.32)		(-0.50, 0.09)
p-value for Treatment by Study Interaction				

[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline SGRQ total score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline SGRQ total score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_sgrq_analy.sas 08JUL2025 14:06

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 27.1
Analysis of Change from Baseline in SGRQ Total Score

Visit: Week 52

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
n [1]	138	282
n [2]	127	260
LS Mean (SE)	34.68 (1.378)	33.08 (0.960)
LS Mean Change (SE)	-12.88 (1.378)	-14.48 (0.960)
Depemokimab vs. Placebo		
Difference		-1.60
95% CI		(-4.91, 1.72)
p-value		0.344
Corrected Hedges g		-0.10
95% CI		(-0.32, 0.11)
p-value for Treatment by Study Interaction		0.616


[1] Number of subjects with analysable data for one or more timepoints.
[2] Number of subjects with analysable data at the given timepoint.
Note: Analysis performed using a repeated measures model with covariates of treatment group, exacerbation history (2, 3, 4+), geographical region, baseline SGRQ total score, baseline pre-bronchodilator percent predicted FEV1, visit, visit by baseline SGRQ total score and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
t_e_sgrq_analy.sas 08JUL2025 14:06

Page 1 of 3
Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.1
Line Plot of Analysis of Change from Baseline in SGRQ Total Score

Study: SWIFT-1




f_e_sgrq_analy_line.sas 08JUL2025 17:23

Page 2 of 3
Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.1
Line Plot of Analysis of Change from Baseline in SGRQ Total Score

Study: SWIFT-2




f_e_sgrq_analy_line.sas 08JUL2025 17:23

Page 3 of 3
Data as of 29APR2024

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup


Figure 27.1
Line Plot of Analysis of Change from Baseline in SGRQ Total Score

Study: SWIFT-1 & SWIFT-2



f_e_sgrq_analy_line.sas 08JUL2025 17:23

Figure 27.2
Forest Plot of Analysis of Change from Baseline in SGRQ Total Score at Week 52



Note: Analysis performed using a repeated measures model with covariates as per corresponding analysis table.
No. of Subjects is the number of subjects with analysable data for one or more timepoints for the two treatment groups of interest.
/mnt/code/gvd/prod/tfl/f_e_sgrq_forest_chg.sas 08JUL2025 17:23

3.2 SGRQ - Responderanalyse

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 1 of 10
Data as of 29APR2024

Table 27.2
Analysis of Proportion of Responders according to SGRQ Total Score
(responder defined as achieving ≥ 15 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 4				
n	71	132	68	158
Responder [1]	18 (25%)	40 (30%)	20 (29%)	58 (37%)
Non-responder	53 (75%)	92 (70%)	48 (71%)	100 (63%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.28 (0.64, 2.62)		1.39 (0.73, 2.73)
Unadjusted Relative Risk (Exact 95% CI)		1.20 (0.75, 2.06)		1.25 (0.83, 2.08)
Risk Difference (%) (Exact 95% CI)		5.0 (-8.8, 17.4)		7.3 (-7.0, 20.2)
z-test p-value		0.457		0.290
Logistic Regression Model				
Odds Ratio (95% CI)		1.16 (0.56, 2.42)		1.41 (0.74, 2.69)
p-value		0.692		0.296
Poisson Regression Model				
Relative Risk (95% CI)		1.11 (0.70, 1.74)		1.26 (0.84, 1.88)
p-value		0.658		0.266

[1] Response is defined as a reduction in SGRQ total score of at least 15 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline SGRQ total score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_sgrq.sas 08JUL2025 16:57

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 2 of 10
Data as of 29APR2024

Table 27.2
Analysis of Proportion of Responders according to SGRQ Total Score
(responder defined as achieving ≥ 15 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 4		
n	139	290
Responder [1]	38 (27%)	98 (34%)
Non-responder	101 (73%)	192 (66%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.36 (0.85, 2.18)
Unadjusted Relative Risk (Exact 95% CI)		1.24 (0.90, 1.78)
Risk Difference (%) (Exact 95% CI)		6.5 (-3.3, 15.5)
z-test p-value		0.179
Logistic Regression Model		
Odds Ratio (95% CI)		1.29 (0.81, 2.06)
p-value		0.277
Poisson Regression Model		
Relative Risk (95% CI)		1.19 (0.88, 1.60)
p-value		0.257

[1] Response is defined as a reduction in SGRQ total score of at least 15 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline SGRQ total score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_sgrq.sas 08JUL2025 16:57

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 3 of 10
Data as of 29APR2024

Table 27.2
Analysis of Proportion of Responders according to SGRQ Total Score
(responder defined as achieving ≥ 15 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 12				
n	71	132	68	158
Responder [1]	22 (31%)	45 (34%)	23 (34%)	69 (44%)
Non-responder	49 (69%)	87 (66%)	45 (66%)	89 (56%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.15 (0.60, 2.26)		1.52 (0.81, 2.89)
Unadjusted Relative Risk (Exact 95% CI)		1.10 (0.73, 1.77)		1.29 (0.90, 2.03)
Risk Difference (%) (Exact 95% CI)		3.1 (-11.0, 16.3)		9.8 (-4.7, 23.1)
z-test p-value		0.654		0.167
Logistic Regression Model				
Odds Ratio (95% CI)		1.00 (0.52, 1.92)		1.55 (0.82, 2.95)
p-value		0.992		0.177
Poisson Regression Model				
Relative Risk (95% CI)		0.99 (0.65, 1.50)		1.30 (0.90, 1.90)
p-value		0.953		0.165

[1] Response is defined as a reduction in SGRQ total score of at least 15 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline SGRQ total score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_sgrq.sas 08JUL2025 16:57

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 4 of 10
Data as of 29APR2024

Table 27.2
Analysis of Proportion of Responders according to SGRQ Total Score
(responder defined as achieving ≥ 15 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 12		
n	139	290
Responder [1]	45 (32%)	114 (39%)
Non-responder	94 (68%)	176 (61%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.35 (0.87, 2.13)
Unadjusted Relative Risk (Exact 95% CI)		1.21 (0.92, 1.67)
Risk Difference (%) (Exact 95% CI)		6.9 (-3.1, 16.4)
z-test p-value		0.164
Logistic Regression Model		
Odds Ratio (95% CI)		1.29 (0.82, 2.03)
p-value		0.261
Poisson Regression Model		
Relative Risk (95% CI)		1.16 (0.88, 1.54)
p-value		0.279

[1] Response is defined as a reduction in SGRQ total score of at least 15 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline SGRQ total score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_sgrq.sas 08JUL2025 16:57

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 5 of 10
Data as of 29APR2024

Table 27.2
Analysis of Proportion of Responders according to SGRQ Total Score
(responder defined as achieving ≥ 15 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 26				
n	71	132	68	158
Responder [1]	22 (31%)	41 (31%)	24 (35%)	63 (40%)
Non-responder	49 (69%)	91 (69%)	44 (65%)	95 (60%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.00 (0.52, 1.98)		1.22 (0.65, 2.31)
Unadjusted Relative Risk (Exact 95% CI)		1.00 (0.66, 1.74)		1.13 (0.78, 1.77)
Risk Difference (%) (Exact 95% CI)		0.1 (-13.9, 13.2)		4.6 (-9.9, 18.0)
z-test p-value		0.992		0.517
Logistic Regression Model				
Odds Ratio (95% CI)		0.86 (0.44, 1.71)		1.22 (0.64, 2.31)
p-value		0.674		0.542
Poisson Regression Model				
Relative Risk (95% CI)		0.91 (0.59, 1.38)		1.14 (0.79, 1.66)
p-value		0.652		0.480

[1] Response is defined as a reduction in SGRQ total score of at least 15 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline SGRQ total score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_sgrq.sas 08JUL2025 16:57

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 6 of 10
Data as of 29APR2024

Table 27.2
Analysis of Proportion of Responders according to SGRQ Total Score
(responder defined as achieving ≥ 15 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 26		
n	139	290
Responder [1]	46 (33%)	104 (36%)
Non-responder	93 (67%)	186 (64%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.13 (0.72, 1.78)
Unadjusted Relative Risk (Exact 95% CI)		1.08 (0.82, 1.55)
Risk Difference (%) (Exact 95% CI)		2.8 (-7.2, 12.2)
z-test p-value		0.574
Logistic Regression Model		
Odds Ratio (95% CI)		1.06 (0.68, 1.67)
p-value		0.787
Poisson Regression Model		
Relative Risk (95% CI)		1.04 (0.79, 1.37)
p-value		0.785

[1] Response is defined as a reduction in SGRQ total score of at least 15 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline SGRQ total score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_sgrq.sas 08JUL2025 16:57

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 7 of 10
Data as of 29APR2024

Table 27.2
Analysis of Proportion of Responders according to SGRQ Total Score
(responder defined as achieving ≥ 15 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 40				
n	71	132	68	158
Responder [1]	21 (30%)	52 (39%)	26 (38%)	70 (44%)
Non-responder	50 (70%)	80 (61%)	42 (62%)	88 (56%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		1.55 (0.80, 3.04)		1.28 (0.69, 2.41)
Unadjusted Relative Risk (Exact 95% CI)		1.33 (0.89, 2.20)		1.16 (0.83, 1.77)
Risk Difference (%) (Exact 95% CI)		9.8 (-4.5, 23.0)		6.1 (-8.5, 19.7)
z-test p-value		0.165		0.398
Logistic Regression Model				
Odds Ratio (95% CI)		1.41 (0.71, 2.79)		1.30 (0.70, 2.43)
p-value		0.322		0.407
Poisson Regression Model				
Relative Risk (95% CI)		1.19 (0.79, 1.80)		1.16 (0.81, 1.67)
p-value		0.402		0.403

[1] Response is defined as a reduction in SGRQ total score of at least 15 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline SGRQ total score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_sgrq.sas 08JUL2025 16:57

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 8 of 10
Data as of 29APR2024

Table 27.2
Analysis of Proportion of Responders according to SGRQ Total Score
(responder defined as achieving ≥ 15 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 40		
n	139	290
Responder [1]	47 (34%)	122 (42%)
Non-responder	92 (66%)	168 (58%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.42 (0.91, 2.22)
Unadjusted Relative Risk (Exact 95% CI)		1.24 (0.95, 1.69)
Risk Difference (%) (Exact 95% CI)		8.3 (-2.0, 17.8)
z-test p-value		0.102
Logistic Regression Model		
Odds Ratio (95% CI)		1.37 (0.88, 2.15)
p-value		0.165
Poisson Regression Model		
Relative Risk (95% CI)		1.19 (0.91, 1.56)
p-value		0.198

[1] Response is defined as a reduction in SGRQ total score of at least 15 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline SGRQ total score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_sgrq.sas 08JUL2025 16:57

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 9 of 10
Data as of 29APR2024

Table 27.2
Analysis of Proportion of Responders according to SGRQ Total Score
(responder defined as achieving ≥ 15 -point reduction from baseline)

	SWIFT-1		SWIFT-2	
	Placebo (N=71)	Depemokimab 100 mg SC (N=132)	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Change from baseline at Week 52				
n	71	132	68	158
Responder [1]	25 (35%)	45 (34%)	24 (35%)	60 (38%)
Non-responder	46 (65%)	87 (66%)	44 (65%)	98 (62%)
Depemokimab vs. Placebo				
Unadjusted Odds Ratio (Exact 95% CI)		0.95 (0.50, 1.83)		1.12 (0.60, 2.13)
Unadjusted Relative Risk (Exact 95% CI)		0.97 (0.66, 1.55)		1.08 (0.75, 1.68)
Risk Difference (%) (Exact 95% CI)		-1.1 (-15.3, 12.4)		2.7 (-11.8, 16.1)
z-test p-value		0.873		0.703
Logistic Regression Model				
Odds Ratio (95% CI)		0.83 (0.43, 1.60)		1.12 (0.59, 2.11)
p-value		0.581		0.724
Poisson Regression Model				
Relative Risk (95% CI)		0.89 (0.60, 1.33)		1.09 (0.75, 1.58)
p-value		0.570		0.666
p-value for Treatment by Study Interaction				

[1] Response is defined as a reduction in SGRQ total score of at least 15 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline SGRQ total score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_sgrq.sas 08JUL2025 16:57

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 10 of 10
Data as of 29APR2024


Table 27.2
Analysis of Proportion of Responders according to SGRQ Total Score
(responder defined as achieving ≥ 15 -point reduction from baseline)

	SWIFT-1 & SWIFT-2	
	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Change from baseline at Week 52		
n	139	290
Responder [1]	49 (35%)	105 (36%)
Non-responder	90 (65%)	185 (64%)
Depemokimab vs. Placebo		
Unadjusted Odds Ratio (Exact 95% CI)		1.04 (0.67, 1.63)
Unadjusted Relative Risk (Exact 95% CI)		1.03 (0.79, 1.43)
Risk Difference (%) (Exact 95% CI)		1.0 (-9.1, 10.5)
z-test p-value		0.847
Logistic Regression Model		
Odds Ratio (95% CI)		0.98 (0.63, 1.54)
p-value		0.938
Poisson Regression Model		
Relative Risk (95% CI)		0.99 (0.75, 1.29)
p-value		0.916
p-value for Treatment by Study		0.590
Interaction		

[1] Response is defined as a reduction in SGRQ total score of at least 15 units compared to baseline.
Note: Analysis performed using logistic and Poisson regression models with covariates of treatment group, geographical region, exacerbation history (2, 3, 4+), baseline pre-bronchodilator % predicted FEV1, baseline SGRQ total score, visit, visit by baseline and visit by treatment group.
For the pooled analysis, study (206713 or 213744) is also included as an additional covariate.
Note: Subjects with missing baseline covariates did not contribute to modelled estimates.
Note: AR(1) covariance structure was used in Poisson regression to enable convergence.
t_e_resp_sgrq.sas 08JUL2025 16:57

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup


Figure 27.3
Forest Plot of Proportion of Responders according to SGRQ Total Score
(responder defined as achieving ≥ 15 -point reduction from baseline)
(odds ratios)



No. of Subjects is the number of subjects with non-missing baseline covariates.
/mnt/code/gvd/prod/tf/f_e_sgrq_forest_or.sas 10JUL2025 08:33

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Figure 27.4
Forest Plot of Proportion of Responders according to SGRQ Total Score
(responder defined as achieving ≥ 15 -point reduction from baseline)
(relative risks)



No. of Subjects is the number of subjects with non-missing baseline covariates.
/mnt/code/gvd/prod/tf/f_e_sgrq_forest_rr.sas 10JUL2025 08:34

4 Sicherheit
4.1 Anzahl an Patienten mit UE (jeglicher Schweregrad)

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Page 1 of 2
Data as of 29APR2024

Table 37.1
Summary and Analysis of Subjects with an On-treatment Adverse Events

	Placebo	Depemokimab 100 mg SC	Odds Ratio	Relative Risk
SWIFT-1	51 / 71 (72%)	100 / 132 (76%)	1.23 (0.60, 2.46)	1.05 (0.89, 1.32)
SWIFT-2	59 / 69 (86%)	115 / 157 (73%)	0.46 (0.19, 1.03)	0.86 (0.75, 1.01)
SWIFT-1 & SWIFT-2	110 / 140 (79%)	215 / 289 (74%)	0.79 (0.48, 1.27)	0.95 (0.75, 1.19)

p-value for Treatment by
Study Interaction

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link, and relative risk and p-value from Poisson regression with a log link. Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tf1/t_s_aeontrt_analy 08JUL2025 17:27

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Page 2 of 2
Data as of 29APR2024

Table 37.1
Summary and Analysis of Subjects with an On-treatment Adverse Events


	Risk Difference (%)	p-value
SWIFT-1	3.9 (-8.5, 17.4)	0.614
SWIFT-2	-12.3 (-22.7, 0.7)	0.059
SWIFT-1 & SWIFT-2	-4.8 (-13.3, 3.8)	0.631
p-value for Treatment by Study Interaction		0.377

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data.
For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link, and relative risk and p-value from Poisson regression with a log link.
Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_analy 08JUL2025 17:27

Page 1 of 1
(Data as of 29APR2024)


Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.1
Forest Plot of Odds Ratio for On-treatment Adverse Events



/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_or.sas 08JUL2025 18:08

Figure 37.2
Forest Plot of Relative Risk for On-treatment Adverse Events



/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:08

4.2 Anzahl an Patienten mit UE (jeglicher Schweregrad) nach SOC und PT

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Page 1 of 10
Data as of 29APR2024

Table 37.3
Summary and Analysis of On-treatment Adverse Events Occurring in >=10% of patients or in >=10 and >=1% of patients

Study: SWIFT-1

	Placebo	Depemokimab 100 mg SC	Odds Ratio	Relative Risk
Any Event	51 / 71 (72%)	100 / 132 (76%)	1.23 (0.60, 2.46)	1.05 (0.89, 1.32)
Infections and infestations	38 / 71 (54%)	82 / 132 (62%)	1.42 (0.76, 2.66)	1.16 (0.91, 1.61)
COVID-19	11 / 71 (15%)	22 / 132 (17%)	1.09 (0.47, 2.67)	1.08 (0.56, 2.35)
Nasopharyngitis	15 / 71 (21%)	18 / 132 (14%)	0.59 (0.26, 1.36)	0.65 (0.34, 1.29)
Influenza	0 / 71	12 / 132 (9%)	Non-Est	Non-Est
Respiratory, thoracic and mediastinal disorders	10 / 71 (14%)	21 / 132 (16%)	1.15 (0.48, 2.93)	1.13 (0.57, 2.48)
Musculoskeletal and connective tissue disorders	12 / 71 (17%)	15 / 132 (11%)	0.63 (0.26, 1.58)	0.67 (0.33, 1.50)
Nervous system disorders	5 / 71 (7%)	19 / 132 (14%)	2.22 (0.75, 7.94)	2.04 (0.83, 8.09)
Gastrointestinal disorders	7 / 71 (10%)	15 / 132 (11%)	1.17 (0.42, 3.58)	1.15 (0.49, 3.26)
Vascular disorders	8 / 71 (11%)	9 / 132 (7%)	0.58 (0.19, 1.81)	0.61 (0.23, 1.76)

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link, and relative risk and p-value from Poisson regression with a log link. Unadjusted risk difference calculated from the raw data is presented for Arthralgia due to a lack of convergence. Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_analy_soc_pt 08JUL2025 17:32

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Page 2 of 10
Data as of 29APR2024

Table 37.3
Summary and Analysis of On-treatment Adverse Events Occurring in >=10% of patients or in >=10 and >=1% of patients

Study: SWIFT-1

	Risk Difference (%)	p-value for Treatment by Study p-value Interaction
Any Event	3.9 (-8.5, 17.4)	0.614
Infections and infestations	8.6 (-5.9, 23.0)	0.295
COVID-19	1.2 (-10.6, 11.4)	>0.999
Nasopharyngitis	-7.5 (-19.8, 3.5)	0.231
Influenza	9.1 (2.2, 15.4)	Non-Est
Respiratory, thoracic and mediastinal disorders	1.8 (-9.7, 11.7)	0.840
Musculoskeletal and connective tissue disorders	-5.5 (-17.2, 4.5)	0.285
Nervous system disorders	7.4 (-2.6, 15.8)	0.171
Gastrointestinal disorders	1.5 (-8.9, 10.1)	0.817
Vascular disorders	-4.4 (-14.9, 3.6)	0.296

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link, and relative risk and p-value from Poisson regression with a log link. Unadjusted risk difference calculated from the raw data is presented for Arthralgia due to a lack of convergence. Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_analy_soc_pt 08JUL2025 17:32

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Table 37.3
Summary and Analysis of On-treatment Adverse Events Occurring in >=10% of patients or in >=10 and >=1% of patients

Study: SWIFT-2

	Placebo	Depemokimab 100 mg SC	Odds Ratio	Relative Risk
Any Event	59 / 69 (86%)	115 / 157 (73%)	0.46 (0.19, 1.03)	0.86 (0.75, 1.01)
Infections and infestations	45 / 69 (65%)	93 / 157 (59%)	0.78 (0.41, 1.45)	0.91 (0.74, 1.19)
Nasopharyngitis	17 / 69 (25%)	24 / 157 (15%)	0.55 (0.26, 1.19)	0.62 (0.35, 1.19)
COVID-19	12 / 69 (17%)	27 / 157 (17%)	0.99 (0.45, 2.30)	0.99 (0.54, 1.98)
Bronchitis	9 / 69 (13%)	9 / 157 (6%)	0.41 (0.14, 1.22)	0.44 (0.16, 1.19)
Upper respiratory tract infection	2 / 69 (3%)	14 / 157 (9%)	3.28 (0.72, 30.43)	3.08 (0.80, 33.84)
Respiratory, thoracic and mediastinal disorders	12 / 69 (17%)	37 / 157 (24%)	1.46 (0.68, 3.32)	1.36 (0.76, 2.98)
Rhinitis allergic	1 / 69 (1%)	15 / 157 (10%)	7.18 (1.06, 306.76)	6.59 (0.99, 177.81)
Musculoskeletal and connective tissue disorders	14 / 69 (20%)	30 / 157 (19%)	0.93 (0.44, 2.05)	0.94 (0.54, 1.80)
Arthralgia	4 / 69 (6%)	11 / 157 (7%)	1.22 (0.35, 5.47)	1.21 (0.41, 6.57)
Gastrointestinal disorders	8 / 69 (12%)	23 / 157 (15%)	1.31 (0.53, 3.58)	1.26 (0.61, 3.83)
Nervous system disorders	7 / 69 (10%)	22 / 157 (14%)	1.44 (0.56, 4.21)	1.38 (0.64, 5.45)
Headache	5 / 69 (7%)	12 / 157 (8%)	1.06 (0.33, 4.00)	1.05 (0.39, 5.54)

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link, and relative risk and p-value from Poisson regression with a log link. Unadjusted risk difference calculated from the raw data is presented for Arthralgia due to a lack of convergence. Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_analy_soc_pt 08JUL2025 17:32

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Table 37.3
Summary and Analysis of On-treatment Adverse Events Occurring in >=10% of patients or in >=10 and >=1% of patients

Study: SWIFT-2

	Risk Difference (%)	p-value for Treatment by Study Interaction
Any Event	-12.3 (-22.7, 0.7)	0.059
Infections and infestations	-6.0 (-19.3, 8.4)	0.460
Nasopharyngitis	-9.4 (-22.1, 2.0)	0.133
COVID-19	-0.2 (-12.4, 10.0)	>0.999
Bronchitis	-7.3 (-18.0, 0.7)	0.106
Upper respiratory tract infection	6.0 (-2.2, 12.4)	0.158
Respiratory, thoracic and mediastinal disorders	6.2 (-6.4, 16.9)	0.382
Rhinitis allergic	8.1 (0.3, 14.3)	0.027
Musculoskeletal and connective tissue disorders	-1.2 (-13.7, 9.7)	0.857
Arthralgia	1.2 (-7.8, 7.8)	>0.999
Gastrointestinal disorders	3.1 (-8.0, 12.0)	0.676
Nervous system disorders	3.9 (-6.8, 12.5)	0.521
Headache	0.4 (-9.2, 7.5)	>0.999

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link, and relative risk and p-value from Poisson regression with a log link. Unadjusted risk difference calculated from the raw data is presented for Arthralgia due to a lack of convergence. Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_analy_soc_pt 08JUL2025 17:32

Table 37.3
Summary and Analysis of On-treatment Adverse Events Occurring in >=10% of patients or in >=10 and >=1% of patients

Study: SWIFT-2

	Placebo	Depemokimab 100 mg SC	Odds Ratio	Relative Risk
General disorders and administration site conditions	7 / 69 (10%)	19 / 157 (12%)	1.22 (0.46, 3.61)	1.19 (0.54, 4.06)
Injury, poisoning and procedural complications	4 / 69 (6%)	19 / 157 (12%)	2.24 (0.70, 9.38)	2.09 (0.77, 10.47)
Skin and subcutaneous tissue disorders	3 / 69 (4%)	15 / 157 (10%)	2.32 (0.62, 12.91)	2.20 (0.70, 14.70)
Eye disorders	3 / 69 (4%)	10 / 157 (6%)	1.50 (0.37, 8.72)	1.46 (0.43, 6.91)

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link, and relative risk and p-value from Poisson regression with a log link. Unadjusted risk difference calculated from the raw data is presented for Arthralgia due to a lack of convergence.
Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_analy_soc_pt 08JUL2025 17:32

Table 37.3
Summary and Analysis of On-treatment Adverse Events Occurring in >=10% of patients or in >=10 and >=1% of patients
Study: SWIFT-2

	Risk Difference (%)	p-value for Treatment by Study Interaction
General disorders and administration site conditions	2.0 (-8.6, 10.3)	0.822
Injury, poisoning and procedural complications	6.3 (-3.3, 13.7)	0.231
Skin and subcutaneous tissue disorders	5.2 (-3.5, 11.9)	0.286
Eye disorders	2.0 (-6.4, 8.1)	0.759

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link, and relative risk and p-value from Poisson regression with a log link. Unadjusted risk difference calculated from the raw data is presented for Arthralgia due to a lack of convergence. Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_analy_soc_pt 08JUL2025 17:32

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Page 7 of 10
Data as of 29APR2024

Table 37.3
Summary and Analysis of On-treatment Adverse Events Occurring in ≥10% of patients or in ≥10 and
≥1% of patients

Study: SWIFT-1 & SWIFT-2

	Placebo	Depemokimab 100 mg SC	Odds Ratio	Relative Risk
Any Event	110 / 140 (79%)	215 / 289 (74%)	0.79 (0.48, 1.27)	0.95 (0.75, 1.19)
Infections and infestations	83 / 140 (59%)	175 / 289 (61%)	1.05 (0.70, 1.59)	1.02 (0.79, 1.32)
Nasopharyngitis	32 / 140 (23%)	42 / 289 (15%)	0.57 (0.34, 0.95)	0.63 (0.40, 1.00)
COVID-19	23 / 140 (16%)	49 / 289 (17%)	1.03 (0.60, 1.78)	1.03 (0.63, 1.69)
Upper respiratory tract infection	8 / 140 (6%)	22 / 289 (8%)	1.36 (0.59, 3.14)	1.33 (0.59, 2.99)
Bronchitis	11 / 140 (8%)	15 / 289 (5%)	0.62 (0.27, 1.39)	0.64 (0.29, 1.39)
Rhinitis	11 / 140 (8%)	14 / 289 (5%)	0.62 (0.27, 1.40)	0.64 (0.29, 1.40)
Sinusitis	8 / 140 (6%)	15 / 289 (5%)	0.90 (0.37, 2.17)	0.90 (0.38, 2.13)
Influenza	4 / 140 (3%)	14 / 289 (5%)	1.81 (0.58, 5.63)	1.76 (0.58, 5.36)
Respiratory tract infection	4 / 140 (3%)	11 / 289 (4%)	1.34 (0.42, 4.30)	1.33 (0.42, 4.19)
Respiratory, thoracic and mediastinal disorders	22 / 140 (16%)	58 / 289 (20%)	1.32 (0.77, 2.27)	1.26 (0.77, 2.05)
Rhinitis allergic	3 / 140 (2%)	22 / 289 (8%)	3.69 (1.08, 12.56)	3.48 (1.04, 11.63)
Asthma	6 / 140 (4%)	11 / 289 (4%)	0.85 (0.31, 2.36)	0.86 (0.32, 2.32)
Musculoskeletal and connective tissue disorders	26 / 140 (19%)	45 / 289 (16%)	0.79 (0.46, 1.35)	0.82 (0.51, 1.33)
Back pain	8 / 140 (6%)	12 / 289 (4%)	0.70 (0.28, 1.76)	0.72 (0.29, 1.75)
Arthralgia	6 / 140 (4%)	11 / 289 (4%)	0.82 (0.29, 2.28)	0.83 (0.31, 2.23)

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data.
For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group
and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link,
and relative risk and p-value from Poisson regression with a log link.
Unadjusted risk difference calculated from the raw data is presented for Arthralgia due to a lack of
convergence.
Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_analy_soc_pt 08JUL2025 17:32

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Table 37.3
Summary and Analysis of On-treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$ of patients

Study: SWIFT-1 & SWIFT-2

	Risk Difference (%)	p-value	p-value for Treatment by Study Interaction
Any Event	-4.8 (-13.3, 3.8)	0.631	0.377
Infections and infestations	1.1 (-8.8, 11.1)	0.884	0.359
Nasopharyngitis	-8.4 (-16.4, -0.3)	0.051	0.934
COVID-19	0.5 (-7.0, 8.0)	0.911	0.868
Upper respiratory tract infection	2.1 (-3.2, 7.3)	0.489	0.097
Bronchitis	-1.7 (-6.9, 3.5)	0.259	0.149
Rhinitis	-2.8 (-7.7, 2.2)	0.264	0.785
Sinusitis	-0.6 (-5.2, 4.0)	0.813	0.818
Influenza	-0.4 (-4.6, 3.8)	0.317	<0.001
Respiratory tract infection	1.0 (-2.6, 4.7)	0.625	0.229
Respiratory, thoracic and mediastinal disorders	3.7 (-3.8, 11.3)	0.364	0.721
Rhinitis allergic	5.1 (0.8, 9.4)	0.043	0.322
Asthma	-0.6 (-4.4, 3.2)	0.760	0.938
Musculoskeletal and connective tissue disorders	-3.6 (-11.2, 3.9)	0.428	0.505
Back pain	-1.5 (-5.9, 3.0)	0.464	0.687
Arthralgia	-0.5 (-5.6, 3.4)	0.706	0.042

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link, and relative risk and p-value from Poisson regression with a log link. Unadjusted risk difference calculated from the raw data is presented for Arthralgia due to a lack of convergence. Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_analy_soc_pt 08JUL2025 17:32

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Table 37.3
Summary and Analysis of On-treatment Adverse Events Occurring in >=10% of patients or in >=10 and >=1% of patients

Study: SWIFT-1 & SWIFT-2

	Placebo	Depemokimab 100 mg SC	Odds Ratio	Relative Risk
Gastrointestinal disorders	15 / 140 (11%)	38 / 289 (13%)	1.25 (0.66, 2.35)	1.21 (0.67, 2.21)
Nervous system disorders	12 / 140 (9%)	41 / 289 (14%)	1.76 (0.89, 3.46)	1.65 (0.87, 3.14)
Headache	10 / 140 (7%)	18 / 289 (6%)	0.85 (0.38, 1.89)	0.86 (0.40, 1.86)
Injury, poisoning and procedural complications	11 / 140 (8%)	25 / 289 (9%)	1.08 (0.52, 2.28)	1.08 (0.53, 2.19)
General disorders and administration site conditions	9 / 140 (6%)	25 / 289 (9%)	1.31 (0.59, 2.92)	1.28 (0.60, 2.75)
Skin and subcutaneous tissue disorders	10 / 140 (7%)	23 / 289 (8%)	1.12 (0.52, 2.42)	1.11 (0.53, 2.33)
Vascular disorders	14 / 140 (10%)	14 / 289 (5%)	0.47 (0.22, 1.02)	0.50 (0.24, 1.04)
Hypertension	11 / 140 (8%)	9 / 289 (3%)	0.39 (0.16, 0.96)	0.41 (0.17, 0.99)
Metabolism and nutrition disorders	8 / 140 (6%)	11 / 289 (4%)	0.64 (0.25, 1.64)	0.66 (0.26, 1.64)
Investigations	6 / 140 (4%)	12 / 289 (4%)	0.98 (0.36, 2.68)	0.99 (0.37, 2.63)
Eye disorders	4 / 140 (3%)	13 / 289 (4%)	1.53 (0.49, 4.80)	1.50 (0.49, 4.61)

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link, and relative risk and p-value from Poisson regression with a log link. Unadjusted risk difference calculated from the raw data is presented for Arthralgia due to a lack of convergence. Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_analy_soc_pt 08JUL2025 17:32

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Table 37.3
Summary and Analysis of On-treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$ of patients

Study: SWIFT-1 & SWIFT-2


	Risk Difference (%)	p-value	p-value for Treatment by Study Interaction
Gastrointestinal disorders	2.2 (-4.2, 8.6)	0.527	0.882
Nervous system disorders	5.6 (-0.5, 11.8)	0.128	0.554
Headache	-1.2 (-6.3, 3.8)	0.698	0.542
Injury, poisoning and procedural complications	-0.6 (-6.3, 5.0)	0.839	0.047
General disorders and administration site conditions	1.8 (-2.7, 6.3)	0.523	0.742
Skin and subcutaneous tissue disorders	0.7 (-4.9, 6.3)	0.783	0.106
Vascular disorders	-5.1 (-10.5, 0.4)	0.065	0.517
Hypertension	-4.4 (-9.3, 0.4)	0.048	0.722
Metabolism and nutrition disorders	-2.0 (-6.4, 2.4)	0.370	0.705
Investigations	0.1 (-4.0, 4.2)	0.976	0.634
Eye disorders	1.2 (-2.0, 4.3)	0.478	0.942

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link, and relative risk and p-value from Poisson regression with a log link. Unadjusted risk difference calculated from the raw data is presented for Arthralgia due to a lack of convergence. Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_analy_soc_pt 08JUL2025 17:32

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Any Event
<<<<Favours Depemokimab Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Eye disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontrt_analy_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Gastrointestinal disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: General disorders and administration site conditions/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Injury, poisoning and procedural complications/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Investigations/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Metabolism and nutrition disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Musculoskeletal and connective tissue disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontrt_analy_occ_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Nervous system disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontrt_analy_occ_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Respiratory, thoracic and mediastinal disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Skin and subcutaneous tissue disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Vascular disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontrt_analy_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Bronchitis
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/COVID-19
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Influenza
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Nasopharyngitis
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Respiratory tract infection
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Rhinitis
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Sinusitis
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Upper respiratory tract infection
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Musculoskeletal and connective tissue disorders/Arthralgia
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Musculoskeletal and connective tissue disorders/Back pain
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontrt_analy_occ_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Nervous system disorders/Headache
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Respiratory, thoracic and mediastinal disorders/Asthma
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Respiratory, thoracic and mediastinal disorders/Rhinitis allergic
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Figure 37.5
Forest Plot of Odds Ratio for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Vascular disorders/Hypertension
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_or.sas 08JUL2025 18:09

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Any Event
<<<<Favours Depemokimab Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Eye disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Gastrointestinal disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: General disorders and administration site conditions/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Injury, poisoning and procedural complications/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Investigations/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Metabolism and nutrition disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Musculoskeletal and connective tissue disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Nervous system disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Respiratory, thoracic and mediastinal disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Skin and subcutaneous tissue disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Vascular disorders/Any Event
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Bronchitis
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/COVID-19
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Influenza
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Nasopharyngitis
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Respiratory tract infection
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Rhinitis
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Sinusitis
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Infections and infestations/Upper respiratory tract infection
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Musculoskeletal and connective tissue disorders/Arthralgia
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Musculoskeletal and connective tissue disorders/Back pain
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Nervous system disorders/Headache
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Respiratory, thoracic and mediastinal disorders/Asthma
<<<<Favours Depemokimab

Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Respiratory, thoracic and mediastinal disorders/Rhinitis allergic
<<<<Favours Depemokimab Favours Placebo >>>>




/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_rr.sas 08JUL2025 18:10

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.6
Forest Plot of Relative Risk for On-Treatment Adverse Events Occurring in $\geq 10\%$ of patients or in ≥ 10 and $\geq 1\%$

SOC and PT: Vascular disorders/Hypertension
<<<<Favours Depemokimab

Favours Placebo >>>>



/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_occ_rr.sas 08JUL2025 18:10

4.3 Anzahl an Patienten mit SUE

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Page 1 of 2
Data as of 29APR2024

Table 37.6
Summary and Analysis of Proportion of Subjects with an On-treatment Serious Adverse Event

	Placebo	Depemokimab 100 mg SC	Odds Ratio	Relative Risk
SWIFT-1	11 / 71 (15%)	8 / 132 (6%)	0.35 (0.12, 1.02)	0.39 (0.16, 0.94)
SWIFT-2	6 / 69 (9%)	15 / 157 (10%)	1.11 (0.38, 3.65)	1.10 (0.45, 4.31)
SWIFT-1 & SWIFT-2	17 / 140 (12%)	23 / 289 (8%)	0.63 (0.32, 1.21)	0.65 (0.35, 1.23)

p-value for Treatment by
Study Interaction

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data.
For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group
and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link,
and relative risk and p-value from Poisson regression with a log link.
Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_ser_analy 08JUL2025 18:04

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Page 2 of 2
Data as of 29APR2024

Table 37.6
Summary and Analysis of Proportion of Subjects with an On-treatment Serious Adverse Event


	Risk Difference (%)	p-value
SWIFT-1	-9.4 (-20.5, -0.4)	0.042
SWIFT-2	0.9 (-9.2, 8.5)	>0.999
SWIFT-1 & SWIFT-2	-4.4 (-10.8, 1.9)	0.187
p-value for Treatment by Study Interaction		0.116

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, risk difference from binomial model with identity link, and relative risk and p-value from Poisson regression with a log link. Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_ser_analy 08JUL2025 18:04

Page 1 of 1
(Data as of 29APR2024)

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation


Figure 37.11
Forest Plot of Odds Ratio for On-treatment SAEs



/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_sae_or.sas 08JUL2025 18:11

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS Subpopulation

Figure 37.12
Forest Plot of Relative Risk for On-treatment SAEs



/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_sae_rr.sas 08JUL2025 18:11

4.4 Anzahl an Patienten mit Therapieabbruch aufgrund von UE

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS

Page 1 of 2
Data as of 29APR2024

Table 37.2
Summary and Analysis of Proportion of Subjects with On-treatment Adverse Events
Leading to Permanent Discontinuation of Study Treatment/Study Withdrawal

	Placebo	Depemokimab 100 mg SC	Odds Ratio	Relative Risk
SWIFT-1	2 / 71 (3%)	2 / 132 (2%)	0.53 (0.04, 7.49)	0.54 (0.04, 8.03)
SWIFT-2	0 / 69	1 / 157 (<1%)	Non-Est	Non-Est
SWIFT-1 & SWIFT-2	2 / 140 (1%)	3 / 289 (1%)	0.77 (0.13, 4.70)	0.78 (0.13, 4.65)
p-value for Treatment by Study Interaction				

For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, and relative risk and p-value from Poisson regression with a log link. Unadjusted risk difference calculated from the raw data is presented due to a lack of convergence.
Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_disc_analy 08JUL2025 17:29

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High-dose ICS


Page 2 of 2
Data as of 29APR2024

Table 37.2
Summary and Analysis of Proportion of Subjects with On-treatment Adverse Events
Leading to Permanent Discontinuation of Study Treatment/Study Withdrawal

	Risk Difference (%)	p-value
-----	-----	-----
SWIFT-1	-1.3 (-8.5, 3.2)	0.613
SWIFT-2	0.6 (-5.0, 3.7)	Non-Est
SWIFT-1 & SWIFT-2	-0.4 (-4.2, 2.0)	0.781
p-value for Treatment by Study Interaction		0.310


For individual studies, confidence intervals (CIs) are exact and calculated directly from the raw data. For pooled data, CIs are asymptotic and derived from regression models with covariates of treatment group and study. Odds ratio is from logistic regression, and relative risk and p-value from Poisson regression with a log link. Unadjusted risk difference calculated from the raw data is presented due to a lack of convergence.
Displayed results are for the comparison of Depemokimab vs. Placebo.
/mnt/code/gvd/prod/tfl/t_s_aeontrt_disc_analy 08JUL2025 17:29

Figure 37.3
Forest Plot of Odds Ratio for On-treatment AEs Leading to Permanent Discontinuation of Study Treatment/Study Withdrawal



/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_disc_or.sas 08JUL2025 18:09

Figure 37.4
Forest Plot of Relative Risk for On-treatment AEs Leading to Permanent Discontinuation of Study Treatment/Study Withdrawal



/mnt/code/gvd/prod/tfl/f_s_aeontr_analy_disc_rr.sas 08JUL2025 18:09

4.5 Anzahl an Patienten mit Therapieabbruch aufgrund von UE nach SOC und PT

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Page 1 of 5
Data as of 29APR2024

Listing 1
Listing of All Adverse Events Leading to Permanent Discontinuation of Study Treatment
or Withdrawal from Study for Participants on High Dose ICS at Baseline

Site Id.: 250170

Treatment	Unique Subject Id./ Subject Id.	Age (YEARS)/ Sex/ Race Detail/ Weight (kg)	SOC/ Preferred Term/ Verbatim Text	Outcome/ Onset Date	Time Since 1st Dose/ Time Since Last Dose	Maximum Intensity / Serious	Action(s) Taken/ Relation to Study Treatment
				Date Time of Resolution/ Duration			
Depemokimab 100 mg SC	206713. 000341/ 000341	50/ F/ WHITE - WHITE/ CAUCASIAN/ EUROPEAN HERITAGE/ 60.2	Investigations/ Alanine aminotransferase increased/ INCREASED ALT VALUES (>=3XULN)	RECOVERED/ RESOLVED/ 2022-02-15/ 2023-01-11/ 331d	63d/ 63d	MODERATE/ N	DRUG WITHDRAWN/ N

li_ae_disc.sas 23DEC2025 16:43

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Page 2 of 5
Data as of 29APR2024

Listing 1
Listing of All Adverse Events Leading to Permanent Discontinuation of Study Treatment
or Withdrawal from Study for Participants on High Dose ICS at Baseline

Site Id.: 250802

Treatment	Unique Subject Id./ Subject Id.	Age (YEARS)/ Sex/ Race Detail/ Weight (kg)	SOC/ Preferred Term/ Verbatim Text	Outcome/ Onset Date Time/ Date Time of Resolution/ Duration	Time Since 1st Dose/ Time Since Last Dose	Maximum Intensity / Serious	Action(s) Taken/ Relation to Study Treatment
Placebo	206713. 003772/ 003772	65/ F/ WHITE - WHITE/ CAUCASIAN/ EUROPEAN HERITAGE/ 71.0	Neoplasms benign, malignant and unspecified (incl cysts and polyps)/ Breast cancer/ BREAST CANCER MALIGNANT	RECOVERING/ RESOLVING/ 2022-06-28/ /	112d/ 112d	MODERATE/ Y	DRUG WITHDRAWN/ N

li_ae_disc.sas 23DEC2025 16:43

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Page 3 of 5
Data as of 29APR2024

Listing 1
Listing of All Adverse Events Leading to Permanent Discontinuation of Study Treatment
or Withdrawal from Study for Participants on High Dose ICS at Baseline

Site Id.: 251647

Treatment	Unique Subject Id./ Subject Id.	Age (YEARS)/ Sex/ Race Detail/ Weight (kg)	SOC/ Preferred Term/ Verbatim Text	Outcome/ Onset Date Time/ Date Time of Resolution/ Duration	Time Since 1st Dose/ Time Since Last Dose	Maximum Intensity / Serious	Action(s) Taken/ Relation to Study Treatment
Depemokimab 100 mg SC	213744. 002401/ 002401	67/ F/ WHITE - WHITE/ CAUCASIAN/ EUROPEAN HERITAGE/ 75.0	Investigations/ Alanine aminotransferase abnormal/ ABNORMAL ALT	RECOVERED/ RESOLVED/ 2022-08-16/ 2022-08-19/ 4d	140d/ 140d	SEVERE/ Y	DRUG WITHDRAWN/ N
			Investigations/ Alanine aminotransferase increased/ ELEVATED ALT LEVEL > 3 ULN	RECOVERED/ RESOLVED/ 2022-08-24/ 2022-09-21/ 29d	148d/ 148d	SEVERE/ N	DRUG WITHDRAWN/ N

li_ae_disc.sas 23DEC2025 16:43

Protocol: 217780 Depemokimab GVD Asthma
Population: Safety - High dose ICS

Page 4 of 5
Data as of 29APR2024

Listing 1
Listing of All Adverse Events Leading to Permanent Discontinuation of Study Treatment
or Withdrawal from Study for Participants on High Dose ICS at Baseline

Site Id.: 252091

Treatment	Unique Subject Id./ Subject Id.	Age (YEARS)/ Sex/ Race Detail/ Weight (kg)	SOC/ Preferred Term/ Verbatim Text	Outcome/ Onset Date Time/ Date Time of Resolution/ Duration	Time Since 1st Dose/ Time Since Last Dose	Maximum Intensity / Serious	Action(s) Taken/ Relation to Study Treatment
Depemokimab 100 mg SC	206713. 003561/ 003561	55/ M/ WHITE - WHITE/ CAUCASIAN/ EUROPEAN HERITAGE/ 103.0	Psychiatric disorders/ Grief reaction/ MENTAL HEALTH ISSUE FOLLOWING A BEREAVEMENT	NOT RECOVERED/ NOT RESOLVED/ 2022-12-01/ /	167d 22h 6m/ 167d 22h 6m	MILD/ N	DRUG WITHDRAWN/ N

li_ae_disc.sas 23DEC2025 16:43

Listing 1
Listing of All Adverse Events Leading to Permanent Discontinuation of Study Treatment
or Withdrawal from Study for Participants on High Dose ICS at Baseline

Site Id.: 253945

Treatment	Unique Subject Id./ Subject Id.	Age (YEARS)/ Sex/ Race Detail/ Weight (kg)	SOC/ Preferred Term/ Verbatim Text	Outcome/ Onset Date Time/ Date Time of Resolution/ Duration	Time Since 1st Dose/ Time Since Last Dose	Maximum Intensity / Serious	Action(s) Taken/ Relation to Study Treatment
Placebo	206713. 000242/ 000242	59/ M/ WHITE - WHITE/ CAUCASIAN/ EUROPEAN HERITAGE/ 104.8	Infections and infestations/ Herpes zoster/ SHINGLES	RECOVERED/ RESOLVED/ 2022-12-03/ 2022-12-10/ 7d 0h 0m	114d 18h 20m/ 114d 18h 20m	MILD/ N	DRUG WITHDRAWN/ Y

li_ae_disc.sas 23DEC2025 16:43

5 Compliance

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 1 of 18
Data as of 29APR2024

Table 47.10

Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-1	
		Placebo (N=71)	Depemokimab 100 mg SC (N=132)
Baseline	# of subjects remaining in study (%)	71 [100%]	132 [100%]
	# of subjects with ACQ-5 score (%)	70 (99%) [99%]	129 (98%) [98%]
	# of subjects with SGRQ total score (%)	70 (99%) [99%]	129 (98%) [98%]
	# of subjects with ADSD weekly mean score (%)	67 (94%) [94%]	124 (94%) [94%]
	# of subjects with ANSD weekly mean score (%)	61 (86%) [86%]	115 (87%) [87%]
	# of subjects with PGI-S score (%)	70 (99%) [99%]	127 (96%) [96%]
Week 1	# of subjects remaining in study (%)	71 [100%]	132 [100%]
	# of subjects with ADSD weekly mean score (%)	64 (90%) [90%]	121 (92%) [92%]
	# of subjects with ANSD weekly mean score (%)	57 (80%) [80%]	113 (86%) [86%]
Week 2	# of subjects remaining in study (%)	71 [100%]	132 [100%]
	# of subjects with ACQ-5 score (%)	71 (100%) [100%]	128 (97%) [97%]
	# of subjects with ADSD weekly mean score (%)	65 (92%) [92%]	119 (90%) [90%]
	# of subjects with ANSD weekly mean score (%)	56 (79%) [79%]	115 (87%) [87%]
Week 3	# of subjects remaining in study (%)	71 [100%]	132 [100%]
	# of subjects with ADSD weekly mean score (%)	64 (90%) [90%]	119 (90%) [90%]
	# of subjects with ANSD weekly mean score (%)	56 (79%) [79%]	115 (87%) [87%]
Week 4	# of subjects remaining in study (%)	71 [100%]	132 [100%]
	# of subjects with ACQ-5 score (%)	70 (99%) [99%]	129 (98%) [98%]
	# of subjects with SGRQ total score (%)	70 (99%) [99%]	129 (98%) [98%]
	# of subjects with ADSD weekly mean score (%)	63 (89%) [89%]	117 (89%) [89%]
	# of subjects with ANSD weekly mean score (%)	57 (80%) [80%]	112 (85%) [85%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 2 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-2	
		Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Baseline	# of subjects remaining in study (%)	68 [100%]	158 [100%]
	# of subjects with ACQ-5 score (%)	68 (100%) [100%]	153 (97%) [97%]
	# of subjects with SGRQ total score (%)	68 (100%) [100%]	153 (97%) [97%]
	# of subjects with ADSD weekly mean score (%)	68 (100%) [100%]	156 (99%) [99%]
	# of subjects with ANSD weekly mean score (%)	66 (97%) [97%]	147 (93%) [93%]
	# of subjects with PGI-S score (%)	68 (100%) [100%]	152 (96%) [96%]
Week 1	# of subjects remaining in study (%)	68 [100%]	157 [>99%]
	# of subjects with ADSD weekly mean score (%)	65 (96%) [96%]	151 (96%) [96%]
	# of subjects with ANSD weekly mean score (%)	62 (91%) [91%]	142 (90%) [90%]
Week 2	# of subjects remaining in study (%)	68 [100%]	157 [>99%]
	# of subjects with ACQ-5 score (%)	67 (99%) [99%]	151 (96%) [96%]
	# of subjects with ADSD weekly mean score (%)	66 (97%) [97%]	154 (98%) [97%]
	# of subjects with ANSD weekly mean score (%)	62 (91%) [91%]	138 (88%) [87%]
Week 3	# of subjects remaining in study (%)	68 [100%]	158 [100%]
	# of subjects with ADSD weekly mean score (%)	65 (96%) [96%]	147 (93%) [93%]
	# of subjects with ANSD weekly mean score (%)	63 (93%) [93%]	135 (85%) [85%]
Week 4	# of subjects remaining in study (%)	68 [100%]	158 [100%]
	# of subjects with ACQ-5 score (%)	67 (99%) [99%]	153 (97%) [97%]
	# of subjects with SGRQ total score (%)	67 (99%) [99%]	151 (96%) [96%]
	# of subjects with ADSD weekly mean score (%)	65 (96%) [96%]	151 (96%) [96%]
	# of subjects with ANSD weekly mean score (%)	60 (88%) [88%]	136 (86%) [86%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance is calculated from the endpoint domains, taking visit windows into account. As a result, compliance percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 3 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-1 & SWIFT-2	
		Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Baseline	# of subjects remaining in study (%)	139 [100%]	290 [100%]
	# of subjects with ACQ-5 score (%)	138 (>99%) [>99%]	282 (97%) [97%]
	# of subjects with SGRQ total score (%)	138 (>99%) [>99%]	282 (97%) [97%]
	# of subjects with ADSD weekly mean score (%)	135 (97%) [97%]	280 (97%) [97%]
	# of subjects with ANSD weekly mean score (%)	127 (91%) [91%]	262 (90%) [90%]
	# of subjects with PGI-S score (%)	138 (>99%) [>99%]	279 (96%) [96%]
Week 1	# of subjects remaining in study (%)	139 [100%]	289 [>99%]
	# of subjects with ADSD weekly mean score (%)	129 (93%) [93%]	272 (94%) [94%]
	# of subjects with ANSD weekly mean score (%)	119 (86%) [86%]	255 (88%) [88%]
Week 2	# of subjects remaining in study (%)	139 [100%]	289 [>99%]
	# of subjects with ACQ-5 score (%)	138 (>99%) [>99%]	279 (97%) [96%]
	# of subjects with ADSD weekly mean score (%)	131 (94%) [94%]	273 (94%) [94%]
	# of subjects with ANSD weekly mean score (%)	118 (85%) [85%]	253 (88%) [87%]
Week 3	# of subjects remaining in study (%)	139 [100%]	290 [100%]
	# of subjects with ADSD weekly mean score (%)	129 (93%) [93%]	266 (92%) [92%]
	# of subjects with ANSD weekly mean score (%)	119 (86%) [86%]	250 (86%) [86%]
Week 4	# of subjects remaining in study (%)	139 [100%]	290 [100%]
	# of subjects with ACQ-5 score (%)	137 (99%) [99%]	282 (97%) [97%]
	# of subjects with SGRQ total score (%)	137 (99%) [99%]	280 (97%) [97%]
	# of subjects with ADSD weekly mean score (%)	128 (92%) [92%]	268 (92%) [92%]
	# of subjects with ANSD weekly mean score (%)	117 (84%) [84%]	248 (86%) [86%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 4 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-1	
		Placebo (N=71)	Depemokimab 100 mg SC (N=132)
Week 5	# of subjects remaining in study (%)	70 [99%]	130 [98%]
	# of subjects with ADSD weekly mean score (%)	60 (86%) [85%]	119 (92%) [90%]
	# of subjects with ANSD weekly mean score (%)	55 (79%) [77%]	110 (85%) [83%]
Week 6	# of subjects remaining in study (%)	70 [99%]	130 [98%]
	# of subjects with ADSD weekly mean score (%)	60 (86%) [85%]	116 (89%) [88%]
	# of subjects with ANSD weekly mean score (%)	53 (76%) [75%]	110 (85%) [83%]
Week 7	# of subjects remaining in study (%)	70 [99%]	130 [98%]
	# of subjects with ADSD weekly mean score (%)	63 (90%) [89%]	114 (88%) [86%]
	# of subjects with ANSD weekly mean score (%)	54 (77%) [76%]	109 (84%) [83%]
Week 8	# of subjects remaining in study (%)	70 [99%]	130 [98%]
	# of subjects with ACQ-5 score (%)	68 (97%) [96%]	126 (97%) [95%]
	# of subjects with ADSD weekly mean score (%)	60 (86%) [85%]	116 (89%) [88%]
	# of subjects with ANSD weekly mean score (%)	53 (76%) [75%]	108 (83%) [82%]
Week 9	# of subjects remaining in study (%)	70 [99%]	130 [98%]
	# of subjects with ADSD weekly mean score (%)	60 (86%) [85%]	114 (88%) [86%]
	# of subjects with ANSD weekly mean score (%)	54 (77%) [76%]	107 (82%) [81%]
Week 10	# of subjects remaining in study (%)	70 [99%]	130 [98%]
	# of subjects with ADSD weekly mean score (%)	61 (87%) [86%]	112 (86%) [85%]
	# of subjects with ANSD weekly mean score (%)	54 (77%) [76%]	108 (83%) [82%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 5 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-2	
		Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Week 5	# of subjects remaining in study (%)	68 [100%]	157 [>99%]
	# of subjects with ADSD weekly mean score (%)	66 (97%) [97%]	149 (95%) [94%]
	# of subjects with ANSD weekly mean score (%)	60 (88%) [88%]	136 (87%) [86%]
Week 6	# of subjects remaining in study (%)	68 [100%]	157 [>99%]
	# of subjects with ADSD weekly mean score (%)	66 (97%) [97%]	147 (94%) [93%]
	# of subjects with ANSD weekly mean score (%)	60 (88%) [88%]	134 (85%) [85%]
Week 7	# of subjects remaining in study (%)	68 [100%]	157 [>99%]
	# of subjects with ADSD weekly mean score (%)	65 (96%) [96%]	147 (94%) [93%]
	# of subjects with ANSD weekly mean score (%)	60 (88%) [88%]	133 (85%) [84%]
Week 8	# of subjects remaining in study (%)	68 [100%]	157 [>99%]
	# of subjects with ACQ-5 score (%)	68 (100%) [100%]	154 (98%) [97%]
	# of subjects with ADSD weekly mean score (%)	63 (93%) [93%]	148 (94%) [94%]
	# of subjects with ANSD weekly mean score (%)	57 (84%) [84%]	132 (84%) [84%]
Week 9	# of subjects remaining in study (%)	68 [100%]	158 [100%]
	# of subjects with ADSD weekly mean score (%)	62 (91%) [91%]	146 (92%) [92%]
	# of subjects with ANSD weekly mean score (%)	59 (87%) [87%]	130 (82%) [82%]
Week 10	# of subjects remaining in study (%)	68 [100%]	158 [100%]
	# of subjects with ADSD weekly mean score (%)	61 (90%) [90%]	142 (90%) [90%]
	# of subjects with ANSD weekly mean score (%)	59 (87%) [87%]	128 (81%) [81%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 6 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-1 & SWIFT-2	
		Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Week 5	# of subjects remaining in study (%)	138 [>99%]	287 [99%]
	# of subjects with ADSD weekly mean score (%)	126 (91%) [91%]	268 (93%) [92%]
	# of subjects with ANSD weekly mean score (%)	115 (83%) [83%]	246 (86%) [85%]
Week 6	# of subjects remaining in study (%)	138 [>99%]	287 [99%]
	# of subjects with ADSD weekly mean score (%)	126 (91%) [91%]	263 (92%) [91%]
	# of subjects with ANSD weekly mean score (%)	113 (82%) [81%]	244 (85%) [84%]
Week 7	# of subjects remaining in study (%)	138 [>99%]	287 [99%]
	# of subjects with ADSD weekly mean score (%)	128 (93%) [92%]	261 (91%) [90%]
	# of subjects with ANSD weekly mean score (%)	114 (83%) [82%]	242 (84%) [83%]
Week 8	# of subjects remaining in study (%)	138 [>99%]	287 [99%]
	# of subjects with ACQ-5 score (%)	136 (99%) [98%]	280 (98%) [97%]
	# of subjects with ADSD weekly mean score (%)	123 (89%) [88%]	264 (92%) [91%]
	# of subjects with ANSD weekly mean score (%)	110 (80%) [79%]	240 (84%) [83%]
Week 9	# of subjects remaining in study (%)	138 [>99%]	288 [>99%]
	# of subjects with ADSD weekly mean score (%)	122 (88%) [88%]	260 (90%) [90%]
	# of subjects with ANSD weekly mean score (%)	113 (82%) [81%]	237 (82%) [82%]
Week 10	# of subjects remaining in study (%)	138 [>99%]	288 [>99%]
	# of subjects with ADSD weekly mean score (%)	122 (88%) [88%]	254 (88%) [88%]
	# of subjects with ANSD weekly mean score (%)	113 (82%) [81%]	236 (82%) [81%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 7 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-1	
		Placebo (N=71)	Depemokimab 100 mg SC (N=132)
Week 11	# of subjects remaining in study (%)	70 [99%]	130 [98%]
	# of subjects with ADSD weekly mean score (%)	61 (87%) [86%]	113 (87%) [86%]
	# of subjects with ANSD weekly mean score (%)	55 (79%) [77%]	104 (80%) [79%]
Week 12	# of subjects remaining in study (%)	70 [99%]	130 [98%]
	# of subjects with ACQ-5 score (%)	68 (97%) [96%]	127 (98%) [96%]
	# of subjects with SGRQ total score (%)	68 (97%) [96%]	127 (98%) [96%]
	# of subjects with ADSD weekly mean score (%)	58 (83%) [82%]	115 (88%) [87%]
	# of subjects with ANSD weekly mean score (%)	54 (77%) [76%]	104 (80%) [79%]
	# of subjects with PGI-S score (%)	67 (96%) [94%]	126 (97%) [95%]
Week 13	# of subjects with PGI-C score (%)	67 (96%) [94%]	125 (96%) [95%]
	# of subjects remaining in study (%)	69 [97%]	127 [96%]
	# of subjects with ADSD weekly mean score (%)	59 (86%) [83%]	108 (85%) [82%]
Week 14	# of subjects with ANSD weekly mean score (%)	53 (77%) [75%]	101 (80%) [77%]
	# of subjects remaining in study (%)	69 [97%]	127 [96%]
	# of subjects with ADSD weekly mean score (%)	62 (90%) [87%]	109 (86%) [83%]
Week 15	# of subjects with ANSD weekly mean score (%)	57 (83%) [80%]	101 (80%) [77%]
	# of subjects remaining in study (%)	69 [97%]	127 [96%]
	# of subjects with ADSD weekly mean score (%)	61 (88%) [86%]	109 (86%) [83%]
	# of subjects with ANSD weekly mean score (%)	54 (78%) [76%]	98 (77%) [74%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

		SWIFT-2	
Visit	Population	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Week 11	# of subjects remaining in study (%)	68 [100%]	158 [100%]
	# of subjects with ADSD weekly mean score (%)	63 (93%) [93%]	140 (89%) [89%]
	# of subjects with ANSD weekly mean score (%)	58 (85%) [85%]	132 (84%) [84%]
Week 12	# of subjects remaining in study (%)	68 [100%]	158 [100%]
	# of subjects with ACQ-5 score (%)	66 (97%) [97%]	154 (97%) [97%]
	# of subjects with SGRQ total score (%)	66 (97%) [97%]	153 (97%) [97%]
	# of subjects with ADSD weekly mean score (%)	64 (94%) [94%]	148 (94%) [94%]
	# of subjects with ANSD weekly mean score (%)	58 (85%) [85%]	130 (82%) [82%]
	# of subjects with PGI-S score (%)	65 (96%) [96%]	153 (97%) [97%]
Week 13	# of subjects remaining in study (%)	67 [99%]	156 [99%]
	# of subjects with ADSD weekly mean score (%)	64 (96%) [94%]	144 (92%) [91%]
	# of subjects with ANSD weekly mean score (%)	56 (84%) [82%]	126 (81%) [80%]
Week 14	# of subjects remaining in study (%)	67 [99%]	156 [99%]
	# of subjects with ADSD weekly mean score (%)	62 (93%) [91%]	140 (90%) [89%]
	# of subjects with ANSD weekly mean score (%)	57 (85%) [84%]	129 (83%) [82%]
Week 15	# of subjects remaining in study (%)	67 [99%]	156 [99%]
	# of subjects with ADSD weekly mean score (%)	63 (94%) [93%]	144 (92%) [91%]
	# of subjects with ANSD weekly mean score (%)	58 (87%) [85%]	130 (83%) [82%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 9 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-1 & SWIFT-2	
		Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Week 11	# of subjects remaining in study (%)	138 [>99%]	288 [>99%]
	# of subjects with ADSD weekly mean score (%)	124 (90%) [89%]	253 (88%) [87%]
	# of subjects with ANSD weekly mean score (%)	113 (82%) [81%]	236 (82%) [81%]
Week 12	# of subjects remaining in study (%)	138 [>99%]	288 [>99%]
	# of subjects with ACQ-5 score (%)	134 (97%) [96%]	281 (98%) [97%]
	# of subjects with SGRQ total score (%)	134 (97%) [96%]	280 (97%) [97%]
	# of subjects with ADSD weekly mean score (%)	122 (88%) [88%]	263 (91%) [91%]
	# of subjects with ANSD weekly mean score (%)	112 (81%) [81%]	234 (81%) [81%]
	# of subjects with PGI-S score (%)	132 (96%) [95%]	279 (97%) [96%]
Week 13	# of subjects with PGI-C score (%)	132 (96%) [95%]	278 (97%) [96%]
	# of subjects remaining in study (%)	136 [98%]	283 [98%]
	# of subjects with ADSD weekly mean score (%)	123 (90%) [88%]	252 (89%) [87%]
Week 14	# of subjects with ANSD weekly mean score (%)	109 (80%) [78%]	227 (80%) [78%]
	# of subjects remaining in study (%)	136 [98%]	283 [98%]
	# of subjects with ADSD weekly mean score (%)	124 (91%) [89%]	249 (88%) [86%]
Week 15	# of subjects with ANSD weekly mean score (%)	114 (84%) [82%]	230 (81%) [79%]
	# of subjects remaining in study (%)	136 [98%]	283 [98%]
	# of subjects with ADSD weekly mean score (%)	124 (91%) [89%]	253 (89%) [87%]
	# of subjects with ANSD weekly mean score (%)	112 (82%) [81%]	228 (81%) [79%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 10 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-1	
		Placebo (N=71)	Depemokimab 100 mg SC (N=132)
Week 16	# of subjects remaining in study (%)	69 [97%]	127 [96%]
	# of subjects with ACQ-5 score (%)	69 (100%) [97%]	124 (98%) [94%]
	# of subjects with ADSD weekly mean score (%)	55 (80%) [77%]	94 (74%) [71%]
	# of subjects with ANSD weekly mean score (%)	45 (65%) [63%]	83 (65%) [63%]
Week 20	# of subjects remaining in study (%)	69 [97%]	126 [95%]
	# of subjects with ACQ-5 score (%)	66 (96%) [93%]	122 (97%) [92%]
	# of subjects with ADSD weekly mean score (%)	49 (71%) [69%]	90 (71%) [68%]
	# of subjects with ANSD weekly mean score (%)	38 (55%) [54%]	77 (61%) [58%]
	# of subjects with PGI-S score (%)	66 (96%) [93%]	122 (97%) [92%]
	# of subjects with PGI-C score (%)	66 (96%) [93%]	121 (96%) [92%]
Week 24	# of subjects remaining in study (%)	68 [96%]	125 [95%]
	# of subjects with ACQ-5 score (%)	67 (99%) [94%]	123 (98%) [93%]
	# of subjects with ADSD weekly mean score (%)	49 (72%) [69%]	92 (74%) [70%]
	# of subjects with ANSD weekly mean score (%)	39 (57%) [55%]	84 (67%) [64%]
Week 26	# of subjects remaining in study (%)	66 [93%]	126 [95%]
	# of subjects with ACQ-5 score (%)	66 (100%) [93%]	124 (98%) [94%]
	# of subjects with SGRQ total score (%)	66 (100%) [93%]	124 (98%) [94%]
	# of subjects with ADSD weekly mean score (%)	51 (77%) [72%]	90 (71%) [68%]
	# of subjects with ANSD weekly mean score (%)	43 (65%) [61%]	83 (66%) [63%]
	# of subjects with PGI-S score (%)	66 (100%) [93%]	123 (98%) [93%]
	# of subjects with PGI-C score (%)	64 (97%) [90%]	123 (98%) [93%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 11 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-2	
		Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Week 16	# of subjects remaining in study (%)	67 [99%]	156 [99%]
	# of subjects with ACQ-5 score (%)	65 (97%) [96%]	153 (98%) [97%]
	# of subjects with ADSD weekly mean score (%)	55 (82%) [81%]	129 (83%) [82%]
	# of subjects with ANSD weekly mean score (%)	48 (72%) [71%]	104 (67%) [66%]
Week 20	# of subjects remaining in study (%)	68 [100%]	155 [98%]
	# of subjects with ACQ-5 score (%)	66 (97%) [97%]	152 (98%) [96%]
	# of subjects with ADSD weekly mean score (%)	53 (78%) [78%]	121 (78%) [77%]
	# of subjects with ANSD weekly mean score (%)	49 (72%) [72%]	107 (69%) [68%]
	# of subjects with PGI-S score (%)	66 (97%) [97%]	152 (98%) [96%]
	# of subjects with PGI-C score (%)	66 (97%) [97%]	152 (98%) [96%]
Week 24	# of subjects remaining in study (%)	68 [100%]	155 [98%]
	# of subjects with ACQ-5 score (%)	64 (94%) [94%]	145 (94%) [92%]
	# of subjects with ADSD weekly mean score (%)	53 (78%) [78%]	115 (74%) [73%]
	# of subjects with ANSD weekly mean score (%)	47 (69%) [69%]	101 (65%) [64%]
Week 26	# of subjects remaining in study (%)	68 [100%]	152 [96%]
	# of subjects with ACQ-5 score (%)	68 (100%) [100%]	151 (>99%) [96%]
	# of subjects with SGRQ total score (%)	68 (100%) [100%]	151 (>99%) [96%]
	# of subjects with ADSD weekly mean score (%)	56 (82%) [82%]	116 (76%) [73%]
	# of subjects with ANSD weekly mean score (%)	49 (72%) [72%]	100 (66%) [63%]
	# of subjects with PGI-S score (%)	68 (100%) [100%]	150 (99%) [95%]
	# of subjects with PGI-C score (%)	68 (100%) [100%]	150 (99%) [95%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 12 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-1 & SWIFT-2	
		Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Week 16	# of subjects remaining in study (%)	136 [98%]	283 [98%]
	# of subjects with ACQ-5 score (%)	134 (99%) [96%]	277 (98%) [96%]
	# of subjects with ADSD weekly mean score (%)	110 (81%) [79%]	223 (79%) [77%]
	# of subjects with ANSD weekly mean score (%)	93 (68%) [67%]	187 (66%) [64%]
Week 20	# of subjects remaining in study (%)	137 [99%]	281 [97%]
	# of subjects with ACQ-5 score (%)	132 (96%) [95%]	274 (98%) [94%]
	# of subjects with ADSD weekly mean score (%)	102 (74%) [73%]	211 (75%) [73%]
	# of subjects with ANSD weekly mean score (%)	87 (64%) [63%]	184 (65%) [63%]
	# of subjects with PGI-S score (%)	132 (96%) [95%]	274 (98%) [94%]
	# of subjects with PGI-C score (%)	132 (96%) [95%]	273 (97%) [94%]
Week 24	# of subjects remaining in study (%)	136 [98%]	280 [97%]
	# of subjects with ACQ-5 score (%)	131 (96%) [94%]	268 (96%) [92%]
	# of subjects with ADSD weekly mean score (%)	102 (75%) [73%]	207 (74%) [71%]
	# of subjects with ANSD weekly mean score (%)	86 (63%) [62%]	185 (66%) [64%]
Week 26	# of subjects remaining in study (%)	134 [96%]	278 [96%]
	# of subjects with ACQ-5 score (%)	134 (100%) [96%]	275 (99%) [95%]
	# of subjects with SGRQ total score (%)	134 (100%) [96%]	275 (99%) [95%]
	# of subjects with ADSD weekly mean score (%)	107 (80%) [77%]	206 (74%) [71%]
	# of subjects with ANSD weekly mean score (%)	92 (69%) [66%]	183 (66%) [63%]
	# of subjects with PGI-S score (%)	134 (100%) [96%]	273 (98%) [94%]
	# of subjects with PGI-C score (%)	132 (99%) [95%]	273 (98%) [94%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 13 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-1	
		Placebo (N=71)	Depemokimab 100 mg SC (N=132)
Week 28	# of subjects remaining in study (%)	65 [92%]	126 [95%]
	# of subjects with ACQ-5 score (%)	61 (94%) [86%]	123 (98%) [93%]
	# of subjects with ADSD weekly mean score (%)	50 (77%) [70%]	97 (77%) [73%]
	# of subjects with ANSD weekly mean score (%)	41 (63%) [58%]	85 (67%) [64%]
Week 32	# of subjects remaining in study (%)	66 [93%]	126 [95%]
	# of subjects with ACQ-5 score (%)	66 (100%) [93%]	119 (94%) [90%]
	# of subjects with ADSD weekly mean score (%)	46 (70%) [65%]	83 (66%) [63%]
	# of subjects with ANSD weekly mean score (%)	40 (61%) [56%]	66 (52%) [50%]
Week 36	# of subjects remaining in study (%)	64 [90%]	123 [93%]
	# of subjects with ACQ-5 score (%)	63 (98%) [89%]	121 (98%) [92%]
	# of subjects with ADSD weekly mean score (%)	44 (69%) [62%]	85 (69%) [64%]
	# of subjects with ANSD weekly mean score (%)	34 (53%) [48%]	71 (58%) [54%]
Week 40	# of subjects remaining in study (%)	65 [92%]	126 [95%]
	# of subjects with ACQ-5 score (%)	65 (100%) [92%]	119 (94%) [90%]
	# of subjects with SGRQ total score (%)	63 (97%) [89%]	119 (94%) [90%]
	# of subjects with ADSD weekly mean score (%)	48 (74%) [68%]	85 (67%) [64%]
	# of subjects with ANSD weekly mean score (%)	36 (55%) [51%]	73 (58%) [55%]
	# of subjects with PGI-S score (%)	63 (97%) [89%]	119 (94%) [90%]
	# of subjects with PGI-C score (%)	63 (97%) [89%]	119 (94%) [90%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 14 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-2	
		Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Week 28	# of subjects remaining in study (%)	68 [100%]	152 [96%]
	# of subjects with ACQ-5 score (%)	66 (97%) [97%]	149 (98%) [94%]
	# of subjects with ADSD weekly mean score (%)	57 (84%) [84%]	119 (78%) [75%]
	# of subjects with ANSD weekly mean score (%)	47 (69%) [69%]	102 (67%) [65%]
Week 32	# of subjects remaining in study (%)	67 [99%]	149 [94%]
	# of subjects with ACQ-5 score (%)	66 (99%) [97%]	147 (99%) [93%]
	# of subjects with ADSD weekly mean score (%)	46 (69%) [68%]	106 (71%) [67%]
	# of subjects with ANSD weekly mean score (%)	40 (60%) [59%]	93 (62%) [59%]
Week 36	# of subjects remaining in study (%)	66 [97%]	150 [95%]
	# of subjects with ACQ-5 score (%)	66 (100%) [97%]	148 (99%) [94%]
	# of subjects with ADSD weekly mean score (%)	48 (73%) [71%]	117 (78%) [74%]
	# of subjects with ANSD weekly mean score (%)	43 (65%) [63%]	97 (65%) [61%]
Week 40	# of subjects remaining in study (%)	66 [97%]	148 [94%]
	# of subjects with ACQ-5 score (%)	66 (100%) [97%]	144 (97%) [91%]
	# of subjects with SGRQ total score (%)	66 (100%) [97%]	143 (97%) [91%]
	# of subjects with ADSD weekly mean score (%)	49 (74%) [72%]	112 (76%) [71%]
	# of subjects with ANSD weekly mean score (%)	42 (64%) [62%]	95 (64%) [60%]
	# of subjects with PGI-S score (%)	66 (100%) [97%]	142 (96%) [90%]
	# of subjects with PGI-C score (%)	66 (100%) [97%]	141 (95%) [89%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Page 15 of 18
Data as of 29APR2024

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

Visit	Population	SWIFT-1 & SWIFT-2	
		Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Week 28	# of subjects remaining in study (%)	133 [96%]	278 [96%]
	# of subjects with ACQ-5 score (%)	127 (95%) [91%]	272 (98%) [94%]
	# of subjects with ADSD weekly mean score (%)	107 (80%) [77%]	216 (78%) [74%]
	# of subjects with ANSD weekly mean score (%)	88 (66%) [63%]	187 (67%) [64%]
Week 32	# of subjects remaining in study (%)	133 [96%]	275 [95%]
	# of subjects with ACQ-5 score (%)	132 (>99%) [95%]	266 (97%) [92%]
	# of subjects with ADSD weekly mean score (%)	92 (69%) [66%]	189 (69%) [65%]
	# of subjects with ANSD weekly mean score (%)	80 (60%) [58%]	159 (58%) [55%]
Week 36	# of subjects remaining in study (%)	130 [94%]	273 [94%]
	# of subjects with ACQ-5 score (%)	129 (>99%) [93%]	269 (99%) [93%]
	# of subjects with ADSD weekly mean score (%)	92 (71%) [66%]	202 (74%) [70%]
	# of subjects with ANSD weekly mean score (%)	77 (59%) [55%]	168 (62%) [58%]
Week 40	# of subjects remaining in study (%)	131 [94%]	274 [94%]
	# of subjects with ACQ-5 score (%)	131 (100%) [94%]	263 (96%) [91%]
	# of subjects with SGRQ total score (%)	129 (98%) [93%]	262 (96%) [90%]
	# of subjects with ADSD weekly mean score (%)	97 (74%) [70%]	197 (72%) [68%]
	# of subjects with ANSD weekly mean score (%)	78 (60%) [56%]	168 (61%) [58%]
	# of subjects with PGI-S score (%)	129 (98%) [93%]	261 (95%) [90%]
	# of subjects with PGI-C score (%)	129 (98%) [93%]	260 (95%) [90%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

		SWIFT-1	
Visit	Population	Placebo (N=71)	Depemokimab 100 mg SC (N=132)
Week 44	# of subjects remaining in study (%)	64 [90%]	124 [94%]
	# of subjects with ACQ-5 score (%)	63 (98%) [89%]	121 (98%) [92%]
	# of subjects with ADSD weekly mean score (%)	47 (73%) [66%]	88 (71%) [67%]
	# of subjects with ANSD weekly mean score (%)	36 (56%) [51%]	67 (54%) [51%]
Week 48	# of subjects remaining in study (%)	65 [92%]	126 [95%]
	# of subjects with ACQ-5 score (%)	64 (98%) [90%]	124 (98%) [94%]
	# of subjects with ADSD weekly mean score (%)	41 (63%) [58%]	88 (70%) [67%]
	# of subjects with ANSD weekly mean score (%)	27 (42%) [38%]	67 (53%) [51%]
Week 52	# of subjects remaining in study (%)	64 [90%]	124 [94%]
	# of subjects with ACQ-5 score (%)	62 (97%) [87%]	122 (98%) [92%]
	# of subjects with SGRQ total score (%)	62 (97%) [87%]	122 (98%) [92%]
	# of subjects with ADSD weekly mean score (%)	45 (70%) [63%]	77 (62%) [58%]
	# of subjects with ANSD weekly mean score (%)	34 (53%) [48%]	61 (49%) [46%]
	# of subjects with PGI-S score (%)	62 (97%) [87%]	121 (98%) [92%]
	# of subjects with PGI-C score (%)	62 (97%) [87%]	121 (98%) [92%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

		SWIFT-2	
Visit	Population	Placebo (N=68)	Depemokimab 100 mg SC (N=158)
Week 44	# of subjects remaining in study (%)	66 [97%]	147 [93%]
	# of subjects with ACQ-5 score (%)	62 (94%) [91%]	142 (97%) [90%]
	# of subjects with ADSD weekly mean score (%)	55 (83%) [81%]	110 (75%) [70%]
	# of subjects with ANSD weekly mean score (%)	46 (70%) [68%]	90 (61%) [57%]
Week 48	# of subjects remaining in study (%)	65 [96%]	147 [93%]
	# of subjects with ACQ-5 score (%)	64 (98%) [94%]	145 (99%) [92%]
	# of subjects with ADSD weekly mean score (%)	50 (77%) [74%]	110 (75%) [70%]
	# of subjects with ANSD weekly mean score (%)	42 (65%) [62%]	87 (59%) [55%]
Week 52	# of subjects remaining in study (%)	65 [96%]	149 [94%]
	# of subjects with ACQ-5 score (%)	66 (102%) [97%]	144 (97%) [91%]
	# of subjects with SGRQ total score (%)	66 (102%) [97%]	144 (97%) [91%]
	# of subjects with ADSD weekly mean score (%)	47 (72%) [69%]	101 (68%) [64%]
	# of subjects with ANSD weekly mean score (%)	44 (68%) [65%]	87 (58%) [55%]
	# of subjects with PGI-S score (%)	66 (102%) [97%]	142 (95%) [90%]
	# of subjects with PGI-C score (%)	65 (100%) [96%]	142 (95%) [90%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25

Protocol: 217780 Depemokimab GVD Asthma
Population: FAS - High-dose ICS Subgroup

Table 47.10
Summary of Compliance of SGRQ, ACQ-5, ADSD, ANSD, PGI-S and PGI-C by Visit

		SWIFT-1 & SWIFT-2	
Visit	Population	Placebo (N=139)	Depemokimab 100 mg SC (N=290)
Week 44	# of subjects remaining in study (%)	130 [94%]	271 [93%]
	# of subjects with ACQ-5 score (%)	125 (96%) [90%]	263 (97%) [91%]
	# of subjects with ADSD weekly mean score (%)	102 (78%) [73%]	198 (73%) [68%]
	# of subjects with ANSD weekly mean score (%)	82 (63%) [59%]	157 (58%) [54%]
Week 48	# of subjects remaining in study (%)	130 [94%]	273 [94%]
	# of subjects with ACQ-5 score (%)	128 (98%) [92%]	269 (99%) [93%]
	# of subjects with ADSD weekly mean score (%)	91 (70%) [65%]	198 (73%) [68%]
	# of subjects with ANSD weekly mean score (%)	69 (53%) [50%]	154 (56%) [53%]
Week 52	# of subjects remaining in study (%)	129 [93%]	273 [94%]
	# of subjects with ACQ-5 score (%)	128 (>99%) [92%]	266 (97%) [92%]
	# of subjects with SGRQ total score (%)	128 (>99%) [92%]	266 (97%) [92%]
	# of subjects with ADSD weekly mean score (%)	92 (71%) [66%]	178 (65%) [61%]
	# of subjects with ANSD weekly mean score (%)	78 (60%) [56%]	148 (54%) [51%]
	# of subjects with PGI-S score (%)	128 (>99%) [92%]	263 (96%) [91%]
	# of subjects with PGI-C score (%)	127 (98%) [91%]	263 (96%) [91%]

Note: (xx%) denotes the percentage of subjects remaining in the study and [xx%] denotes the percentage of N
Subjects remaining in the study is calculated using the visit domain. Individual study endpoint compliance
is calculated from the endpoint domains, taking visit windows into account. As a result, compliance
percentages (xx%) may exceed 100% if endpoint data collected at unscheduled visits are assigned to the
nearest scheduled visit, as per the SWIFT-1 or SWIFT-2 protocol.
t_sp_sum_compli.sas 09JUL2025 00:25